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 ABSTRACT 
 
SPECTROSCOPIC STUDIES ON ACTIVE METALLO-β-LACTAMASES 
 
by 
 
Mahesh Kumar Aitha 
 
 
 
Antibiotic resistance is a major challenge in the treatment of bacterial infections. 
According to a Centers for Disease Control report in 2013, more than two million people 
were affected by antibiotic resistance in 2012 and more than 23,000 people in the United 
States died. Zinc-dependent metallo-β-lactamases (MBLs) are an emerging class of 
enzymes that render bacteria resistant to most β-lactam containing antibiotics, such as 
penicillins, cephalosporins, and carbapenems. It is essential to understand the catalytic 
mechanism of these enzymes to design effective inhibitors, which could be given in 
combination with existing antibiotics to combat antibiotic resistant bacterial infections. To 
better understand the role(s) of the zinc ions in the active sites of these enzymes, several 
MBLs were characterized using kinetic, crystallographic, and spectroscopic studies. Our 
results demonstrated the first successful preparation of a Co(II)-substituted analog of MBL 
VIM-2, which allowed for a better understanding of zinc binding to VIM-2 and how VIM-
2 is different from other MBLs. The roles of the metal binding sites in MBL L1 were 
investigated by using rapid freeze quench Extended X-ray Absorption Fine Structure 
spectroscopic studies on an analog of L1 that binds zinc in one metal binding site and cobalt 
in the other site. To understand the role of an invariant hairpin loop in most MBLs, rapid-
freeze quench Double Electron Electron Resonance spectroscopy was used to measure the 
distances between site-specifically introduced sping label in MBLs L1, CcrA, and NDM-
1 as the enzymes hydrolyzed substrate. Our results showed that the hairpin loop is crucial 
for the catalysis and that the loop undergoes large movements during catalysis. The results 
in this dissertation will be used to guide future inhibitor design efforts on MBLs. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1. Antibiotics 
1.1.1. Pre antibiotic era. Before the 20th century bacterial infections were the most 
common cause of human death. The era of modern antimicrobial chemotherapy began with the 
discovery of arsphenamine by Alfred Bertheim and Paul Ehrlich in 1907, and it was used to treat 
syphilis.[1] Prontosil (4-[(2,4-diaminophenyl)azo]benzenesulfonamide) was the first drug to treat 
a broad range of bacterial infections, and it was discovered in 1933 by Gerhard Domagk; Domagk 
was awarded the Nobel Prize in 1939 for his invention.[2] The primary action of the sulfonamides 
is believed to be bacteriostatic, rather than bacteriocidal, by affecting folate metabolism.[3] 
However, these compounds exhibit significant side effects, including urinary tract and 
haemopoietic disorders, porphyria, and hypersensitivity reactions, and large doses cause strong 
allergic reactions.[3] 
1.1.2. Discovery and function of β-lactam antibiotics. In September, 1928, Alexander 
Fleming noticed that a compound secreted by Penicillium notatum had the ability to stop the 
growth of several bacteria, such as Streptococcus, Meningococcus, and diphtheria-causing 
Bacillus.[4] A few years later, he named the compound penicillin and showed that it was effective 
against Gram-positive bacteria but not against Gram-negative bacteria and fungi.[4] Fleming and 
a few other researchers showed that penicillin was less toxic and more effective than other 
available antimicrobial agents at that time. However, Fleming concluded that penicillin would not 
last long as an antibiotic because of evolutionary resistance issues, and he stopped research on 
penicillin in 1931.[5] In addition, Fleming, a microbiologist with no expertise in medicinal 
chemistry, did not know how to produce large quantities of penicillin.[5] Several years later, 
Howard Florey, Ernst Chain, and Norman Heatley at Oxford University optimized large-scale 
preparation of penicillin.[6, 7] Florey recognized that the large-scale production of penicillin was 
impossible in Britain, since all of the chemical industry was committed to the war effort. So Florey 
travelled to the United States and worked with faculty/staff at Yale University and at the Northern 
Regional Research Laboratory (NRRL) to produce enough penicillin to be used in the clinic. The 
first successful clinical trial with penicillin was conducted by John Bumstead and Orvan Hess in 
1942. It is estimated that penicillin saved more than 3 million lives of World War II soldiers.[8] 
Later, several synthetic analogs of penicillin were developed, and other classes of β-lactam 
antibiotics, such as cephalosporins, carbapenems, and cephamycins, were identified and isolated 
from natural sources. 
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β-Lactam antibiotics target bacteria by inhibiting cell wall synthesis. The bacterial cell wall 
is composed of phospholipid and peptidoglycan layers. The peptidoglycan layer is responsible for 
the integrity/rigidity of the cell wall. Two enzymes responsible for the synthesis of the 
peptidoglycan layer are transglycosidase and transpeptidase. Transpeptidases are responsible for 
the crosslinking of pentapeptide building blocks, and transglycosidases are responsible for the 
elongation of the glycan chain by fusing N-acetylmuramic acid (NAM) and N-acetylglucosamine 
(NAG) units.[9, 10] β-Lactam antibiotics and glycopeptide antibiotics target peptidoglycan 
crosslinking, inhibiting bacterial cell wall growth.[11] In the presence of β-lactam antibiotics, 
transpeptidases (also called penicillin binding proteins, PBP) form a covalent intermediate when 
hydrolyzing β-lactam antibiotics; the covalently-linked transpeptidase can no longer catalyze the 
crosslinking of pentapeptide building blocks. The resulting cell wall (peptidoglycan layer) is 
“under” crosslinked, weakened, and susceptible to osmotic lysis.[12] β-Lactam containing 
compounds are the most commonly prescribed antibiotics in the clinic. 
1.1.3. Different generations of β-lactam antibiotics. In order to improve efficacy, increase 
solubility, improve uptake, and to reduce side effects, derivatives of penicillin, such as ampicillin, 
amoxicillin, and methicillin, were designed, synthesized, and tested. The first modified penicillin 
was methicillin, which was effective against penicillin-resistant Staphylococci. However after a 
few years of clinical use, most S. aureus strains were resistant to methicillin.[13] The penicillins 
consist of a four-membered, β-lactam ring fused to a five-membered thiazolidine ring, and 
substituents in the 3- and 6-positions have been modified to offer improved chemical/biological 
properties (Figure 1.1). Derivatives of penicillins have been classified into three major classes 
based on their activities: narrowspectrum penicillins (benzylpenicillin, benzathinepenicillin, and 
methicillin), broad spectrum penicillins (amoxicillin, and ampicillin), and extended spectrum 
penicillins (carbenicillin, ticarcillin, and piperacillin).  The second class of -lactam antibiotics 
contains the cephalosporins, and these differ from the penicillins in that five-membered 
thiazolidine ring is replaced by a six-membered dihydrothiazine ring. Like the penicillins, the 
cephalosporins have been modified, at positions 3 and 7, to enhance biological properties. To date, 
five generations of cephalosporins have been developed. The first two generations, which contain 
cephalexin, cephalothin, cefaclor, and cefoxitin, exhibit moderate spectrum activities. The other 
three generations, which contain compounds like cefixime, cefotaxime, ceftazidime, cefepime, and 
ceftaroline, exhibit broad spectrum activities. The third class of -lactam antibiotics contains the 
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carbapenems, which are 
similar to the penicillins 
except the sulfur of 
thiazolidine ring is 
replaced by a sp3-
hybridized carbon in the 
carbapenems. Examples 
of carbapenems are 
biapenem, doripenem, 
imipenem, and 
penipenem. The fourth 
class of -lactam 
antibiotics contains the 
monobactams, which 
include aztreonam and 
tigemonam. These 
compounds, as their 
name implies, contain only a single 4-membered ring and act against aerobic, Gram-negative 
bacteria 
1.1.4. Antibiotic resistance. In response to the use of antibiotics, bacteria become resistant 
in two ways: 1) by a genetic mutation or 2) by acquiring resistance. All resistance mechanisms 
require the acquisition of DNA from another organism that is already resistant to the specific 
antibiotic. One common resistance mechanism involves the expression of an efflux pump, which 
pumps the antibiotic out of the cell so that the drug cannot reach its target.[11] Efflux pumps are 
encoded by multi-drug resistance (MDR) genes, which allow them to target a broad spectrum of 
antibiotics.[11] Another common resistance mechanism involves the expression of enzymes, 
which hydrolyze, reduce, oxidize, or add groups to the antibiotic to alter its activity. β-Lactamases 
are a class of bacterial enzymes that use this second mechanism to inactivate β-lactam-containing 
antibiotics.[14] β-Lactamases cleave the C-N bond in the 4-membered β-lactam ring, and the 
resulting hydrolyzed product no longer inhibits cell wall synthesis. Bacterial production of -
lactamases is, by far, the most common antibiotic resistance mechanism, which is consistent with 
 
Figure 1.1. Structures of some β-Lactam antibiotics: penicillin, 
cephalosporin, carbapenem, and monobactam. 
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-lactam containing antibiotics being the largest class of antibiotics. To counter antibiotic 
resistance in the clinic, two main efforts have been adopted. The first effort involves the search for 
new antibiotics and bacterial targets. Daptomycin is a recently discovered antibiotic that kills 
bacteria by depolarizing the cell membrane.[15] However, daptomycin-resistant bacteria appeared 
even before the drug was approved for clinical use.[16] Bedaquiline is another recently-discovered 
anti-tuberculosis drug that kills the bacteria by targeting subunit c of mycobacterial ATP 
synthase.[17]  Bedaquilin was introduced into the clinic in 2012, but bedaquiline-resistant 
Mycobaterium tuberculosis had already been reported in 2006.[16] The second main effort to 
combat antibiotic resistance in the clinic involves the production of inhibitors that target the 
bacterial enzymes/proteins that render bacteria resistant to antibiotics. By far, the most prevalent 
are β-lactamase inhibitors, which can be given in combination with existing -lactam containing 
antibiotics to combat bacteria that produce -lactamases. Clavulanic acid is used clinically in 
drug/inhibitor combinations, such as Augmentin (amoxicillin + clavulanic acid) and Timentin 
(ticarcillin + clavulanic acid). Other -lactamase inhibitor/-lactam antibiotic combinations 
include Unasyn (ampicillin + sulbactam), Zosyn (piperacillin + tazobactam), and Avycaz 
(ceftazidime + avibactam).[18]  
A recent report by the British Government speculated that antibiotic resistance will cost up 
to $100 trillion globally by the year 2050 and result in 10 million deaths annually.[19] According 
to a 2013 CDC report, more than 2 million people were affected by antibiotic resistant bacterial 
infections in 2012 in the United States, and greater than 23,000 people died.[20]  
It is clear that research in the general area of antibiotic resistance is critical. Major efforts 
to probe resistance pathways are being made, and billions of dollars are being spent to discover 
new antibiotics. These efforts resulted in discovery of novel antibiotics, such as daptomycin, 
fidaxomicin, and bedaquiline.[16] The Infectious Diseases Society of America (IDSA) has started 
the 10 X ’20 (ten new antibiotics by 2020) program, which is a global commitment to develop new 
antibacterial drugs.[21] The United States awarded GlaxoSmithKline $200 million to discover new 
antibiotics, and in 2012, the U.S. Congress passed the GAIN act (Generating Antibiotics Incentives 
Now), which extends the patent rights of pharmaceutical companies and speeds the development 
and approval of new antibiotics.[22] The GAIN act resulted in two recently-approved antibiotics: 
dalbavancin from Durata Therapeutics and Sivextro from Cubist Pharmaceuticals (their chief 
science director was Dr. Steve Gilman (1973 Microbiology major from Miami)). While work on 
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resistance to all antibiotics is needed, the Crowder group focuses on -lactam containing 
antibiotics because these compounds belong to the largest and, by most measures, most successful 
class of antibiotics. 
1.1.5. Other targets to attack bacteria. Over the last 5-6 decades, scientists identified other 
bacterial processes, such as protein synthesis and nucleic acid synthesis, to target bacteria (Table 
1.1). Bacterial protein synthesis involves several enzymes and biomolecules, which can be targeted 
for inhibitors. Multistep protein synthesis involves initiation, elongation, and termination by the 
ribosome.[11] Macrolide antibiotics such as erythromycin[23] target the 50S subunit of the 
ribosome. Tetracyclines[24] and aminoglycosides (kanamycin)[25] target the 30S subunit of the 
ribosome. The newer oxazolidinones[26] also target the 30S subunit but at a different site. 
Fluoroquinolones are synthetic antibiotics, which kill bacteria by targeting DNA gyrase (DNA 
synthesis).[27] Rifampicin inhibits mRNA synthesis by targeting RNA polymerase activity in the 
early stages of transcription.[28] However, β-lactam antibiotics are the largest class, making up 
more than 50% of the prescribed and available clinical antibiotics. With the availability of multiple 
antibiotics and bacterial targets, the U.S. Surgeon General in 1969 declared that infectious diseases 
are no longer a clinical problem in the U.S. The Surgeon General failed to anticipate that bacteria 
rapidly evolve and acquire resistance.  
 
1.2. β-Lactamases 
1.2.1. Classes. By the end of 2013, more than 1,300 β-lactamases have been identified and 
isolated, and there are a number classification schemes available.[29] The most commonly used 
scheme was initially proposed by Ambler and later expanded by Bush.[29, 30] According to this 
classification scheme, there are four distinct classes (A-D) of β-lactamases, based on amino acid 
sequence and conserved motifs. Classes A, C, and D contain the serine β-lactamases (SBLs), which 
use an active site serine as a nucleophile during β-lactam hydrolysis (Figure 1.2).[31] Class B 
contains the metallo-β-lactamases (MBLs), which require one or two Zn(II) ions for full catalytic 
activity.[14] MBLs have been further classified into three subgroups (B1-B3) based on their 
sequence homologies and number of metal ions in their active sites (Figure 1.3 and Table 1.2).[14] 
Most of the B1 and B3 enzymes bind two equivalents of Zn(II); one at the Zn1 site and one at the 
Zn2 site. One major difference between the B1 and B3 enzymes is the Zn2 site: in the B1 enzymes 
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Zn(II) is coordinated by 1 His, 1 Cys, 1 Asp, a terminally-bound water, and a bridging solvent 
molecule, while in the B3 enzymes the Cys is replaced by a second His. The B2 enzymes bind  
only one Zn(II) ion at the Zn2 site.[14] 
 
Figure 1.2. β-Lactam antibiotic hydrolysis by SBLs. 
  
            
             B1                                                B2                                       B3 
 
Figure 1.3. Active sites of B1, B2, and B3 MBLs. 
 Table 1.2. Examples of MBL subclasses.[32] 
Subgroup Examples 
B1 BcII, CcrA, IND, JOHN, EBR, CGB, MUS, 
TUS, SPM, GIM, KHM, DIM, IMP-type, 
NDM-type, and VIM-type 
B2 ImiS, CphA, and Sfh 
B3 L1, FEZ, THIN-B, LRA, AIM, SMB, CAU, 
BJP, and GOB-type 
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1.2.2. Inhibitors. There are two main strategies to prepare inhibitors of β-lactamases.[31] 
First, researchers have designed substrates, which reversibly and/or irreversibly bind the enzyme 
with high affinity to form stable acyl-enzyme complexes (extended-spectrum cephalosporins 
(cefotaxime), monobactams (aztreonam), or carbapenems (doripenem)). Second, researchers have 
developed mechanism-based or irreversible “suicide inhibitors”. Inhibitors of this class, such as 
clavulanic acid, sulbactam, tazobactam, or avibactam, can permanently inactivate the β-lactamases 
through chemical modification of the enzyme active site. Combinations of a β-lactamase inhibitor 
and a β-lactam containing antibiotic are currently being used to treat antibiotic resistant infections, 
in which the bacteria produce an SBL.[14, 18, 31, 33] To date, no clinical inhibitors are available 
to target the MBLs.  
 
1.3. MBL (Verona Integron Metallo--lactamase) VIM-2  
 Unlike other B1 enzymes such as BcII, CcrA, IMP-1, and NDM-1, none of the VIM-type 
MBLs are well-characterized. The first VIM-type MBL was discovered in 1999 in a clinical strain 
of P. aeruginosa, which was 
isolated from an Italian 
patient.[34] A second variant 
of VIM, VIM-2, was 
identified in 2000, from a P. 
aeruginosa isolate collected 
in France in 1996.[35] VIM-
1 and VIM-2 share 90% 
amino acid sequence 
identity, and most VIM 
enzymes exhibit less than 
40% amino acid homologies 
with the MBLs belonging to 
the IMP (IMiPenemase) 
class.[35] To date, 46 
variants of VIM have been 
identified and isolated,[36] and these variants exhibit 74.3–99.6% sequence similarities.[37, 38] 
                          
 
Figure 1.4. Crystal structure of VIM-2, (PDB ID: 4NQ2). 
Figure was generated using VMD[52] software program. 
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Among these VIM variants, VIM-2 appears to be the one most commonly found in the clinic, and 
VIM-2 expressing bacterial strains have been found in many countries.[35, 39-47] VIM-2 contains 
266 amino acids, with a molecular mass of 29.7 KDa and a pI of 5.6.VIM-2 shares 32% amino 
acid identity with BcII from Bacillus cereus, 31% with IMP-1 from Serratia marcescens, 27% 
with CcrA from Bacteroides fragilis, 24% with BlaB from Chryseobacterium meningosepticum, 
and 24% with IND-1 from Chryseobacterium indologenes.[24] VIM-2-expressing bacteria have 
been shown to be resistant to an array of β-lactam-containing antibiotics, including 
ureidopenicillins, ticarcillin-clavulanic acid, cefepime, ceftazidime, imipenem, and meropenem, 
but strains expressing VIM-2 remained susceptible to the monobactam aztreonam.[35] The activity 
of VIM-type enzymes is 
inhibited by EDTA, 
suggesting that zinc is 
essential for activity. 
Before starting the work 
described in this 
dissertation, nine crystal 
structures of VIM 
variants were available 
on the Protein Data Bank 
(PDB), including two 
crystal structures of 
VIM-2 at resolutions of 
1.9 and 2.2 Å.[48, 49] 
To date, there are 
twenty-three crystal 
structures available of all VIM-type MBLs, including eight VIM-2 crystal structures in the PDB. 
Crystallographic studies showed that the metal ion bound in the Zn1 site was coordinated to 3 His 
and a bridging hydroxide and that the metal ion bound in the Zn2 was coordinated to 1 His, 1 Cys, 
1 Asp, 1 water, and the bridging hydroxide (Figures 1.4 and 1.5). 
 VIM-2 is considered to be one of the three most dangerous carbapenemases because 
bacteria that produce VIM-2 exhibit high mortality rates (18% to 67%) and the gene for VIM-2 
 
Figure 1.5. Active site of VIM-2, (PDB ID: 4NQ2). Figure was 
generated using VMD[52] software program. 
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rapidly spreads to other organisms.[50] Despite significant efforts to study VIM-2, there are 
conflicting data in the literature. Steady-state kinetic constants kcat and Km range from 9.9 to 34 s
-
1 and 9 to 10 M, respectively, for VIM-2 when using imipenem as substrate.[35, 51] The reported 
metal-metal (M-M) distances between the Zn(II) ions in  VIM-2 are different (4.20 vs. 3.75 Å).[48, 
49] Before this work, there were no detailed structural or mechanistic results reported on any VIM-
2 variant. In Chapter 2 of this dissertation, data are reported on recombinant VIM-2, which involve 
over-expression, purification, and characterization (kinetics, crystallography, spectroscopy) of the 
enzyme.                   
 
1.4. Using X-ray Absorption Spectroscopy (XAS) to study MBLs 
Several strategies have been used to monitor substrate binding to the MBLs. 
Crystallography is a powerful tool to gain structural information; however, the use of X-ray 
crystallography to probe substrate binding and/or catalysis requires diffraction-quality crystals of 
species that react on the millisecond or submillisecond timescale. NMR spectroscopy offers 
information on dynamics; however, the time required to signal average is far too long to probe 
enzymatic reactions that occur on the millisecond timescale.[53] Rapid-freeze quench techniques, 
coupled with spectroscopic methods, afford the ability to monitor these short reactions.[12, 54, 55] 
X-ray absorption spectroscopy (XAS) has been a reliable technique to study metalloprotein 
active sites since the early 1970s.[56] This technique offers two major advantages over X-ray 
crystallography: 1) XAS does not require crystalline material and can be applied on frozen 
solutions, allowing frozen reaction intermediates to be investigated, and 2) XAS is element-
specific, which allows researchers to study multiple metal centers in a single sample as long as the 
metal ions are different (as in heterobimetallic enzymes).[57] The Crowder and Tierney groups 
have used XAS to probe the metal binding sites in several metalloproteins, including MBLs.[12, 
24, 54, 58-64] All known MBLs are zinc-dependent metalloenzymes[14] and the presence of a 
metal ion(s) affords a “spectroscopic handle” to monitor the structure and mechanism of the 
enzyme. In biology, zinc exists as Zn(II) and is spectroscopically-silent for all spectroscopic 
techniques except XAS and 67Zn NMR.[57] In most Zn(II) metalloenzymes zinc can be readily 
replaced with a spectroscopically-active element, like Co(II), yielding catalytically-active 
enzymes.[24, 55, 58, 60-62, 65-68] Recently, the Crowder and Tierney groups developed 
strategies to prepare heterobimetallic analogues of the MBLs,[58, 60, 61, 63, 69, 70], allowing 
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them to probe both metal centers in the same sample independently. In chapter 3, we propose the 
use of XAS to address three distinct, but related, issues involving MBLs: (1) we investigated the 
metal binding sites of NDM-1 to address controversies about metal binding to this enzyme, (2) we 
used Extended X-ray Absorption Fine Structure (EXAFS) spectroscopy to confirm the metal 
centers in heterobimetallic analogs of NDM-1, and (3) we used XAS and RFQ-XAS to probe the 
reaction mechanism of a MBL from each of the representative MBL classes.  
 
1.5. MBL L1  
MBL L1 was first identified and isolated from S. maltophilia, which is an opportunistic, 
pathogenic bacterium that can be found in aquatic environments, soil, on vegetation, and in some 
animals. S. maltophilia infections are commonly found in immunocompromised patients suffering 
from cancer, cystic fibrosis, drug addiction, and AIDS, as well as in patients with organ transplants 
or on dialysis.[71, 72] S. maltophilia is inherently resistant to most antibiotics due to its low outer 
membrane permeability and 
its production of 
chromosomally-expressed 
serine β-lactamase L2 and 
MBL L1.[55, 73-75]
 MBL L1 has been 
cloned, over-expressed and 
purified by several 
groups.[76] L1 exists as a 
118 KDa homotetramer in 
solution and in the 
crystalline state.[76] The 
structure and function of L1 
have been extensively 
studied. L1 is arguably the 
best characterized among all 
MBLs, and kinetic (steady-
state kinetic, presteady-state kinetic, and transient state) crystallographic, and spectroscopic 
 
Figure 1.6. Active site of MBL L1 (PDB ID: 1SML). The 
bridging water/hydroxide and terminally-bound water on the 
metal ion in the Zn2 site are not included in the structure above. 
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studies (UV-vis, NMR, EPR, and EXAFS) have been reported.[54, 55, 63, 65, 66, 76-89]  A few 
computational studies have also been reported on L1 by Spencer and Guo, and those studies were 
used to predict substrate binding and reaction mechanisms.[77, 90] The crystal structure of each 
L1 monomer shows an αββα motif, which is now called the -lactamase fold, a disulfide bond 
between the only two cysteine residues in the enzyme at positions 256 and 284, and a characteristic 
hairpin loop located above the active site (Figure 1.7).[77] L1 belongs to the B3 class of MBLs, 
and it tightly binds two Zn(II) ions and requires both metal ions for full catalytic activity. The Zn1 
site is coordinated by 3 His and a bridging water/hydroxide molecule, resulting in a distorted 
tetrahedral geometry. The Zn2 site is coordinated by 2 His, 1 Asp, 1 water molecule, and the 
bridging water/hydroxide molecule, resulting in a distorted penta-coordinate geometry (Figure 
1.6).[77]                            
There are fourteen crystal structures of L1 available in the Protein Data Bank (PDB.ORG). 
Six of these structures are L1-inhibitor/product complexes.[66, 91, 92]  A structure of L1 bound 
to hydrolyzed moxalactam showed that the metal ion in the Zn1 site interacts with the oxygen of 
the newly-formed carboxylate (initially was the -lactam carbonyl) and that the metal ion in the 
Zn2 site coordinates the β-lactam nitrogen as well as one of the oxygen atoms of the invariant 
carboxylate on substrate. The metal-metal distance of this L1-product complex was reported to be 
3.68 Å, which was longer than the metal-metal distance in the resting enzyme (3.50 Å). This X-
ray crystallographic study was the first of its kind to show the orientation of substrate relative to 
the dinuclear Zn(II) center, and the conclusions from this study supported previous computational 
studies on L1 by the same group.[77] The metal-metal distances of L1-inhibitor complex crystals 
were not consistent and varied between 3.55 to 4.56 Å.[66, 91, 92]  
Previously, our lab used RFQ-EPR and –EXAFS to probe the metal binding site in L1 
during catalysis.[54, 55] Previous studies on L1 showed that the mononuclear Zn(II)-containing 
analog of L1, where Zn(II) is bound at the Zn1 site, did not stabilize a ring-opened, nitrogen anionic 
intermediate that formed when nitrocefin was used as substrate. Previous studies also showed that 
mononuclear Co(II)- and Fe(III)-containing L1 showed that these metal ions preferentially bind at 
the Zn2 site and that these analogs were catalytically-inactive.REF Spectroscopic studies showed 
that the heterobimetallic analog of L1 (ZnCo-L1) binds Zn(II) at the Zn1 site and Co(II) at the Zn2 
site. RFQ-EPR studies on ZnCo-L1 suggested that Co(II) is five-coordinate in the resting state, 
proceeds through a four-coordinate species during the reaction, and is five-coordinate in the 
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enzyme-product complex. RFQ-EXAFS studies on L1 revealed interesting facts about the role of 
the metal center.[54] Breece et al. observed an increase in the metal-metal distance in the sample 
of L1 reacted with nitrocefin and quenched at 10 ms, compared to that in the resting and product-
bound forms of the enzyme. Unlike in the results using RFQ-EPR, the analysis of the EXAFS data 
suggested the average coordination number of the metals remained unchanged throughout the 
reaction.[54, 85] The analysis of the EXAFS data on the L1-product complex revealed an 
improved fit residual when a Zn-sulfur interaction was included in the fit.[54] This result strongly 
suggested that there is a rotation around the C6-C7 bond in product, which positioned the ring 
sulfur in product in contact with one of the metal ions in the active site. However, the ZnZn-L1 
analog was used in this study, and it was not possible to unambiguously probe the role of each 
metal ion site during catalysis. In addition, the enzyme-product complex was prepared by 
incubating substrate with enzyme and freezing the sample. With this study, it was not possible to 
determine if the enzyme-product complex was catalytically-competent (i.e., if the rotated product 
was produced when the product was in the active site or if the product released, rotated, and 
rebound in the conformation suggested by the EXAFS data). With previous X-ray crystallographic 
and spectroscopic studies on L1, it was also not possible to determine the orientation of substrate 
in the active site (i.e. whether the -lactam carbonyl oxygen bind to Zn1 or Zn2), although the 
structure of L1 bound to hydrolyzed moxalactam suggested that the -lactam binds at or near the 
Zn1 site. In chapter 4 studies are presented that used RFQ-EXAFS and the ZnCo-analog of L1 
when reacted with chromacef.  The RFQ-EXAFS results were used to revise a reaction mechanism 
for L1 that was previously offered.[55]  
 
1.6. Hairpin loop in MBLs 
The crystal structures of several B1 and B3 MBLs identified a position-conserved loop that 
extends over the metal binding site,[93-97] and similar loops have been observed in other enzymes 
belonging to the -lactamase fold superfamily, suggesting a common role for these loops.[98-100] 
Crystal structures of MBL-inhibitor complexes showed decreased flexibility and reorientation of 
the loop towards the metal center upon inhibitor binding.[93-96, 101-104] NMR studies indicated 
that Trp49 on the hairpin loop in CcrA may play a role in inhibitor binding, suggesting that Trp49 
and the loop plays a role in promotion of catalysis.[105, 106] These results were supported by 
mutagenesis studies in which mutations of Trp to other amino acids resulted in over 50-fold 
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decreases in kcat/Km (depending on the identity of the residue that replaced Trp49).[106] Deletion 
of residues 47-49 induced an almost 100-fold decrease in kcat/Km for CcrA [106] and deletion of 
the entire loop led to a reduction of kcat/Km by factors of up to 5,000.[107] It should be noted, 
however, that Trp49 is not conserved across the MBLs. Studies of IMP-1 and BcII variants 
containing deletions or substitutions in the loop region identified altered kinetic parameters. The 
work on IMP-1 suggested that Trp64 plays a role in substrate binding by interacting with 
hydrophobic portions of the substrate,[106, 108] thus extending the mechanistic importance of the 
loop beyond CcrA.  It was speculated, however, that enzyme molecules from which the loop was 
deleted may have altered folding, and caution should be exercised when interpreting the data in 
terms of a structure-function relationship.[108] Vila speculated that the differences in reaction 
mechanisms indicated for BcII relative to other B1 and B3 MBLs may be due to a comparatively 
smaller loop over the BcII active site.[109] 
 The B2 enzymes have an -helix in the same position as the hairpin loop in the B1 and B3 
enzymes, yet this helix appears to have the same function.[110, 111] The helix in the resting state 
of the B2 ML CphA was structurally characterized by X-ray diffraction, but mechanistic data are 
lacking. An earlier EPR spectrokinetic study of the related enzyme ImiS identified rotation of the 
helix about its axis during the catalytic cycle.[111] The available data suggest that the loop in B1 
and B3 MBLs, as well as the position-conserved α-helix in B2 MBLs, play a role in substrate 
binding and catalysis.  
1.6.1. L1 DEER. In studies described in chapter 5, we proposed to use double electron-
electron resonance (pELDOR or "DEER") spectroscopy to investigate the dynamics of the hairpin 
loop in L1 during substrate binding (Figure 1.7). We chose L1 because it was the best studied 
enzyme in our lab, and we had extensive experience in preparing and characterizing site-directed 
mutants of L1. In addition, previous stopped-flow fluorescence studies in the lab suggested a rate-
limiting movement of the loop during catalysis.[81] After preparing and characterizing several 
site-directed mutants of L1 with site-specific spin labels (one on the hairpin loop and one on an 
alpha helix roughly 25 A away), we found only one doubly spin-labeled mutant that retained the 
correct metal binding and steady-state kinetic constants. We used DEER spectroscopy to 
characterize this mutant. We obtained distance domain spectra that had peaks corresponding to the 
desired intramolecular spin interaction and additional peaks corresponding to intermolecular spin 
interactions between the subunits in tetrameric L1. To solve this problem, we developed a "spin-
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dilution" technique in which we unfolded the double mutant and mixed it with 4 equivalents of 
wild-type L1. The unfolded mixture was refolded, and DEER spectra demonstrated that a 
tetrameric protein with only one subunit spin labeled could be prepared.  
1.6.2. CcrA DEER. MBL CcrA is produced by B. fragilis, which is one of the most 
important anaerobic pathogens in humans and is manifested under conditions such as 
immunosuppression, appendicitis, or malignancy.[112] This organism is resistant to many 
antibiotics due to the presence of lipopolysaccharide layer and the absence of nonspecific channels 
and porins.[112-114] CcrA has been cloned, over-expressed, and characterized by kinetic, 
crystallographic, and spectroscopic studies.[60, 115-119]  CcrA belongs to the B1 class of MBLs, 
and the enzyme exists as a monomer of ca. 26 KDa in the solution and in the crystalline state. 
CcrA contains a hairpin loop, which extends over the active site, much like L1 (Figure 1.8). 
Previous NMR studies on CcrA demonstrated that the hairpin loop in CcrA is dynamic,[105, 106]  
and mutagenesis studies have demonstrated an important catalytic role of this loop.[106, 107] 
These studies lead Dyson and coworkers to hypothesis that the hairpin loop in CcrA is involved in 
 
Figure 1.7. Crystal structure of the tetrameric form (left) and monomeric form (right) of L1. 
Metal ions are labeled in red, the hairpin loop is labeled in blue, and residues chosen for site- 
directed spin labeling are indicated in the picture as T163 and K286 (PDB ID: 1SML). 
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the "promotion of catalysis," possibly by raising the ground state energy of substrate (or ES) and 
lowering the activation barrier for the reaction.  
In chapter 6, we describe the role of the hairpin loop in CcrA, which exists as a monomer 
in solution. RFQ-DEER studies were used to probe three separate doubly spin-labeled mutants of 
CcrA. These 
mutants had one 
spin label on the 
hairpin loop and 
another spin 
label on α-
helices roughly 
25-30 Å away 
from the loop 
(Figure 1.8). 
This study 
demonstrated 
that the loop in 
CcrA does 
move over the 
active site and 
that this motion 
occurs on the millisecond timescale. 
 1.6.3. NDM-1 DEER. New Delhi Metallo-β-lactamase (NDM-1) was first discovered in 
Klebsiella and Escherichia coli cultured from a Sweden patient[120], and NDM-1 is considered 
one of the three most dangerous carbapenamases. Bacteria containing NDM-1 are not susceptible 
to any regular antibiotic, except colistin and tigecyclin. To date 16 variants of NDM have been 
identified and isolated on all continents except Central and South America and Antarctica.[36, 
121] A few groups reported over-expression and purification methods; considerable efforts also 
have been made to kinetically, structurally and spectroscopically characterize the enzyme.[122-
128] 
Figure 1.8. Crystal structure of CcrA, indicating the residues chosen for 
spin labelling. W49 on the hairpin loop and N82, D126, and E233 on 3 
different α-helices (PDB ID: 2BMI). 
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Previous crystallographic studies have shown that NDM-1 belongs to the B1 class and 
binds to two 2 Zn(II) ions in the active site. NDM-1 contains hairpin loop (Figure 1.9), which 
extends over the 
active site. Previous 
studies suggested that 
the hairpin loop in 
NDM-1 appears to be 
more flexible than the 
loops in other MBLs. 
This increased 
flexibility may 
explain the extended 
spectrum of activity 
exhibited by NDM-
1.[123] In chapter 7, 
we used RFQ-DEER 
to examine the 
dynamics of the 
hairpin loop during 
substrate binding. 
Our work shows that the residues chosen for spin labeling are very mobile, resulting in broad 
DEER spectra. Nonetheless, we were able to demonstrate movement of the loop over the active 
site during catalysis.       
 
1.7. Sections of dissertation 
 This dissertation contains two major themes. The first part (chapters 2, 3, and 4) describes 
kinetic, crystallographic, and spectroscopic characterization of recombinant and metal substituted 
analogues of MBLs. It also describes the investigation of the catalytic mechanisms of several 
MBLs (NDM-1, BcII, SfhI, GOB18, and L1). The second part (chapters 5, 6, and 7) describes the 
role of the hairpin loop in several MBLs (L1, CcrA, and NDM-1) during substrate binding. 
 
Figure 1.9. Crystal structure of NDM-1, indicating the residues chosen 
for spin labeling. Gly69 on the hairpin loop and Ala 235 on the α-helix 
(PDB ID: 3ZR9). 
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 Chapter 2 describes the preparation and characterization of Co(II)-substituted VIM-2. The 
highest resolution crystal structure of VIM-2 is reported (at 1.55 Å), and several spectroscopic 
techniques (UV-vis, NMR, EPR and EXAFS) were used to interrogate the metal binding sites of 
this enzyme. This chapter has been published in Biochemistry. 
 Chapter 3 describes the use of XAS to several different MBLs and MBL analogs. The metal 
centers of MBL NDM-1 and three heterobimetallic analogs (ZnCo, CoCo, and CoCd) of NDM-1 
were evaluated with EXAFS. The fidelities of the heterobimetallic analogs were verified using 
EXAFS spectroscopy. The catalytic mechanisms of three distinct MBLs (BcII, SfhI, and GOB18) 
were studied using RFQ-EXAFS. EXAFS data of the recombinant ZnZn-analog of NDM-1 were 
published in Biochemistry. EXAFS results on the heterobimetallic forms of NDM-1 were 
published in J. Am. Chem. Soc. Results on BcII, SfhI, and GOB18 will be included in a paper that 
will be submitted later this year. 
 Chapter 4 describes RFQ-EXAFS studies on the ZnCo-analog of L1. These results were 
used to revise a previous reaction mechanism for L1, which was based on RFQ-EPR and 
crystallographic studies. This chapter will be submitted for publication later this year. 
 Chapter 5 described a technique to remove intermolecular spin couplings from a 
multimeric protein. DEER spectroscopy was used to demonstrate the loss of the intermolecular 
couplings. This chapter was published in J. Inorg. Biochem. 
 Chapter 6 describes the first, to the best of our knowledge, use of RFQ-DEER to probe 
motions in a protein during catalysis. The hairpin loop in CcrA was site-specifically spin labeled, 
and several doubly-spin labeled mutants of CcrA were prepared and characterized. This technique 
demonstrated loop motions in CcrA occur on the millisecond time scale. This chapter was 
published in J. Biol. Inorg. Chem. 
 Chapter 7 describes the use of RFQ-DEER to probe the motion of the hairpin loop in NDM-
1 during substrate binding. Reactions were freeze-quenched as fast as 500 sec, and the data, while 
not optimized, demonstrate a movement of the loop over the active site during catalysis. This 
chapter has been submitted to the J. Inorg. Biochem. 
 Chapter 8 describes the conclusions of the work in this dissertation and future directions. 
 
 
 
19 
 
1.7. References 
1 K. J. Williams (2009) J R Soc Med 102:343-348 
2 R. I. Aminov (2010) Front Microbiol 1:134 
3 R. J. Henry (1943) Bacteriol Rev 7:175-262 
4 A. Fleming (1929) Br J Exp Pathol 10:226-236 
5 M. Rodriguez-Saiz, B. Diez and J. L. Barredo (2005) Fungal Genet Biol 42:464-470 
6 M. H. Dawson, G. L. Hobby, K. Meyer and E. Chaffee (1943) Ann Intern Med 19:707-717 
7 E. Chain, H. W. Florey, M. B. Adelaide, A. D. Gardner, N. G. Heatley, M. A. Jennings, J. 
Orr-Ewing and A. G. Sanders (1993) Clin Orthop Relat Res:3-7 
8 F. Jacobs (1985) Breakthrough: The true story of penicillin. Dodd, Mead & Company, New 
York,  
9 C. Goffin and J. M. Ghuysen (1998) Microbiol Mol Biol Rev 62:1079-1093 
10 E. Sauvage, F. Kerff, M. Terrak, J. A. Ayala and P. Charlier (2008) FEMS Microbiol Rev 
32:234-258 
11 C. Walsh (2000) Nature 406:775-781 
12 H. Yang, M. Aitha, A. R. Marts, A. Hetrick, B. Bennett, M. W. Crowder and D. L. Tierney 
(2014) J Am Chem Soc 136:7273-7285 
13 L. K. McDougal, C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister and F. 
C. Tenover (2003) J Clin Microbiol 41:5113-5120 
14 M. W. Crowder, J. Spencer and A. J. Vila (2006) Acc Chem Res 39:721-728 
15 J. Pogliano, N. Pogliano and J. A. Silverman (2012) J Bacteriol 194:4494-4504 
16 K. Lewis (2013) Nat Rev Drug Discov 12:371-387 
17 A. C. Haagsma, R. Abdillahi-Ibrahim, M. J. Wagner, K. Krab, K. Vergauwen, J. 
Guillemont, K. Andries, H. Lill, A. Koul and D. Bald (2009) Antimicrob Agents 
Chemother 53:1290-1292 
18 G. G. Zhanel, C. D. Lawson, H. Adam, F. Schweizer, S. Zelenitsky, P. R. Lagace-Wiens, 
A. Denisuik, E. Rubinstein, A. S. Gin, D. J. Hoban, J. P. Lynch, 3rd and J. A. Karlowsky 
(2013) Drugs 73:159-177 
19 J. O'Neill (2014) Review on Antimicrobial Resistance. AMA report by United Kingdom.  
20 Eurosurveillance editorial team (2013) Antibiotic resistance threats in the united states, 
2013. Eurosurveillance, CDC. 
20 
 
21 Infectious Diseases Society of America (2010) Clin Infect Dis 50:1081-1083 
 
22 GSK press release (2013). GlaxoSmithKline, London UK and Philadelphia, PA,  
23 A. Brisson-Noel, P. Trieu-Cuot and P. Courvalin (1988) J Antimicrob Chemother 22:13-
23 
24 M. Aitha, A. R. Marts, A. Bergstrom, A. J. Moller, L. Moritz, L. Turner, J. C. Nix, R. A. 
Bonomo, R. C. Page, D. L. Tierney and M. W. Crowder (2014) Biochemistry 53:7321-
7331 
25 D. Fourmy, M. I. Recht, S. C. Blanchard and J. D. Puglisi (1996) Science 274:1367-1371 
26 P. Kloss, L. Xiong, D. L. Shinabarger and A. S. Mankin (1999) J Mol Biol 294:93-101 
27 G. J. Anderson (2004) Emerging Infect Dis 10:1177-1177 
28 E. N. Powell, II (2000) Curr Surg 59:178-179 
29 K. Bush (2013) J Infect Chemother 19:549-559 
30 R. P. Ambler (1980) Philos Trans R Soc, B B 289:321-331 
31 S. M. Drawz and R. A. Bonomo (2010) Clin Microbiol Rev 23:160-201 
32 M. Fischer, Q. K. Thai, M. Grieb and J. Pleiss (2006) BMC Bioinf 7:495 
33 D. E. Ehmann, H. Jahic, P. L. Ross, R. F. Gu, J. Hu, T. F. Durand-Reville, S. Lahiri, J. 
Thresher, S. Livchak, N. Gao, T. Palmer, G. K. Walkup and S. L. Fisher (2013) J Biol 
Chem 288:27960-27971 
34 L. Lauretti, M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana and G. 
M. Rossolini (1999) Antimicrob Agents Chemother 43:1584-1590 
35 L. Poirel, T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo and P. Nordmann (2000) 
Antimicrob Agents  Chemother 44:891-897 
36 K. Bush, T. Palzikill, G. Jacoby. http://www.lahey.org/studies/other.asp#table1.Jürgen 
Pleiss  
37 I. Frasson, M. A. Biasolo, A. Bartolini, A. Cavallaro, S. N. Richter and G. Palu (2013) Int 
J Antimicrob Agents 42:68-71 
38 G. Cornaglia, H. Giamarellou and G. M. Rossolini (2011) Lancet Infect Dis 11:381-393 
39 J. J. Yan, P. R. Hsueh, W. C. Ko, K. T. Luh, S. H. Tsai, H. M. Wu and J. J. Wu (2001) 
Antimicrob Agents Chemother 45:2224-2228 
40 A. Mavroidi, A. Tsakris, E. Tzelepi, S. Pournaras, V. Loukova and L. S. Tzouvelekis 
(2000) J Antimicrob Chemother 46:1041-1042 
21 
 
41 L. Pallecchi, M. L. Riccio, J. D. Docquier, R. Fontana and G. M. Rossolini (2001) FEMS 
Microbiol Lett 195:145-150 
42 K. Lolans, A. M. Queenan, K. Bush, A. Sahud and J. P. Quinn (2005) Antimicrob Agents 
Chemother 49:3538-3540 
43 Y. S. Yu, T. T. Qu, J. Y. Zhou, J. Wang, H. Y. Li and T. R. Walsh (2006) J Clin Microbiol 
44:4242-4245 
44 W. Duljasz, M. Gniadkowski, S. Sitter, A. Wojna and C. Jebelean (2009) Antimicrob 
Agents Chemother 53:2221-2222 
45 S. Pournaras, M. Maniati, E. Petinaki, L. S. Tzouvelekis, A. Tsakris, N. J. Legakis and A. 
N. Maniatis (2003) J Antimicrob Chemother 51:1409-1414 
46 O. Cardoso, A. F. Alves and R. Leitao (2008) Int J Antimicrob Agents 31:375-379 
47 M. Castanheira, J. M. Bell, J. D. Turnidge, D. Mathai and R. N. Jones (2009) Antimicrob 
Agents Chemother 53:1225-1227 
48 Y. Yamaguchi, W. Jin, K. Matsunaga, S. Ikemizu, Y. Yamagata, J. I. Wachino, N. Shibata, 
Y. Arakawa and H. Kurosaki (2007) J Med Chem 50:6647-6653 
49 I. Garcia-Saez, J. D. Docquier, G. M. Rossolini and O. Dideberg (2008) J Mol Biol 
375:604-611 
50 G. L. Daikos, P. Petrikkos, M. Psichogiou, C. Kosmidis, E. Vryonis, A. Skoutelis, K. 
Georgousi, L. S. Tzouvelekis, P. T. Tassios, C. Bamia and G. Petrikkos (2009) Antimicrob 
Agents Chemother 53:1868-1873 
51 J. D. Docquier, J. Lamotte-Brasseur, M. Galleni, G. Amicosante, J. M. Frere and G. M. 
Rossolini (2003) J Antimicrob Chemother 51:257-266 
52 W. Humphrey, A. Dalke and K. Schulten (1996) J Mol Graphics 14:33-38 
53 S. D. B. Scrofani, J. Chung, J. J. A. Huntley, S. J. Benkovic, P. E. Wright and H. J. Dyson 
(1999) Biochemistry 38:14507-14514 
54 R. M. Breece, Z. Hu, B. Bennett, M. W. Crowder and D. L. Tierney (2009) J Am Chem 
Soc 131:11642-11643 
55 Z. Hu, G. Periyannan, B. Bennett and M. W. Crowder (2008) J Am Chem Soc 130:14207-
14216 
56 R. A. Scott (1985) Methods Enzymol 117:414-459 
57 D. L. Tierney and G. Schenk (2014) Biophys J 107:1263-1272 
22 
 
58 D. H. Griffin, T. K. Richmond, C. Sanchez, A. J. Moller, R. M. Breece, D. L. Tierney, B. 
Bennett and M. W. Crowder (2011) Biochemistry 50:9125-9134 
59 H. Yang, M. Aitha, A. M. Hetrick, T. K. Richmond, D. L. Tierney and M. W. Crowder 
(2012) Biochemistry 51:3839-3847 
60 G. R. Periyannan, A. L. Costello, D. L. Tierney, K. W. Yang, B. Bennett and M. W. 
Crowder (2006) Biochemistry 45:1313-1320 
61 M. J. Hawk, R. M. Breece, C. E. Hajdin, K. M. Bender, Z. X. Hu, A. L. Costello, B. 
Bennett, D. L. Tierney and M. W. Crowder (2009) J Am Chem Soc 131:10753-10762 
62 R. M. Breece, L. I. Llarrull, M. F. Tioni, A. J. Vila and D. L. Tierney (2012) J Inorg 
Biochem 111:182-186 
63 Z. Hu, L. J. Spadafora, C. E. Hajdin, B. Bennett and M. W. Crowder (2009) Biochemistry 
48:2981-2989 
64 J. Moran-Barrio, J. M. Gonzalez, M. N. Lisa, A. L. Costello, M. D. Peraro, P. Carloni, B. 
Bennett, D. L. Tierney, A. S. Limansky, A. M. Viale and A. J. Vila (2007) J Biol Chem 
282:18286-18293 
65 Z. Hu, G. R. Periyannan and M. W. Crowder (2008) Anal Biochem 378:177-183 
66 J. D. Garrity, B. Bennett and M. W. Crowder (2005) Biochemistry 44:1078-1087 
67 N. P. Sharma, C. Hajdin, S. Chandrasekar, B. Bennett, K. W. Yang and M. W. Crowder 
(2006) Biochemistry 45:10729-10738 
68 H. Yang, M. Aitha, A. R. Marts, A. M. Hetrick, B. Bennett, M. W. Crowder and D. L. 
Tierney (2014) J Am Chem Soc 136:7273-7285 
69 H. Yang, M. Aitha, A. R. Marts, A. Hetrick, B. Bennett, M. W. Crowder and D. L. Tierney 
(2014) J Am Chem Soc 136:7273-7285 
70 M. Aitha, A. R. Marts, A. Bergstrom, A. J. Moller, L. Moritz, L. Turner, J. C. Nix, R. A. 
Bonomo, R. C. Page, D. L. Tierney and M. W. Crowder (2014) Biochemistry 53:7321-
7331 
71 Y. Saino, F. Kobayashi, M. Inoue and S. Mitsuhashi (1982) Antimicrob Agents Chemother 
22:564-570 
72 N. Khardori, L. Elting, E. Wong, B. Schable and G. P. Bodey (1990) Rev Infect Dis 12:997-
1003 
73 W. J. Smit, A. L. Boquest, J. E. Geddes and F. A. Tosolini (1994) Pathology 26:321-324 
23 
 
74 E. Charpentier and P. Courvalin (1999) Antimicrob Agents Chemother 43:2103-2108 
75 L. Zhang, X. Z. Li and K. Poole (2000) Antimicrob Agents Chemother 44:287-293 
76 M. W. Crowder, T. R. Walsh, L. Banovic, M. Pettit and J. Spencer (1998) Antimicrob 
Agents Chemother 42:921-926 
77 J. H. Ullah, T. R. Walsh, I. A. Taylor, D. C. Emery, C. S. Verma, M. Galleni and J. Spencer 
(1998) J Mol Biol 284:125-136 
78 J. Spencer, J. Read, R. B. Sessions, S. Howell, G. M. Blackburn and S. J. Gamblin (2005) 
J Am Chem Soc 127:14439-14444 
79 S. McManus-Munoz and M. W. Crowder (1999) Biochemistry 38:1547-1553 
80 M. W. Crowder, K. W. Yang, A. L. Carenbauer, G. Periyannan, M. E. Seifert, N. E. Rude 
and T. R. Walsh (2001) J Biol InorgChem 6:91-99 
81 J. D. Garrity, J. M. Pauff and M. W. Crowder (2004) J Biol Chem 279:39663-39670 
82 J. D. Garrity, A. L. Carenbauer, L. R. Herron and M. W. Crowder (2004) J Biol Chem 
279:920-927 
83 J. Spencer, A. R. Clarke and T. R. Walsh (2001) J Biol Chem 276:33638-33644 
84 G. Periyannan, P. J. Shaw, T. Sigdel and M. W. Crowder (2004) Protein Sci 13:2236-2243 
85 A. Costello, G. Periyannan, K. W. Yang, M. W. Crowder and D. L. Tierney (2006) J Biol 
Inorg Chem 11:351-358 
86 A. L. Carenbauer, J. D. Garrity, G. Periyannan, R. B. Yates and M. W. Crowder (2002) 
BMC Biochem 3:4-9 
87 Z. Hu, T. S. Gunasekera, L. Spadafora, B. Bennett and M. W. Crowder (2008) 
Biochemistry 47:7947-7953 
88 M. Aitha, T. K. Richmond, Z. Hu, A. Hetrick, R. Reese, A. Gunther, R. McCarrick, B. 
Bennett and M. W. Crowder (2014) J Inorg Biochem 136C:40-46 
89 M. Aitha, T. K. Richmond, Z. Hu, A. Hetrick, R. Reese, A. Gunther, R. McCarrick, B. 
Bennett and M. W. Crowder (2014) J Inorg Biochem 136C:40-46 
90 D. Xu, H. Guo and Q. Cui (2007) J Am Chem Soc 129:10814-10822 
91 L. Nauton, R. Kahn, G. Garau, J. F. Hernandez and O. Dideberg (2008) J Mol Biol 
375:257-269 
24 
 
92 B. M. Lienard, G. Garau, L. Horsfall, A. I. Karsisiotis, C. Damblon, P. Lassaux, C. 
Papamicael, G. C. Roberts, M. Galleni, O. Dideberg, J. M. Frere and C. J. Schofield (2008) 
Org Biomol Chem 6:2282-2294 
93 N. O. Concha, C. A. Janson, P. Rowling, S. Pearson, C. A. Cheever, B. P. Clarke, C. Lewis, 
M. Galleni, J. M. Frere, D. J. Payne, J. H. Bateson and S. S. Abdel-Meguid (2000) 
Biochemistry 39:4288-4298 
94 C. Mollard, C. Moali, C. Papamicael, C. Damblon, S. Vessilier, G. Amicosante, C. J. 
Schofield, M. Galleni, J. M. Frere and G. C. K. Roberts (2001) J Biol Chem 276:45015-
45023 
95 S. D. Scrofani, J. Chung, J. J. Huntley, S. J. Benkovic, P. E. Wright and H. J. Dyson (1999) 
Biochemistry 38:14507-14514 
96 J. H. Toney, P. M. Fitzgerald, N. Grover-Sharma, S. H. Olson, W. J. May, J. G. Sundelof, 
D. E. Vanderwall, K. A. Cleary, S. K. Grant, J. K. Wu, J. W. Kozarich, D. L. Pompliano 
and G. G. Hammond (1998) Chemistry & Biology 5:185-196 
97 J. H. Ullah, T. R. Walsh, I. A. Taylor, D. C. Emery, C. S. Verma, S. J. Gamblin and J. 
Spencer (1998) J Mol Biol 284:125-136 
98 A. D. Cameron, M. Ridderstrom, B. Olin and B. Mannervik (1999) Structure 7:1067-1078 
99 I. L. de la Sierra-Gallay, O. Pellegrini and C. Condon (2005) Nature 433:657-661 
100 G. P. K. Marasinghe, I. M. Sander, B. Bennett, G. Periyannan, K. W. Yang, C. A. Makaroff 
and M. W. Crowder (2005) J Biol Chem 280:40668-40675 
101 P. M. D. Fitzgerald, J. K. Wu and J. H. Toney (1998) Biochemistry 37:6791-6800 
102 D. T. King and N. C. Strynadka (2013) Future Med Chem 5:1243-1263 
103 T. Palzkill (2013) Ann N Y Acad Sci 1277:91-104 
104 J. F. Wang and K. C. Chou (2013) Curr Topics Med Chem 13:1242-1253 
105 J. J. A. Huntley, S. D. B. Scrofani, M. J. Osborne, P. E. Wright and H. J. Dyson (2000) 
Biochemistry 39:13356-13364 
106 J. J. A. Huntley, W. Fast, S. J. Benkovic, P. E. Wright and H. J. Dyson (2003) Protein Sci 
12:1368-1375 
107 Y. Yang, D. Keeney, X. J. Tang, N. Canfield and B. A. Rasmussen (1999) Journal of 
Biological Chemistry 274:15706-15711 
25 
 
108 C. Moali, C. Anne, J. Lamotte-Brasseur, S. Groslambert, B. Devreese, J. Van Beeumen, 
M. Galleni and J. M. Frere (2003) Chem Biol 10:319-329 
109 M. Dal Peraro, A. J. Vila and P. Carloni (2002) J Biol Inorg Chem 7:704-712 
110 G. Garau, C. Bebrone, C. Anne, M. Galleni, J. M. Frere and O. Dideberg (2005) J Mol Biol 
345:785-795 
111 N. Sharma, Z. Hu, M. W. Crowder and B. Bennett (2008) J Am Chem Soc 130:8215-8222 
112 D. J. Payne (1993) J Med Microbiol 39:93-99 
113 K. Coleman, M. Athalye, A. Clancey, M. Davison, D. J. Payne, C. R. Perry and I. Chopra 
(1994) J Antimicrob Chemother 33:1091-1116 
114 G. J. Cuchural, Jr., M. H. Malamy and F. P. Tally (1986) Antimicrob Agents Chemother 
30:645-648 
115 S. D. B. Scrofani, J. Chung, J. J. A. Huntley, S. J. Benkovic, P. E. Wright and H. J. Dyson 
(1999) Biochemistry 38:14507-14514 
116 Z. G. Wang and S. J. Benkovic (1998) J Biol Chem 273:22402-22408 
117 Y. Yang, D. Keeney, X. J. Tang, N. Canfield and B. A. Rasmussen (1999) J Biol Chem 
274:15706-15711 
118 M. P. Yanchak, R. A. Taylor and M. W. Crowder (2000) Biochemistry 39:11330-11339 
119 Z. Wang, W. Fast and S. J. Benkovic (1999) Biochemistry 38:10013-10023 
120 K. K. Kumarasamy, M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. 
Chaudhary, M. Doumith, C. G. Giske, S. Irfan, P. Krishnan, A. V. Kumar, S. Maharjan, S. 
Mushtaq, T. Noorie, D. L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J. B. 
Sarma, M. Sharma, E. Sheridan, M. A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, 
W. Welfare, D. M. Livermore and N. Woodford (2010) Lancet Infect Dis 10:597-602 
121 P. Nordmann, L. Poirel, T. R. Walsh and D. M. Livermore (2011) Trends Microbiol 
19:588-595 
122 V. L. Green, A. Verma, R. J. Owens, S. E. Phillips and S. B. Carr (2011) Acta Crystallogr, 
Sect F: Struct Biol Cryst Commun 67:1160-1164 
123 Y. Kim, C. Tesar, J. Mire, R. Jedrzejczak, A. Binkowski, G. Babnigg, J. Sacchettini and 
A. Joachimiak (2011) PLoS One 6:e24621 
124 D. King and N. Strynadka (2011) Protein Sci 20:1484-1491 
125 H. Zhang and Q. Hao (2011) FASEB J 25:2574-2582 
26 
 
126 Y. Guo, J. Wang, G. Niu, W. Shui, Y. Sun, H. Zhou, Y. Zhang, C. Yang, Z. Lou and Z. 
Rao (2011) Protein & cell 2:384-394 
127 D. T. King, L. J. Worrall, R. Gruninger and N. C. Strynadka (2012) J Am Chem Soc 
134:11362-11365 
128 H. Feng, J. Ding, D. Zhu, X. Liu, X. Xu, Y. Zhang, S. Zang, D. C. Wang and W. Liu (2014) 
J Am Chem Soc 136:14694-14697 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
27 
 
Chapter 2 
 
 
 
 
 
 
 
 
 
 
Biochemical, mechanistic, and spectroscopic characterization of 
 
metallo--lactamase VIM-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Biochemical, mechanistic, and spectroscopic characterization of 
 
metallo--lactamase VIM-2 
 
 
Mahesh Aitha†, Amy R. Marts†, Alex Bergstrom†, Abraham Jon Moller†, Lindsay Moritz†, Lucien 
Turner†, Jay C. Nix‡, Robert A. Bonomo§,¶, Richard C. Page†, David L. Tierney†, and Michael W. 
Crowder*,†. 
 
†Department of Chemistry and Biochemistry, Miami University, 650 East High Street, Oxford, 
Ohio 45056, USA 
‡Molecular Biology Consortium, Beamline 4.2.2, Advanced Light Source, Lawrence Berkeley 
National Laboratory, Berkeley, California 94720, USA 
§ Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 
East Boulevard, Cleveland, Ohio 44106, United States 
¶Department of Medicine, Pharmacology, and Molecular Biology and Microbiology, Case 
Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106, United States 
 
*Corresponding author: Michael W. Crowder 
Phone: (513) 529-7274; Fax: (513) 529-5715; e-mail: crowdemw@MiamiOH.edu 
 
 
Contributions to the chapter. Alex Bergstrom, Lindsay Mortiz, and Lucien Turner helped with 
the protein preparations. Jay Nix and Richard Page helped to collect and analyze the crystal 
structure data. The rest of the samples preparation, data collection, and data analysis performed by 
Mahesh Aitha under the supervision of David Tierney and Michael Crowder. This chapter was 
written by Mahesh Aitha and edited by Michael Crowder. 
 
This paper appeared in Biochemistry 53, 7321-7331. Reprinted (adapted) with permission from 
the American Chemical Society, Copyrights 2014. 
 
 
29 
 
2.1. Abstract 
This study examines metal binding to metallo--lactamase VIM-2, demonstrating the first 
successful preparation of a Co(II)-substituted VIM-2 analog. Spectroscopic studies of the half and 
fully metal loaded enzymes show that both Zn(II) and Co(II) bind cooperatively, where the major 
species present, regardless of stoichiometry, are apo- and di-Zn (or di-Co) enzymes. We 
determined the di-Zn VIM-2 structure to a resolution of 1.55 Å, and this structure supports results 
from spectroscopic studies. Kinetics, both steady-state and pre-steady-state, show that VIM-2 
utilizes a mechanism that proceeds through a very short-lived anionic intermediate. Comparison 
with other B1 enzymes shows that those that bind Zn(II) cooperatively are better poised to 
protonate the intermediate on its formation, compared to those that bind Zn(II) non-cooperatively, 
which uniformly build up substantial amounts of the intermediate.  
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2.2. Introduction 
According to the 2013 Antibiotic Resistance Threat Report, more than 2 million people in 
the U.S. were infected with an antibiotic-resistant bacterial infection, and more than 23,000 of 
these patients died.[1] During the last decade, the incidence of carbapenemase-producing 
Enterobacteriaceae and Klebsiella pneumoniae has increased, and death rates associated with 
MBL producers range from 18 to 67%.[2] MBL-producing bacteria that exhibited carbapenemase 
activity were first reported in 1990.[3] Since then the emergence of VIM-, IMP-, and NDM-type 
MBLs has been reported in many countries.[2] The activities of these MBLs are not inhibited by 
clavulanic acid or any other commercially available -lactamase inhibitors.[4] The IMiPenamase 
(IMP), Verona integrin-encoded (VIM), and New Delhi metallo--lactamase (NDM) enzymes are 
the most clinically-significant MBLs because they (and their derivatives) appear in bacterial strains 
that exhibit high mortality rates.[2] All three MBLs belong to the B1 subclass.[5] IMP was first 
identified in the early 1990’s in strains of Pseudomonas aeruginosa and Serratia marcescens in 
Japan,[3, 6] and currently includes 51 variants isolated in countries across the globe, on every 
continent except Africa and Antarctica.[7, 8] So far, 16 variants of NDM MBL have been isolated 
from 40 countries worldwide except Antarctica.[8, 9]  
VIM was first identified in a patient in Italy who was infected with Pseudomonas 
aeruginosa.[10, 11] To date, 46 variants of VIM have been identified,[8] and these variants exhibit 
74.3 to 99.6% sequence similarity.[12, 13] Among these VIM variants, VIM-2 appears to be the 
one most commonly found in the clinic, and VIM-2-expressing bacterial strains have been found 
in many countries.[14-23] IMP-1 and NDM-1 have been extensively studied biochemically, 
crystallographically, and spectroscopically.[24-27] In contrast, while there are 9 crystal structures 
of VIM variants available, including two of VIM-2 at 1.9 and 2.2 Å resolution,[28, 29] presently 
detailed kinetic/mechanistic or spectroscopic studies reported on any variant of VIM are not 
available. To address this deficit, we have investigated the kinetic mechanism of VIM-2 using 
stopped-flow kinetics. To further probe the structure of the VIM-2 active site, X-ray 
crystallographic and X-ray absorption fine structure (EXAFS) spectroscopic studies were 
performed on the native Zn(II)-containing enzyme. Co(II)-substituted VIM-2 was also prepared 
and characterized using UV-vis, electron paramagnetic resonance (EPR), and EXAFS 
spectroscopies. Results of these studies offer insights into metal binding by VIM-2, elucidate 
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emerging patterns in reactivity that track with metal-binding properties, and add to the current 
efforts in medicinal chemistry to design clinical inhibitors of this class. 
 
2.3. Methods 
Materials. pET24a vector was used clone blaVIM-2 , that was initially isolated from a clinical 
strain of Pseudomonas aeruginosa.[30] E. coli BL21(DE3) cells (Invitrogen) were used for protein 
over-expression. Lysogeny broth (LB) medium was purchased from Invitrogen (Carlsbad, CA), 
and minimal medium was prepared according to a previously-described procedure.[31] Isopropyl-
-D-thiogalactoside (IPTG) was purchased from Gold Biotechnology (St. Louis, MO). Q-
Sepharose (GE Healthcare) anion exchange and Sephacryl S-200 gel filtration (Amersham 
Biosciences AB, Uppasala, Sweden) columns were used to purify recombinant VIM-2. Purified 
protein solutions were pooled and concentrated with an Amicon ultrafiltration cell equipped with 
YM-10 DIAFLO membranes from Amicon, Inc. (Beverly, MA). Steady-state kinetics and pre-
steady state kinetics studies were conducted using chromacef (Sopharmia, Inc. (Missouri)).[26] 
Over-expression and purification of VIM-2 in LB and minimal media. Plasmid pet24a-
VIM-2 was transformed into BL21(DE3) E. coli cells, and the cell mixture was plated on LB-agar 
plates containing 25 g/ml kanamycin. A single colony was transferred into 50 ml of LB 
containing 25 g/ml kanamycin, and the culture was allowed to shake overnight at 37 oC. Ten 
milliters of the overnight culture were used to inoculate 4 X 1 L of LB containing 25 g/ml 
kanamycin, and the cultures were shaken at 200 rpm and 37 oC to an OD600nm of 0.6-0.8. Protein 
production was induced by making the cultures 0.5 mM in IPTG. The resulting cultures were 
allowed to shake for 3 h at 37 oC, and the cells were harvested by centrifugation for 10 min at 
7,000 rpm and 4 oC. The cell pellets were resuspended in 30 ml of 30 mM Tris, pH 7.6, containing 
500 mM NaCl. The cells were lysed by passing the suspension three times through a French press 
at a pressure of 1,000 psi. The mixture containing the lysed cells was centrifuged for 25 mins at 
15,000 rpm at 4 oC to remove insoluble components. The cleared solution was dialyzed versus 2 
L of 30 mM Tris, pH 7.6, overnight at 4 oC. After centrifugation for 25 min at 15,000 rpm, the 
cleared solution was loaded onto a Q-Sepharose column (1.5 cm X 20 cm with a 28 ml bed 
volume). Bound proteins were eluted with a linear gradient of 0-500 mM NaCl in 30 mM Tris, pH 
7.6.  
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Fractions containing VIM-2 were identified using SDS-PAGE, pooled, and then 
concentrated using an Amicon ultrafiltration concentrator equipped with a YM-10 membrane. The 
concentrated protein solution (ca. 3 ml) was loaded onto a Sephacryl S-200 gel filtration column 
(1.5 cm X 40 cm, bed volume of 60 ml), using 30 mM Tris, pH 7.6, containing 100 mM NaCl as 
the running buffer. The concentration of VIM-2 was determined using an extinction coefficient of 
28,500 M-1 cm-1 at 280 nm.[32] As-isolated enzyme contained 0.4 equivalents of Zn(II). To prepare 
more fully-load Zn(II) analogs of VIM-2, 0.6 or 1.6 equivalents of Zn(II) were added to purified 
VIM-2, and the resulting solutions were dialyzed versus 2 liters of Chelex-treated 50 mM Hepes, 
pH 6.8, for 16 hours.  
 VIM-2 was also over-expressed in minimal medium as previously described.[31, 33] The 
protein was purified as described above, except that Chelex-treated 50 mM Hepes, pH 6.8, was 
used as the buffer during the chromatography steps. One milliliter of 100 mM Co(II) was added to 
each 1 L flask at the time of induction.  
Preparation of Co(II)-substituted VIM-2. Metal analyses of purified VIM-2, which was 
over-expressed in minimal medium, revealed that the protein binds 0.5 equivalents of Co(II) and 
less than 0.1 equivalents of Zn(II). Co(II)-containing VIM-2 was concentrated to 1 mM using an  
Amicon concentrator equipped with a YM-10 membrane. Concentrated Co(II)-containing VIM-2  
was centrifuged at 14,000 rpm for 10 min to remove any precipitated protein. CoCl2 solution (0.5 
or 1.5 equivalents) was added, and the mixtures were incubated on the ice for 20 mins. The 
resulting solutions were dialyzed versus 2 liters of Chelex-treated 50 mM Hepes, pH 6.8, for 16 
hours, and the resulting enzyme was pink and remained pink for several months at 4 oC. UV-vis 
spectra were obtained on a Hewlett-Packard 5480A UV-vis spectrophotometer, at 25 oC. 
Difference spectra were generated by subtracting the spectrum of VIM-2 isolated from LB medium 
from the spectrum of Co(II)-substituted VIM-2.  
Metal Analyses. The metal content of the VIM-2 samples was determined using a Perkin-
Elmer Optima 7300V Inductively Coupled Plasma with Optical Emission Spectroscopy (ICP-
OES) spectrometer. Protein samples were diluted to 1 - 3 M with 50 mM Hepes, pH 6.8 or 7.6. 
Calibration curves were generated using serial dilutions of Fisher metal standards (Zn, Co, Fe, and 
Cu) ranging from 1.0 M to 8.0 M. Emission lines at 202.548, 228.616, 238.196 and 327.394 nm 
were chosen to ensure the lowest possible detection limits for zinc, cobalt, iron, and copper, 
respectively. 
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Steady-state kinetics. Steady-state kinetic studies were conducted on a Hewlett-Packard 
5480A UV-vis spectrophotometer at 25 οC for Zn(II) anologues and at 4 οC for Co(II) anologues . 
The hydrolysis of chromacef was monitored by formation of the hydrolyzed product at 442 nm, 
and absorbance data were converted to concentration data using an extinction coefficient of 18,600 
M-1cm-1.[26] The buffer used for the steady-state kinetic studies was 50 mM cacodylate, pH 7.0, 
and substrate concentrations ranging from 1 to 100 M were used in these studies. Rate vs. 
substrate concentration curves were fitted to the Michelis-Menton equation using Igor-Pro to 
determine KM and Vmax. 
Pre-steady state kinetics. Stopped-flow UV-vis studies were conducted using an Applied 
Photophysics SX 20 stopped-flow spectrophotometer, equipped with a photodiode array detector. 
Reactions of VIM-2 with chromacef were thermostated at 22 oC, and Chelex-treated, 50 mM 
cacodylate, pH 7.0, was 
used as the buffer. 
Reaction progress 
curves were generated 
by converting the 
absorbance data to 
concentration data 
using the following extinction coefficients: substrate ε378 = 22,000 M-1cm-1, product ε442 = 18,600 
M-1cm-1, and intermediate ε620 = 22,000 M-1cm-1.[26] Simulated progress curves were generated 
using a previously described MATLAB script,[24] derived for the reaction mechanisms shown in 
Scheme 1. Theoretical kcat and Km values were calculated using the King-Altman method,[34] 
assuming k2 or k3 as the rate-limiting step.[26] 
Crystallization and X-ray diffraction data collection. Crystallization trials were prepared 
in 96-well sitting drop Intelliplate vapor diffusion plates (Art Robbins Instruments). The 1.0 µl 
sitting drops consisted of a 1:1 ratio of 10 mg/ml VIM-2 and reservoir solution. Initial screening 
was carried out using the sparse matrix crystallization screens MCSG 1-4 (Microlytic). 
Optimization of initial hits from the sparse matrix screens identified a reservoir solution of 0.2 M 
ammonium acetate, 100 µM zinc chloride, 0.1 M Hepes, pH 7.5, and 25 % PEG 3350. Crystals of 
VIM-2 were cryoprotected by brief transfer through LV CryoOil (MiTeGen) and frozen in liquid 
Scheme 2.1.      
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nitrogen. X-ray diffraction data were collected at 1.0000 Å for a single VIM-2 crystal on beamline 
4.2.2 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory. 
Phases were calculated by molecular replacement using the PHASER[35] component of 
PHENIX[36] utilizing the structure of zinc-bound VIM-2[29] (accession code 1KO3) as the search 
model. The molecular replacement solution was subjected to iterative rounds of model building in 
Coot[37] and refinement in PHENIX.[36] All molecular structure figures were prepared with 
PyMOL.[38] Atomic coordinates and structure factors have been deposited in the PDB (accession 
code 4NQ2). Stereochemical and geometric analyses of the VIM-2 structure were conducted with 
MolProbity version 4.02b.[39] 
EXAFS spectroscopy. Samples for EXAFS (protein concentrations of approximately 1.5 
mM) were prepared with 20% (v/v) glycerol as a glassing agent. Samples were loaded in Lucite 
cuvettes with 6 m polypropylene windows and frozen rapidly in liquid nitrogen. Data were 
collected at the National Synchrotron Light Source (NSLS), beamline X3B, equipped with a Si 
(111) double-crystal monochromator. Harmonic rejection was accomplished using a Ni focusing 
mirror. Fluorescence excitation spectra for all samples were measured with a 31-element solid-
state Ge detector array. Samples were held at approximately 15 K in a Displex cryostat. EXAFS 
data collection and reduction were performed according to published procedures.[40] Data were 
measured in duplicate, 6 scans for zinc and 8 scans for cobalt each on two samples from 
independent purifications; fits to the two data sets were equivalent. As both data sets gave similar 
results, the data were averaged using EXAFSPAK (EXAFSPAK is available free of charge from 
http://www-ssrl.slac.stanford.edu/exafspak.html); the experimental spectra presented here are the 
averaged data sets (12 or 16 scans per sample). The data were converted from energy to k-space 
using E0 = 9,680 eV for Zn and E0 = 7,730 eV for Co.  
Fourier-filtered EXAFS data were fitted using the nonlinear least-squares engine of 
IFEFFIT, which is distributed with SixPack (SixPack is available free of charge from http://www-
ssrl.slac.stanford.edu/~swebb/sixpack.htm; IFEFFIT is open source software available from 
http://cars9.uchicago.edu/ifeffit/Ifeffit). Theoretical amplitude and phase functions were 
calculated with FEFF v. 8.00.[41] Zinc-nitrogen single-scattering and zinc-imidazole multiple-
scattering were calibrated to the experimental EXAFS of zinc tetrakis-1-methylimidazole Zn(II) 
perchlorate, [Zn(MeIm)4][ClO4]2. Zinc-sulfur scattering was calibrated to the experimental 
EXAFS spectrum of tetrabutylammonium zinc tetramesitylthiolate, [Bu4N]2[Zn(Smes)4]. 
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Optimum scale factors (Sc) and ∆E0 were derived from fits to the model data (Sc = 0.78 (Zn-N) or 
0.91 (Zn-S); ∆E0= -21 eV), and they were held fixed at these values for fits to metalloprotein data. 
The models used for the calibration of cobalt-nitrogen (and cobalt-imidazole) and cobalt-sulfur 
scattering were, respectively, hexakis-imidazole cobalt(II) perchlorate, [Co(Im)6][ClO4]2 and 
tetrabutylammonium cobalt(II) tetramesitylthiolate, [Bu4N]2[Co(Smes)4], respectively. The 
resulting Sc and ∆E0 (Sc = 0.79 (Co-N) or 0.85 (Co-S); E0 = -21 eV) were held fixed at these 
calibrated values in subsequent fits to metalloprotein data. First shell fits were then obtained for 
all reasonable coordination numbers, including mixed nitrogen/oxygen/sulfur ligation, while 
allowing the absorber-scatterer distance, Ras, and the Debye-Waller factor, σas2, to vary. Detailed 
summaries of the fitting results are presented in Supplementary Information. Multiple scattering 
contributions from histidine ligands were fitted according to published procedures.[40] Metal-
metal (zinc-zinc and cobalt-cobalt)  scattering were modeled with reference to the experimental 
EXAFS of Zn2 (salpn)2 and Co2 (salpn)2. 
EPR spectroscopy. Low temperature EPR spectra were obtained on a Bruker Elexsys EMX 
EPR spectrometer equipped with an Oxford Instruments liquid helium flow cryostat. The spectra 
in Figure 6 were recorded at 9.64 (B0⊥B1) or 9.38 GHz (B0‖B1) using a Bruker DM4116 dual-
mode cavity, with 10 G magnetic field modulation (100 kHz). Other parameters: time 
constant/conversion time = 42 ms, receiver gain = 1 X 105, average of 4 scans.  
 
2.3. Results 
Over-expression, purification, and characterization of VIM-2. Recombinant VIM-2 was 
over- expressed in LB medium and purified as described above (referred to as “as isolated (LB)” 
hereafter). VIM-2 eluted from a Q-Sepharose column between 150 – 250 mM NaCl, and the purity 
of the protein was shown to be > 90 % by SDS-PAGE. Gel filtration chromatography further 
increased the purity to > 95 %. The overall yield was 10 mg per liter of LB growth medium. VIM-
2 was also over-expressed in minimal medium in the presence of Co(II) and purified as described 
above (referred to as “as isolated (MM)” hereafter). The overall yield of VIM-2 after both columns 
was 5 mg per liter of minimal medium. The purified enzymes were shown to bind 0.4 + 0.1 
equivalents of Zn(II) (LB) or 0.5 + 0.1 Co(II) (minimal medium), and < 0.1 equivalents of any 
other metal ion. Metal analyses were not reported for preceding VIM-2 preparations.[14, 30, 32]  
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a Values in parentheses are 
for the highest resolution 
shell. b The merging R 
factor is defined as 
  
Rmerge =
I i hkl( ) - I hkl( )
i
å
hkl
å
I i hkl( )
i
å
hkl
å
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1. X-ray data collection and structure refinement. 
Psuedomonas aeruginosa VIM-2 
Data Collection 
Beam Line ALS 4.2.2 
Wavelength (Å) 1.0000 
Space group I222 
Cell dimensions 
a, b, c (Å) 68.3, 78.3, 79.8 
, ,  (°) 90, 90, 90 
Resolution (Å)a 55.87-1.55 (1.63-1.55) 
Rmerge
b 0.070 (0.447) 
<I/I> 16.9 (4.0) 
Wilson B factor (Å2) 15.17 
Completeness (%) 99.8 (99.2) 
Redundancy 7.2 (7.2) 
No. of reflections 228,457 
No. of unique reflections 32,317 
Refinement 
Resolution (Å) 55.87-1.55 
No. reflections for refinement 31,217 
Rwork/Rfree 0.176 / 0.209 
No. atoms 1,992 
Protein 1,714 
Water 267 
Zinc 3 
Acetate 8 
Average B factors 
Protein 22.4 
Water 33.8 
Zinc 20.2 
Acetate 20.4 
R.m.s deviations 
Bond lengths (Å) 0.007 
Bond angles (°) 1.049 
Ramachandran plot statistics 
Favored regions % (#) 97.4 (224/230) 
Allowed regions % (#) 100.0 (230/230) 
Disallowed regions 0.0 
MolProbity validation statistics 
C deviations >0.25Å 0 
MolProbity clash score 2.96 (99th percentile, N=730, 1.550Å ± 0.25Å) 
MolProbity score 1.21 (98th percentile, N=6,779, 1.550Å ± 0.25Å) 
PDB ID 4NQ2 
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Direct addition of Zn(II) or Co(II) to as-isolated VIM-2. To prepare VIM-2 analogs that 
contained 1 or 2 Zn(II) ions, 0.5 and 1.5 equivalents of Zn(II) were added to as isolated (LB) VIM-
2, , followed by overnight dialysis against Chelex-treated 30 mM Tris, pH 7.6. ICP-OES studies 
showed that the resulting enzymes bound 1.0 and 1.9 equivalents of Zn(II) (+ 0.1), respectively 
(referred to as “1Zn-VIM-2” and “2Zn-VIM-2” hereafter). 1Zn-VIM-2 demostrated a kcat of 10 + 
2 s-1 and a Km of 9 + 2 M, compared to a kcat of 22 + 2 s-1 and a Km of 8 + 2 M for 2Zn-VIM-2, 
when using chromacef as substrate (Table 2.2). Similarly, VIM-2 analogs containing 1 or 2 Co(II) 
ions were prepared by adding 0.5 and 1.5 equivalents of Co(II) to as isolated (MM) VIM-2, 
followed by overnight dialysis against 2 liters of Chelex-treated 50 mM HEPES, pH 6.8 (a slightly 
acidic pH was seen to help prevent oxidation of Co(II)). The resulting enzymes bound 0.8 and 1.8 
equivalents of Co(II), respectively (referred to as “1Co-VIM-2” and “2Co-VIM-2” hereafter). 
1Co-VIM-2 exhibited a kcat of 6 + 1 s
-1 and a Km of 5 + 2 M, while 2Co-VIM-2 showed a kcat of 
10 + 1 s-1 and a Km of 6 + 2 M (Table 2.2). The kcat/ Km values of the Co(II)-substituted enzymes 
were roughly equal to that of their Zn(II) analogs, with the 2Zn analog clearly the most efficient 
catalyst.  
Pre-steady state kinetics. To probe the kinetic mechanism of VIM-2, stopped-flow kinetic 
studies were conducted. The reaction of chromacef with 2Zn-VIM-2 (85 M, Figure 2.1A) and 
2Co-VIM-2 (125 M, Figure 2.1B) was monitored over 500 ms using a stopped-flow mixer and 
diode-array detection between 300 and 700 nm. Three distinct absorbance bands were observed 
Table 2.2. Steady-state kinetic constants and metal contents of VIM-2 samples.  
     Sample kcat 
(s-1) 
Km 
(M) 
kcat/Km 
(M-1 s-1) 
Metal content 
(equiv) a 
 As isolated (LB)   4 + 1   5 + 2 0.8 0.4 
1Zn-VIM-2 10 + 2   9 + 2 1.1 1.0 
2Zn-VIM-2 22 + 2   8 + 2 2.8 1.9 
As isolated (MM)   2 + 1 10 + 1 0.2 0.5 
1Co-VIM-2   6 + 1   5 + 2 1.2 0.8 
2Co-VIM-2 10 + 1   6 + 2 1.7 1.8 
a Uncertainty ± 0.1. 
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(378, 442, and 620 nm). The three bands correspond to substrate decay, product formation and 
intermediate formation/decay, respectively.[26] The resulting progress curves were fitted to the 
kinetic mechanisms shown in 
Scheme 2.1, using the rate 
constants in Table 2.3.[24] The use 
of the mechanism in Scheme 1 
resulted in good fits to the 
MATLAB generated progress 
curves (Figure 2.1). The shapes of 
the theoretical progress curves 
were greatly influenced by the 
values of k2, k-2, and k3 and not 
significantly influenced by other 
microscopic rate constants. We 
tested other mechanisms with 
aditional intermediates, and no 
intermediates; however, the use of 
these mechanisms did not result in improved fits. The “dip” in the substrate decay versus time data 
  
Figure 2.1 (A). UV-vis spectra monitoring the reaction of 2Zn-VIM-2 (80 M) and chromacef 
(80 M) at pH 7.0 and 22 oC. (B). Progress curves for chromacef hydrolysis by 2Zn-VIM-2 
(left) and 2Co-VIM-2 (right). Concentrations of substrate, product, and intermediate were 
calculated as described in Experimental Procedures. Theoretical progress curves are shown as 
open symbols, and the experimental progress curves are solid lines. The kinetic mechanism in 
Scheme 2.1 and the rate constants in Table 2.3 were used to generate the theoretical progress 
curves.  
Table 2.3. Pre-steady state kinetic parameters of 2Zn-
VIM2 and 2Co-VIM2 against the chromacef.a 
 2Zn-VIM-2 2Co-VIM-2 
k1 (M-1 s-1) 1 X 108 1 X 108 
k-1 (s-1) 500 + 50 200 + 30 
k2 (s-1) 35 + 4 40 + 5 
k-2 (s-1) < 1 < 1 
k3 (s-1) 170 + 10 300 + 30 
k-3 (s-1) < 1 < 1 
k4 (s-1) 5000 + 1000 5000 + 1000 
k-4 (M-1 s-1) 1 X 108 1 X 108 
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has been observed in the past and has been attributed to overlapping absorbances of substrate and 
product/intermediate.[24, 26, 42-45]  
To determine whether the kinetic mechanism (Scheme 2.1) and rate constants in Table 2.3 
correspond to the steady state experimental data, the King-Altman method was used to determine 
equations for theoretical kcat and Km values. The theoretical kcat value for 2Zn-VIM-2 was 29 s
-1, 
which nicely matches the experimental kcat value of 22 s
-1, and the theoretical Km value was 4.4 
M, within a factor of two of the experimental Km (8 M). The theoretical kcat and Km values for 
2Co-VIM-2 were 35 s-1 and 2.1 M within a factor of three of the experimental kcat and Km values 
of 10 s-1 and 6 M. 
X-ray crystal structure of VIM-2. The X-ray crystal structure of 2Zn-VIM-2 was 
determined to examine the active site structure surrounding the bound Zn(II) atoms (Figure 2.2). 
Our structure is the highest 
resolution (1.55 Å) VIM-2 
structure determined to date[29] 
and is of excellent quality as judged 
by multiple validation parameters, 
including no Cb-deviations, a 
MolProbity clash score of 2.96 
(99th percentile, N=730, 1.550 Å ± 
0.25 Å), and MolProbity[39] score 
of 1.21 (98th percentile, N=6,779, 
1.550 Å ± 0.25 Å). 
The overall structure of our 
recombinant VIM-2 (PDB ID: 
4NQ2) is very similar to those 
reported by Garcia-Saez, et al. (PDB ID: 1KO3, reduced form) and Yamaguchi, et al. (PDB ID: 
2YZ3, reduced form with bound phenylC3SH inhibitor),[28, 29] and to those of VIM-7 (PDB ID: 
2Y87, reduced form)[46] and VIM-31 (PDB ID: 4FR7). In the VIM-4 crystal structure there was 
a citrate molecule bound in the active site, which results in an unusual six-coordinate Zn2 ion and 
the bridging water/hydroxide was replaced by the citrate ion.[47] 
 
Figure 2.2. Active site from the VIM-2 crystal structure 
(PDB id: 4NQ2) reported here. Zn1 is coordinated by 
three His and two water molecules and Zn2 is coordinated 
by one His, one Cys, one Asp and two water molecules. 
Zn1 and Zn2 are connected by a hydroxyl bridge. 
 
40 
 
Our structure of VIM-2 showed the Zn(II) in the Zn1 site bound to His114, His116, and 
His179, and the Zn(II) in the Zn2 site bound to Asp118, Cys198, and His240. In our structure, three 
water molecules are 
found at 2.3-2.6 Å 
from the Zn(II) atoms 
(Figure 2.2); while in 
the previous structures, 
two water molecules 
are observed in the 
VIM-2 structure (PDB 
ID: 1KO3) and one 
water molecule is 
observed in the VIM-
2/inhibitor structures 
(PDB ID: 2YZ3) 
(Figure 2.3).  The 
present structure 
showed a Zn-Zn internuclear distance of 3.46 Å (Table 2.4), which is similar to the value that we 
observed by EXAFS (Table 2.4, below). Saez, et al. (PDB ID: 1KO3) and Yamaguchi, et al. (PDB 
ID: 2YZ3) reported different values for the metal-metal (Zn(II)-Zn(II)) distance (4.20 and 3.75 Å, 
respectively) in VIM-2.[28, 29]. In our structure, a third Zn(II) binding site is found, coordinated 
by His178 and two acetate ions from the asymmetric unit and His285 from the symmetry mate 
found at –x + ½, -y + ½, z + ½. Given coordination by residues from two separate VIM-2 molecules, 
the third Zn(II) binding site is likely a crystallographic artifact. A similar Zn(II) site was reported 
in the Saez, et al. structure.[29] 
EXAFS spectroscopy. X-ray absorption spectroscopy was used examine the local metal-
site structure in the Zn(II)-containing enzymes, for direct comparison with the Co(II)-containing 
enzymes, in frozen solution. The Fourier-transformed spectra and corresponding best fits are 
shown in Figure 2.4, and summarized in Table 2.5. (Detailed fitting results are presented in Figure 
2.5-2.10 and Table 2.6-2.11). 
Table 2.4. Zinc(II)-ligand distances (Å) from previous native VIM-2 
Enzyme (1KO3), VIM-2 (4NQ2) from this study and from EXAFS 
experiments. 
 
Zn(II) - ligand VIM-
2(1KO3) 
VIM-2 
(4NQ2) 
EXAFS 
Zn1 
His114(116/94) 
His116(118/96) 
His179(196/159) 
O(W1) 
O(W2) 
2.2 
2.1 
2.2 
2.1 
2.2 
2.2 
2.2 
2.2 
2.6 
2.01 
2.01 
2.01 
2.01 
Zn2 
Asp118(120/98) 
Cys198(221/178) 
His240(263/220) 
Cl 
O(W1) 
O(W3) 
2.3 
2.3 
2.3 
2.9 
2.5 
 
2.3 
2.3 
2.3 
 
2.2 
2.3 
2.01 
2.31 
2.01 
 
2.01 
2.01 
Zn1 Zn2 4.2 3.5 3.36 
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Figure 2.3. Structure of 2Zn-VIM-2. (A) Cartoon representation of VIM-2 (pale blue). 
Active site side chains are shown as sticks, Zn(II) ions (grey) and water molecules (red) are 
shown as spheres. (B) Close-up highlighting coordination of the two Zn(II) ions by residues 
at the VIM-2 active site. A and B are from this study PDB id, 4NQ2. (C) Active site close-
up for VIM-2 structures 4NQ2 (pale blue), 1KO2 (light teal), 1KO3 (light orange) and 
2YZ3 (grey). Residues coordinating the Zn(II) ions including the 1KO2 cysteinesulfonic 
acid and the 2YZ3 mercaptocarboxylate inhibitor are shown as sticks. Zn(II) ions (pale 
blue, light teal, light orange and grey) and water molecules are shown as spheres. (D) Active 
site close-up for VIM-2 (4NQ2, pale blue), IMP-1 (1DDK, light pink) and NDM-1 (3PSU, 
light green). Residues coordinating the Zn(II) ions and the Zn(II)-bound acetate ion from 
1DDK are shown as sticks, Zn(II) ions (pale blue, light pink and light green) and water 
molecules (red) are shown as spheres. 
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Table 2.5. Best fits to the EXAFS of Zn(II)- and Co(II)-containing VIM-2. 
 
Sample Model M-M a % I b Fitc 
As isolated LB (0.5 Zn) 4 N/O (2 His) + 0.5 S + Zn-Zn 3.36 51 S1-4 
1Zn-VIM-2 4 N/O (2 His) + 0.5 S + Zn-Zn 3.37 23 S2-4 
2Zn-VIM-2 4 N/O (2 His) + 0.5 S + Zn-Zn 3.36 27 S3-4 
As isolated MM (0.5 Co) 4 N/O (2 His) + 0.5 S + Co-Co 3.51 53 S4-4 
1Co-VIM-2 4 N/O (2 His) + 0.5 S + Co-Co 3.52 53 S5-4 
2Co-VIM-2 4 N/O (2 His) + 0.5 S + Co-Co 3.51 37 S6-4 
a Metal-metal separation in Å. 
b Percent improvement over a similar fit that lacks a M-M vector. 
c Fitting results table S1 to S6 available in the supplementary information. 
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Figure 2.4. EXAFS Fourier-transforms for Zn(II)- and Co(II)-containing VIM-2 (solid lines) 
and corresponding best fits (open symbols). See Table 4, Tables S1-S6, and Figures S1-S6 for 
details. From top to bottom: Recombinant LB VIM-2 (Zn K-edge), 1Zn-VIM-2 (Zn K-edge), 
2Zn-VIM-2 (Zn K-edge), Recombinant MM VIM-2 (Co K-edge), 1Co-VIM-2 (Co K-edge), 
and 2Co-VIM-2 (Co K-edge). 
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The best fit obtained for as-isolated VIM-2, containing 0.5 equivalents of Zn(II), indicates 
first shell coordination to 4 N/O at 2.00 Å and 0.5 S scatterers at 2.28 Å (Figure 2.5 and Table 2.6, 
compare fit S1-1 to S1-2). Multiple scattering analyses indicate 2 imidazoles per Zn, while 
inclusion of a metal-metal interaction at 3.36 Å improved the fit by 51% (Figure 2.5 and Table 
2.6, compare fit S1-3 to S1-4). Best fit results for 1Zn-VIM-2 are nearly indistinguishable, 
including a first shell of 4 N/O and 0.5 S scatterers, 2 imidazoles per Zn, and a metal-metal 
interaction at 3.37 Å. The metal-metal interaction improved the fit by 23% (Figure 2.6 and Table 
2.7, compare fit S2-3 to S2-4).  These results are consistent with VIM-2 containing ≤ 1 equiv of 
Zn(II) having both metal binding sites partially-occupied. Further, the substantial improvement in 
fit residual on addition of the metal-metal vector suggests that metal binding is cooperative, with 
the dominant species present at substoichiometric metal loading being the apo- and dizinc 
enzymes. 
EXAFS of 2Zn-VIM-2 is no different, with a first shell of 4 N/O and 0.5 S, 2 imidazoles 
per Zn, and a metal-metal interaction at 3.36 Å that improved the fit by nearly 27% (Figure 2.7 
and Table 2.8, compare fit S3-3 to S3-4). These results are clearly consistent with previous 
crystallographic studies,[28, 29] and our own structure (Figure 2.2 and Table 2.4). The average 
coordination number of 4.5 and Zn-Zn distance of 3.36 Å, are in excellent agreement with our 
crystallographic studies, which showed an average coordination number of 5 and a Zn-Zn 
separation of 3.5 Å. The difference in coordination number arises from the second terminal water 
molecule bound to Zn1 in the crystal structure (Figure 2.2), which may not be present in the flash 
frozen EXAFS samples. 
The EXAFS of all three forms of Co(II)-containing VIM-2 (as-isolated (0.5Co), 1Co and 
2Co) gave similar results, including a first shell of 4 N/O and 0.5 S scatters, 2 histidines per Co(II) 
and a metal-metal interaction at ~ 3.51 Å that improved the fits by 53% (0.5 eq, Figure 2.8 and 
Table 2.9, compare fit S4-3 to S4-4), 53% (1Co-VIM-2, Figure 2.9 and Table 2.10) and 37% 2Co-
VIM-2, Figure 2.10 and Table 2.11). The same trend was observed in the Zn(II)-containing 
enzymes, suggesting that Co(II) is also bound cooperatively. The longer Co-Co distance in 2Co-
VIM-2 relative to 2Zn-VIM-2 (3.36 Å) is consistent with the slightly larger covalent radius of 
high-spin Co(II). As Co(II) binding mirrored Zn(II) binding, we examined the Co(II)-substituted 
enzymes spectroscopically, with confidence the results could be extrapolated back to the native 
Zn(II)-containing enzymes. 
44 
 
 
 
Figure 2.5. Fourier transforms (A) of Zn K-edge EXAFS (B) for as isolated (LB) VIM-2 (0.5 
Zn). The solid lines represent the data, the open symbols represent the various fits, 
corresponding to Table 2.6. 
 
Table 2.6. Fitting results for Zn K-edge EXAFS of as isolated (LB) VIM-2.a 
 
Fit Model Zn-N/O Zn-S Zn-Hisb Zn-Zn Rfc Ruc 
S1-1 5 N/O 2.00 (7.1)    87 186 
S1-2 4 N/O + 0.5 S 2.01 (4.7) 2.28 (4.1)   33 165 
S1-3 4 N/O (2His) 
+ 0.5S 
2.00 (4.8) 2.27 (4.9) 2.91(3.4) 3.15(1.5) 
4.13(23) 4.42(13) 
 39   57 
S1-4 4N/O(2His)+ 
0.5S+Zn-Zn 
2.00 (4.9) 2.28 (6.0) 2.94(5.6) 3.23(8.5) 
4.14(9.3) 4.41(18) 
3.36(9.2) 18   48 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-13 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 
3-4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 2.6. Fourier transforms (A) of Zn K-edge EXAFS (B) for 1Zn-VIM-2. The solid lines 
represent the data, the open symbols represent the various fits, corresponding to Table 2.7. 
 
Table 2.7. Fitting results for Zn K-edge EXAFS of 1Zn-VIM-2.a 
 
Fit Model Zn-N/O Zn-S Zn-Hisb Zn-Zn Rfc Ruc 
S2-1 5 N/O 2.01 (6.9)    46 119 
S2-2 4 N/O + 0.5 S 2.00 (4.9) 2.27 (5.4)   14 103 
S2-3 4 N/O (2His)+ 
0.5S 
2.00 (5.1) 2.27 (6.5) 2.89(6.0) 3.11(3.7) 
4.10(19)  4.40(16) 
 22   34 
S2-4 4N/O(2His)+ 
0.5S+Zn-Zn 
2.00 (5.2) 2.27 (6.6) 2.88(6.1) 3.10(2.8) 
4.05(28)  4.40(15) 
3.37(15) 17   30 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-13 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 3-
4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 2.7. Fourier transforms (A) of Zn K-edge EXAFS (B) for 2Zn-VIM-2. The solid lines 
represent the data, the open symbols represent the various fits, corresponding to Table 2.8. 
 
Table 2.8. Fitting results for Zn K-edge EXAFS of 2Zn-VIM-2.a 
 
Fit Model Zn-N/O     Zn-S Zn-Hisb Zn-Zn Rfc Ruc 
S3-1 5 N/O 2.02 (7.4)    127 222 
S3-2 4 N/O + 0.5 S 2.01 (5.1) 2.31 (2.9)     22 172 
S3-3 4 N/O (2His)+ 
0.5S 
2.01 (5.0) 2.31 (3.2) 2.93(4.0) 3.15(4.0) 
4.11(9.3) 4.41(19) 
   23   61 
S3-4 5N/O(2His)+ 
0.5S+Zn-Zn 
2.01 (5.1) 2.31 (3.2) 2.94(4.4) 3.20(8.3) 
4.12(8.2) 4.40(22) 
3.36(15)   17   60 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-13 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 3-
4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 2.8. Fourier transforms (A) of Co K-edge EXAFS (B) for as isolated (MM) VIM-2 
containing 0.5 eq of Co. The solid lines represent the data, the open symbols represent the 
various fits, corresponding to Table 2.9. 
 
Table 2.9. Fitting results for Co K-edge EXAFS of as isolated (MM) VIM-2.a 
 
Fit Model Co-N/O Co-S Co-Hisb Co-Co Rfc Ruc 
S4-1 5 N/O 2.04 (7.0)    41 247 
S4-2 4 N/O + 0.5 S 2.03 (5.1) 2.27 (4.0)   28 230 
S4-3 4 N/O (2His)+ 
0.5S 
2.04 (6.1) 2.26 (12) 2.98(4.5) 3.20(1.1) 
4.20(7.5) 4.56(12) 
 30   86 
S4-4 5N/O(2His)+ 
0.5S+Co-Co 
2.04 (6.0) 2.26 (11) 2.98(4.8) 3.19(1.0) 
4.15(18)  4.55(11) 
3.51(15) 24   78 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 3-
4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 2.9. Fourier transforms (A) of Co K-edge EXAFS (B) for 1Co-VIM-2. The solid lines 
represent the data, the open symbols represent the various fits, corresponding to Table 2.10. 
 
Table 2.10. Fitting results for Co K-edge EXAFS of 1Co-VIM-2.a 
 
Fit Model Co-N/O Co-S Co-Hisb Co-Co Rfc Ruc 
S5-1 5 N/O 2.08 (3.5)    37 90 
S5-2 4 N/O + 0.5 S 2.07 (2.1) 2.29 (2.4)   23 79 
S5-3 4 N/O (2His) 
+ 0.5S 
2.07 (3.3) 2.28 (1.8) 3.00(5.6) 3.14(2.5) 
4.10(6.4) 4.59(14) 
 34 45 
S5-4 5N/O(2His)+ 
0.5S+Co-Co 
2.07 (3.0) 2.29 (2.1) 3.01(5.6) 3.15(0.5) 
4.10(6.9) 4.59(17) 
3.52(7.3) 16 39 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 
3-4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 2.10. Fourier transforms (A) of Zn K-edge EXAFS (B) for 2Co-VIM-2. The solid lines 
represent the data, the open symbols represent the various fits, corresponding to Table 2.11. 
 
Table 2.11. Fitting results for Zn K-edge EXAFS of 2Co-VIM-2.a 
 
Fit Model Co-N/O Co-S Co-Hisb Co-Co Rfc Ruc 
S6-1 5 N/O 2.09 (2.1)    43 118 
S6-2 4 N/O + 0.5 S 2.07 (2.2) 2.31 (1.3)   26   99 
S6-3 4 N/O (2His) 
+ 0.5S 
2.07 (2.4) 2.31 (0.9) 3.00(3.9) 3.14(1.6) 
4.29(2.9) 4.58(26) 
 72   62 
S6-4 5N/O(2His)+ 
0.5S+Co-Co 
2.07 (2.3) 2.31 (0.8) 3.01(4.0) 3.15(0.8) 
4.28(2.2) 4.58(33) 
3.51(9.1) 45   54 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 
3-4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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UV-visible spectroscopy. The UV-visible spectrum of 1Co-VIM-2 (Figure 2.11) revealed 
a broad absorption at 342 nm (ε342 = 170 M-1cm-1) that is readily assigned to a Cys-S to Co(II) 
ligand-to-metal charge 
transfer transition, 
requiring Co(II) 
binding at the Zn2 
site.[24, 48-50] The 
ligand field transitions 
between 500 and 650 
nm (ε550 = 85 M-1cm-1) 
are similar in shape to 
other B1 MBLs,[24, 
51] and they roughly 
double in intensity for 
2Co-VIM-2, as does 
the charge transfer 
transition (ε342 = 293 
M-1 cm-1 and ε550 = 131 
M-1 cm-1), suggesting 
binding of Co(II) to 
both sites in VIM-2 
independent of 
stoichiometry. 
Similarly low 
extinction coefficients 
were observed for 
Co(II)-substituted 
IMP-1 (342 = 95 M-1 
cm-1 and 550 = 256 M-1 
cm-1).[24]  
 
Figure 2.11. Optical spectra of 1Co- and 2Co-VIM-2 (1 mM protein 
containing 50 mM HEPES 100 mM NaCl at pH 6.8). 
 
 
Figure 2.12. X-band EPR spectra of 1Co- and 2Co-VIM-2, taken 
with B1||B0 (gray lines) and B1B0 (black lines). The 1Co-VIM-2 
spectra have been scaled by a factor of 2; all other sample and 
spectrometer conditions were identical. 
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EPR spectroscopy. The EPR spectra of 1Co- and 2Co-VIM-2, obtained in both parallel 
and perpendicular modes, are shown in Figure 6. The perpendicular mode spectra (black lines in 
Fig. 6) are typical of Co(II)-substituted metalloproteins,[52] with the sharp feature near 1600 – 
1700 G corresponding to a small fraction of Fe(III) contamination. Comparison of the 1Co- and 
2Co-VIM-2 spectra shows that they are nearly indistinguishable, consistent with the EXAFS and 
optical studies suggesting that only the apo- and di-Co enzymes are present at measurable 
concentrations. Neither signal could be simulated using an axial g-tensor, indicating the lack of a 
unique solution based on the EPR alone.[52] Both 1Co- and 2Co-VIM-2 showed strong parallel 
mode responses (gray lines in Fig. 2.12), nearly half the normalized intensity of the perpendicular 
response, with the 2Co enzyme’s signal intensity nearly twice that of the 1Co enzyme. The EPR 
data indicate that similar metal centers are present in 1Co- and 2Co-VIM-2. Such strong, loading-
dependent coupling, apparent at substoichiometric levels of metal, support positive cooperative 
binding of Co(II) by VIM-2.  
 
2.5. Discussion   
VIM-2. VIM-1 was first isolated in 1997 from a patient in Italy,[10] and a year later, VIM-
2 was isolated from a Pseudomonas aeruginosa strain in France.[14] There are 34 variants of VIM 
isolated and charaterized.[12] Among those 34 variants, VIM-2 is the most clinically-important 
because of its high relative dissemination to other organisms as compared to other variants.[14-
23] VIM-2 contains 266 amino acids, with a mass of 29.7 KDa and a pI of 5.6, exhibiting 7% 
structural variation from VIM-1. VIM-2-expressing bacteria have been shown resistant to an array 
of β-lactam-containing antibiotics, including ureidopenicillins, ticarcillin-clavulanic acid, 
cefepime, ceftazidime, imipenem, and meropenem, but strains expressing VIM-2 remained 
susceptible to the monobactam aztreonam.[14] VIM-2 shares 32 % amino acid identity with BcII 
from Bacillus cereus, 31 % with IMP-1, 27 % with CcrA from Bacteroides fragilis, 24 % with 
BlaB from Chryseobacterium meningosepticum, 24 % and with IND-1 from Chryseobacterium 
indologenes. There are significant differences in the steady-state kinetic constants reported for 
VIM-2 thus far, kcat and Km ranging from 9.9 to 34 s
-1 and 9 to 10 M respectively with 
imipenem.[14, 32] The steady-state kinetic results are difficult to compare, as metal content has 
not been uniformly reported.  
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    Pre-steady-state kinetic studies have been reported previously for CcrA[49, 53], Bla2[54], 
BcII[55], IMP-1[24], and NDM-1[26] using either nitrocefin or chromacef as substrate (Scheme 
2.2). For CcrA[49, 53], and NDM-1[26] the rate-limiting step was reported to be protonation of 
the anionic, ring-opened intermediate. For Bla2, the mono-Co(II) enzyme quantitively formed the 
intermediate, suggesting cooperativity in metal binding.[54] A similar intermediate was not 
observed with IMP-1[24] or BcII[55]. In the present study, stopped-flow experiments on 2Zn-
VIM-2 showed only small amounts of intermediate, up to ~ 10 % of the total enzyme concentration 
(Figure 1A). Interestingly, the chromacef-derived intermediate formed in the reaction with 2Zn-
VIM-2 absorbed at 620 nm, a significant shift from the 575 nm max observed with NDM-1[26], 
L1 and CcrA (M. Aitha and M. W. Crowder, unpublished results). The red shift suggests a more 
weakly bound intermediate in VIM-2. This is a point under further investigation.  
We have previously reported kinetic and spectroscopic studies on Co(II)-substituted 
analogs of L1[33, 43, 44, 54], ImiS[56], IMP-1[24], CcrA[57], Bla2[54], NDM-1[27], and 
BcII[58]. In this study we have over-expressed, purified, characterized, and structurally-probed 
VIM-2. The conditions reported above allowed, for the first time, for Co(II)-substituted VIM-2 to 
be prepared and characterized. Optimization of each preparation required different conditions, with 
the Zn(II)-containing enzyme obtained from normal culture in LB medium, while our initial efforts 
to prepare Co(II)-substituted VIM-2 using standard methods, including exposure to metal chelators 
first to generate apoenzyme followed by direct addition of Co(II), failed. Previous studies have 
shown that Cys221 is readily oxidized when VIM-2 is exposed to chelators, and the resulting 
enzyme is unable to bind two equivalents of metal.[29, 32] We have successfully used a biological 
incorporation method to prepare catalytically-active Co(II)-substituted MBLs (L1[33] and 
CcrA[57]) previously, and this method resulted in an over-expressed VIM-2 that bound 0.5 
equivalents of Co(II), and no other detectable metals. VIM-2 analogs containing 0.8 and 1.8 
equivalents of Co(II) were readily generated from this enzyme by direct addition.   
Scheme 2.2. Comparison of nitrocefin (left) and chromacef (right) chromogenic substrates. 
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Metal binding. EXAFS of the Zn(II)-containing analogs clearly show that both metal 
binding sites are occupied, independent of stoichiometry. The data obtained herein further indicate 
that they likely reside in a binuclear cluster, based on the improvement in the curve fits on inclusion 
of a metal-metal interaction around 3.36 Å (see Table 2.5). The metal-metal distances are 
consistent with the EXAFS-derived distances in other B1 MBLs,[24, 26, 27, 54, 57, 58] and in the 
present crystal structure (Figure 2.2 and Table 2.4). Together with the steady-state kinetics (Table 
2.2), which showed a near-linear dependence in kcat on Zn(II) content, the EXAFS data indicate 
positive-cooperative binding of Zn(II) to VIM-2, where the major species present, at any 
stoichiometry, are apo- and di-Zn enzyme.  
The present data show that VIM-2 also exhibits positive-cooperative Co(II) binding. The 
EXAFS of the Co(II)-containing enzymes suggest near-stoichiometric formation of dinuclear 
enzymes on metal addition, based on even more pronounced fit improvements on inclusion of the 
M-M interaction (Table 2.5). EPR studies are clearly consistent with this model, where the 
perpendicular-mode spectra showed virtually indistinguishable signals whose intensity doubled 
from 1Co- to 2Co-VIM-2, and strong parallel-mode responses, indicating the presence of relatively 
strongly spin-coupled dinuclear Co(II) centers in both 1Co- and 2Co-VIM2. This may explain the 
exceptionally poor NMR response of Co(II)-substituted VIM-2 (Figure 2.13). Finally, the optical 
 
Figure 2.13. 200 MHz 1H NMR spectrum of 2Co-VIM-2 in 90 % H2O. Solvent exchangeable 
protons are indicated by an asterisk. 
 
54 
 
spectra are also consistent with distributed, cooperative binding, showing both d-d band structure 
and charge transfer intensity that roughly doubled from 1Co- (ε342 = 170 M-1cm-1 and ε550 = 85 M-
1 cm-1 ) to 2Co-VIM-2 (ε342 = 293 M-1 cm-1 and ε550 = 131 M-1 cm-1). These extinction coefficients 
are substantially smaller than those reported for the majority of B1 MBLs, but very similar to IMP-
1 (ε342 = 256 M-1cm-1), which also showed highly cooperative Co(II) binding.[24] 
Comparison with other dinuclear B1 MBLs. Among the B1 MBLs studied, VIM-2 
appears to show the highest level of metal-binding cooperativity, based on the spectroscopic and 
kinetic properties reported here. Behavior varies widely across the B1 MBL subclass, as 
summarized in Table 5.[24-27, 48, 49, 55, 57-60] To support this, we include two reports on CcrA 
here. One is based on an early study by Benkovic and co-workers that reported an optical titration 
consistent with distributed Co(II) binding.[49] The second is based on our later study, working 
with the same construct, which suffered from a significant level of irretrievable cysteine oxidation, 
rendering many of the spectroscopic observables in Table 2.12 unavailable.[57] We have since 
attempted to repeat these experiments without success. Given that caveat, all six that have been 
examined both kinetically and spectroscopically show evidence of distributed Co(II) binding, with 
both sites populated at substoichiometric levels of metal. All, save CcrA, show some level of 
cooperativity, based on the loading-dependence of kcat and an EXAFS-detected M-M interaction 
at substoichiometric loading. However, while half of the enzymes bind Zn(II) in the same fashion 
(BcII, IMP-1 and now VIM-2), with varying levels of cooperativity, the other half (NDM-1, Bla2 
and CcrA) bind Zn(II) sequentially, without cooperativity. Without exception, those that bind 
Zn(II) cooperatively appear less capable of stabilizing the anionic intermediate with these 
chromogenic substrates, suggesting a shift in the rate-limiting step relative to those that bind Zn(II) 
sequentially, which uniformly build up a large percentage of the intermediate.  
To gain insight into this apparent distinction, we examined more closely the available 
structures of the six MBLs in Table 2.12. Limiting ourselves to doubly zinc-loaded enzymes, and 
accepting that there are no such structures of Bla2, the 27 available structures (including the present 
one) of the other 5 MBLs show minimal variability in the position and orientation of metal-
coordinating side chains.[28, 29, 61-74] Comparing nearby side chains and structured waters, as 
illustrated in Figure 2.14, shows two striking differences between the cooperative and non-
cooperative groups. The first is the variability in the position of the Zn2 ion in the cooperative 
group (Fig. 2.14A), compared to the non-cooperative structures, where placement of the metals is 
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tightly grouped (Fig. 2.14B). Efforts to re-engineer BcII through mutagenesis have shown similar 
variability in the position of Zn2, with dramatic effects on the reactivity of the resulting 
enzymes.[75]  
The second, perhaps more pertinent observation is that the occupancy of the terminally 
zinc-coordinated water molecule, which has been suggested to serve as the proton source in decay 
of the intermediate,[26, 42-44, 49, 53] is substantially lower in the CcrA and NDM-1 structures 
(non-cooperative, Fig. 2.14B). While this water molecule occupies a much more variable position 
in the cooperative group (BcII, IMP-1 and VIM-2, Fig. 2.14A), it is present in a much higher 
fraction of the structures, suggesting these enzymes are better poised to turn over the intermediate, 
once it is formed. The terminally-coordinated water in VIM-2 structures occupies positions similar 
to those seen in BcII and IMP-1, despite being held in place by a unique hydrogen bond donor. In 
all the other five B1 enzymes, the terminal water hydrogen bonds to another water that, in turn, 
hydrogen bonds to a nearby lysine. VIM-2 lacks the lysine, which is replaced by a tyrosine oriented 
 
Figure 2.14. Comparison of available crystal structures for doubly zinc-loaded MBLs. (A) 
VIM-2 (PDB IDs: 4nq2 chain A, grey; 2yz3 chains A,B, purple; 1ko3 chain A, purple), IMP-
1 (PDB IDs: 1dd6 chains A and B, orange; 1ddk chain A, orange; 1vgn chains A and B, orange; 
2doo chains A and B, orange; 1jjt chains A and B, orange; and 1jje chains A and  B, orange), 
and BcII (PDB IDs: 2uyx chain A, blue; 2bfx chains A and B, blue; 2bfl chains A and B, blue; 
and 2bg2 chains A and B, blue). (B) NDM-1 (PDB IDs: 4hl2 chains A and B, cyan; 4eyb chains 
A and B, cyan; 4exs chains A and B, cyan; 4exy chains A and B, cyan; 4ey2 chains A and B, 
cyan; 4eyf chains A and B, cyan; 4eyl chains A and B, cyan; 3spu chains B, C, D and E, cyan; 
and 3q6x chains A and B, cyan) and CcrA (PDB IDs: 1a7t chains A and B, green; 1a8t chains 
A and B, green; 2bmi chains A and B, green; and 1znb chains A and B, green). All zinc ions 
are represented as dark grey spheres. Structured waters within the active sites are shown as red 
spheres. 
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away from the metal site. The necessary hydrogen bond in VIM-2 is provided by an arginine that 
is 4 residues away, and oriented as shown in Fig. 7A. In the cooperative group (Fig. 2.14A), the 
hydrogen bond donor appears to sample a larger conformational space than in the non-cooperative 
group (Fig. 2.14B), which shows little variation in the position of the lysine side chain. It is also 
worth note that the bridging solvent molecule is readily apparent in most of the cooperative group 
structures (Fig. 2.14A), and conspicuously absent in the non-cooperative group structures (Fig. 
2.14B). 
Within the Co(II) enzymes in Table 2.12, the lines are not as clear. Those that show strong 
S to Co(II) CT bands (BcII and NDM-1) are the only ones that have shown clearly identifiable 
NMR resonances from the cys -CH2 protons, with weaker CT bands presumably associated with 
substantially reduced hyperfine couplings, and chemical shifts. The strength of the CT band 
appears loosely correlated to the strength of the magnetic coupling in the di-Co(II) enzymes, based 
on the strength of the parallel mode EPR signal, suggesting that more tightly coupled metal ions 
allow for weaker coupling to the thiolate, which has been shown to aid in stabilization of the 
anionic intermediate in several B1 MBLs.[76] However, this is not a perfect correlation, as among 
the group that doesn't stabilize the intermediate, BcII shows the strongest CT band of all six. We 
are continuing to examine these correlations to better understand the variability in B1 MBLs. 
 
2.6. Summary 
In summary, this study examines metal binding to the metallo--lactamase VIM-2, 
demonstrating the first successful preparation of a Co(II)-substituted VIM-2 analog. The 
spectroscopic studies reveal that Zn(II) and Co(II) bind similarly to VIM-2, with both metal ions 
showing cooperative binding where the major species present, regardless of stoichiometry, are 
apo- and di-Zn (or di-Co) enzyme. The crystal structure of the di-Zn enzyme that is presented is 
the highest resolution VIM-2 structure to date. Kinetic studies strongly suggest that VIM-2 utilizes 
a mechanism that proceeds through a very short-lived anionic intermediate. Comparison with other 
B1 enzymes shows that those that bind metal ions cooperatively are better poised to protonate the 
intermediate on its formation, compared to those that bind Zn(II) non-cooperatively, which 
uniformly build up substantial amounts of the intermediate. Future studies will address why 
positive-cooperative metal binding correlates with the abilty to protonate the anionic intermediate. 
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Table 2.12. Comparison of Metal-Binding, Kinetic and Spectroscopic Studies of B1 MBLs. a 
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Chapter 3 
 
 
 
 
 
 
 
 
 
Extended X-ray Absorption Fine Structure (EXAFS) studies on 
metallo--lactamases (MBLs) 
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3.1. Abstract 
The recent outbreak of NDM-1 became a huge challenge in treating bacterial infection in 
the clinic.[1] The design of an efficient, single MBL inhibitor has been limited by the structural 
diversity of the different members of this family of enzymes. The metal sites of the MBLs are 
crucial for antibiotic hydrolysis. In this study X-ray absorption spectroscopy (XAS) was used to 
study the three distinct issues with the MBLs. 1) The active site of recombinant NDM-1 was 
characterized, and our results showed 4 N/O and 0.5 S ligands coordinated to first shell per Zn(II) 
and 2 imidazoles coordinated to second shell per Zn(II). The metal-metal (M-M) distance is 3.38 
Å in NDM-1, which is consistent with the other B1 class MBLs and settles a controversy about 
different metal-metal distances in NDM-1. 2) Heterobimetallic forms of NDM-1 were 
characterized, and EXAFS data, along with other spectroscopic results, indicate that Zn(II) binds 
preferentially to the consensus Zn1 site, while cobalt binds to the Zn2 site in the ZnCo analog of 
NDM-1. In the CoCd analog, cobalt binds to the Zn1 site, and cadmium binds to the Zn2 site. 3) 
The catalytic mechanism of one representative MBL from the distinct B1, B2, and B3 classes was 
probed using rapid-freeze quench (RFQ) EXAFS spectroscopy, and the resting, product-bound, 
and 10 ms quenched analogs of the enzymes were analyzed. While stopped-flow UV-Vis studies 
suggest a common reaction mechanism for the three enzymes, our EXAFS results suggest that the 
metal centers do not behave the same way during catalysis.  
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3.2. Introduction 
Carbapenems are “last resort” drugs for treating infections from multi-resistant Gram-
negative, pathogenic bacteria.[2] Their beneficial action is continuously challenged by the 
emergence and spread of new resistance mechanisms. As a consequence, infections caused by 
resistant microorganisms fail to respond to standard treatments, resulting in prolonged illness and 
greater risk of death. Carbapenem-resistant bacteria are rapidly emerging due to opportunistic 
healthcare-associated infections and plasmid-mediated dissemination, resulting in a mortality of 
almost 50% in infected patients. This situation has led to a “global crisis” of antibiotic 
resistance.[3] 
Resistance to carbapenems is mostly due to the production of carbapenemases (carbapenem-
hydrolyzing enzymes). Metallo-β-lactamases (MBLs) are the most catalytically-efficient 
carbapenemases. These enzymes employ Zn(II) as an essential cofactor to cleave the β-lactam ring 
in penicillin-class antibiotics and inactivate these antibacterial agents.[4] MBLs are broad-
spectrum enzymes, being able to also hydrolyze penicillins and cephalosporins. These facts, 
together with the worldwide dissemination of MBL-encoding genes, signal an alarming clinical 
problem. In particular, the gene, which encodes for the MBL NDM-1 and other proteins, which 
result in resistance phenotypes, have spread all over the globe.[1, 5-9] Inhibitors developed for the 
classic serine-β-lactamases are not effective against MBLs, and specific inhibitors for MBLs are 
not commercially available yet.[10]  
NDM-1 was first discovered in Klebsiella and Escherichia coli from a Swedish patient. 
Bacteria harboring NDM-1 are not susceptible to any commonly-used antibiotic except colistin 
and tigecycline,[1] and NDM-1 containing genes have been isolated from almost all continents, 
except Central and South America and Antarctica.[5] To date 16 variants of NDM have been 
identified and isolated.[11] Several research groups have reported efforts to purify and characterize 
NDM-1, and there are 28 crystal structure available in the Protein Data Bank.[12-18] Previous 
studies reported varied steady-state kinetic constants for NDM-1; the variability may be due to 
different metal content, which was not reported in most cases, of the purified enzymes.[12, 15, 16] 
Most of the crystal structures showed metal ions bound to the consensus Zn sites in NDM-1: the 
Zn1 site contains three His and one bridging hydroxide, and the Zn2 site contains one His, one Asp, 
one Cys, one terminally-bound water, and the bridging hydroxide (Figure 3.1). The metal-metal 
distances varied in the different crystal structures between 3.29 Å and 4.8 Å; [12-18] however, 
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most B1 class MBLs exhibit a metal-metal distance less than 3.5 Å.[19] Since NDM-1 is a 
clinically-significant enzyme, it is important to ascertain the number of metal ions bound to NDM-
1 and the metal-
metal distance of 
the enzyme, 
particularly if 
inhibitors to target 
the metal binding 
site are going to be 
designed. Herein, 
we report 
characterization of 
recombinant NDM-
1 using EXAFS 
spectroscopy.  
The naturally-occurring analogs of the MBLs contain Zn(II), and structural characterization 
of these analogs is limited to X-ray crystallography and X-ray absorption spectroscopy (XAS), 
although 67Zn NMR spectroscopy, which would be costly and would not yield much useful 
information, could also be used. In most Zn(II)-containing proteins, Zn(II) can be readily replaced 
by Co(II), resulting in catalytically-active analogs that can be interrogated using optical and 
magnetic resonance spectroscopic techniques. However, as all known examples of B1 MBLs bind 
2 equivalents of divalent metal tightly, spectroscopic signatures from fully-substituted (CoCo-
analogs) enzymes are difficult to assign to specific metal sites. Heterobimetallic analogs of the 
MBLs are ideal to investigate the Zn1 and Zn2 sites independently. Previous studies on 
heterobimetallic forms of BcII (ZnCo)[20] and L1 (ZnCo) have been reported [21, 22]. Herein, we 
report the characterization of several heterobimetallic forms of NDM-1 (ZnCo, CoCo, and CoCd) 
using EXAFS spectroscopy.                  
The design of an efficient MBL inhibitor has been limited by the structural diversities of the 
different members of this family of enzymes.[4, 24-28] Indeed, MBLs are classified into three 
different subgroups: B1, B2, and B3, which differ in their active site structures, zinc 
stoichiometries, loop architectures, and substrate profiles.[29] As mentioned above, most MBLs 
 
Figure 3.1. Active site of NDM-1 and this figure was rendered using 
VMD[23] and PDB entry (3Q6X)[15] 
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possess a dinuclear active site in which two Zn(II) ions are bridged by a hydroxide, generally 
accepted to be the attacking nucleophile. This metal site stoichiometry is found in the B1 enzymes 
and in most B3 enzymes, in which Zn1 is tetrahedrally-coordinated by three histidine ligands (3H 
site) and the bridging OH- molecule.[24, 25, 27, 30] However, the ligand set of Zn2 varies. In the 
B1 enzymes the ligands for the Zn2 site are Asp120, Cys221, and His263 (DCH site),[25, 28] while 
in the B3 MBLs, the Zn2 site is composed of residues Asp120, His121, and His263 (DHH site). In 
both cases, the Zn2 site has one or two water molecules.[27, 30, 31] Notably, residue His116 is 
replaced by less common metal binding ligands, such as Asn or Gln, in the B2 MBLs and in some 
B3 enzymes, giving rise to catalytically-active mono-Zn(II) MBLs with a metal ion located only 
in the Zn2 site. These mononuclear enzymes display functional and structural diversities: B2 
enzymes hydrolyze only carbapenems[26, 32] and display a DCH-like Zn2 site, while the 
mononuclear B3 MBL GOB-18 from Elizabethkingia meningoseptica is a broad-spectrum enzyme 
with one Zn(II) ion bound to the canonical Zn2 (DHH) site present in dinuclear B3.[33] 
The structural diversity has led to different mechanistic proposals for MBLs, which mostly 
have involved a controversy about the essentiality of the different Zn(II) sites. It was recently 
shown that B1 enzymes in the periplasm require a dinuclear Zn(II) site to provide resistance.[34, 
35] Herein, we report a mechanistic study of carbapenem hydrolysis by MBLs from subclasses 
B1, B2, and B3 with different metal content, by using rapid freeze quench (RFQ) EXAFS 
spectroscopy. Our collaborators showed that all MBLs from different subclasses hydrolyze 
imipenem via a similar catalytic mechanism, with accumulation of the same anionic reaction 
intermediate. However, EXAFS studies show that the metal centers in the enzymes do not change 
in the same way during catalysis. These results provide a unique case of mechanistic convergent 
evolution, despite the different metal site structures. Inhibitor design strategies on MBLs should 
be based on common mechanistic features, thus overcoming the limitation posed by the structural 
diversity of these enzymes. 
 
3.3. Methods 
Sample preparation. Samples for EXAFS (approximately 1 mM in protein) were prepared 
with 20% (v/v) glycerol as a glassing agent. EXAFS samples were loaded in Lucite cuvettes with 
6 m polypropylene windows and frozen rapidly in liquid nitrogen. Rapid freeze quenched 
EXAFS samples were generated using a modified Update Instruments (Madison, WI) rapid-freeze-
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quench (RFQ) system. All enzyme and substrate starting concentrations were 1 mM, prepared in 
metal-free (Chelex 100, Bio-Rad) 50 mM HEPES, pH 7.0, containing 20% v/v glycerol. A model 
715 Update Instruments ram controller was used to drive a PMI-Kollmorgen stepping motor 
(model 00D12F-02001-1) connected to a ram that in turn drove the Update Instrument syringes. 
The syringes, mixer, and tubing were all contained in a watertight bath that was maintained at 2 
°C. Immediately prior to sample collection, the nozzle (and, for the shortest reaction times, the 
attached mixer) was removed from the bath and held 5 mm above the surface of 2-methylbutane 
contained in a collecting funnel and maintained at -130 °C by a surrounding bath (Update 
Instruments) of liquid nitrogen cooled 2-methylbutane. Samples were packed into home-designed 
EXAFS sample holders at -130 °C; excess 2-methylbutane was decanted, and samples were stored 
in liquid nitrogen until data collection. The RFQ system was calibrated by comparing the 
development of a low-spin Fe(III) EPR signal and the disappearance of a high-spin Fe(III) EPR 
signal with the associated optical changes at 636 nm using stopped-flow spectrophotometry, upon 
mixing myoglobin with an excess of sodium azide. The shortest, total effective reaction time that 
could be achieved with the RFQ system was 10 ms.[36, 37] X-ray absorption spectra were 
measured at the National Synchrotron Light Source (NSLS), beamline X3B, with a Si (111) 
double-crystal monochromator; harmonic rejection was accomplished using a Ni focusing mirror. 
Fluorescence excitation spectra for all samples were measured with a 31-element solid-state Ge 
detector array. Samples were held at approximately 15 K in a Displex cryostat. EXAFS data 
collection and reduction were performed according to published procedures.[38] Data were 
measured in duplicate, six scans at the zinc K-edge, eight scans at the cobalt K-edge, each on two 
samples from independent purifications; fits to the two data sets were equivalent. As both data sets 
gave similar results, the data were averaged using EXAFSPAK (EXAFSPAK is available free of 
charge from http://www-ssrl.slac.stanford.edu/~george/exafspak/exafs.htm); the experimental 
spectra presented here are the averaged data sets (12-16 scans per sample). The data were 
converted from energy to k-space using E0 = 9,680 eV (Zn) or 7,730 eV (Co).  
Fourier-filtered EXAFS data were fitted using the nonlinear least-squares engine of 
IFEFFIT, which is distributed with SixPack (SixPack is available free of charge from 
http://www.sssrl.slac.stanfrd.edu/_swebb/index.html; IFEFFIT is open source software available 
from http://www.cars9.uchicago.edu/ifeffit). Theoretical amplitude and phase functions were 
calculated with FEFF v. 8.00.[39] Zinc-nitrogen single-scattering and zinc-imidazole multiple-
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scattering were calibrated to the experimental EXAFS of zinc tetrakis-1-methylimidazole Zn(II) 
perchlorate, [Zn(MeIm)4][ClO4]2. Zinc-sulfur scattering was calibrated to the experimental 
EXAFS of tetrabutylammonium zinc tetramesitylthiolate, [Bu4N]2[Zn(Smes)4]. Optimum scale 
factors (Sc) and ∆E0 were derived from fits to the model data (Sc = 0.78 (Zn-N) or 0.91 (Zn-S); 
∆E0= -21 eV), and they were held fixed at these values for fits to metalloprotein data. The models 
used for the calibration of cobalt-nitrogen (and cobalt-imidazole) and cobalt-sulfur scattering were, 
respectively, hexakis-imidazole cobalt(II) perchlorate, [Co(Im)6][ClO4]2 and tetrabutylammonium 
cobalt(II) tetramesitylthiolate, [Bu4N]2[Co(Smes)4], respectively. The resulting Sc and ∆E0 (Sc = 
0.79 (Co-N) or 0.85 (Co-S); ∆E0 = -21 eV) were held fixed at these calibrated values in subsequent 
fits to metalloprotein data. First shell fits were then obtained for all reasonable coordination 
numbers, including mixed nitrogen/oxygen/sulfur ligation, while allowing the absorber-scattered 
distance, Ras, and the Debye-Waller factor, σas2, to vary. Detailed summaries of the fitting results 
are presented in Supporting Information. Multiple scattering contributions from histidine ligands 
were fitted according to published procedures.[38] Metal-metal (zinc-cobalt and cobalt-cobalt) 
scattering were modeled with reference to the experimental EXAFS of Zn2 (salpn)2 and Co2 
(salpn)2; cobalt-cadmium scattering was fitted empirically, assuming a scale factor of Sc = 1.0. 
  
3.4. Results 
Active site of recombinant NDM-1. Being a B1 class MBL, NDM-1 contains two Zn(II) 
ions in the active site. Previous crystal structural studies revealed the metal ion in the Zn1 site binds 
to the 3 histidines, and the metal ion in the Zn2 site is coordinated by His, Cys, Asp, and water. 
The metal ions are bridged by a hydroxyl group. To date 28 crystals structures of unbound and 
inhibitor/product/intermediate bound analogs of NDM-1 have been reported.[12-18] A few 
structures of NDM-1 showed the enzyme bound to only one Zn(II), and this analog is most likely 
due to oxidation of the cysteine in the Zn2 site. The metal-metal distances in these structures were 
not consistent, varying between 3.29 Å and 4.8 Å. It is important to note that the metal-metal 
distances in all well-characterized B1 class MBLs are less than 3.5 Å.[19]  
In an effort to address the conflicting data on NDM-1,[12-18] EXAFS data were obtained 
on a recombinant enzyme.[10] Fourier-transformed Zn K-edge EXAFS data for NDM-1 are shown 
in Figure 3.2. Detailed EXAFS curve-fitting results are presented in Table 3.1. The data are best 
fitted with a first shell (0.5–2.3 Å) of 4 nitrogen/oxygen donors at 2.01 Å and a 0.5 S donor at 2.26 
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Å per Zn(II). Fit residuals improved dramatically upon inclusion of the sulfur contribution (Figure 
3.2 and Table 3.1). Multiple scattering analysis indicates an average of 2.0 ± 0.5 imidazole ligands 
per Zn(II) (Table 3.1, Fit 1-3, Figure 3.2). Inclusion of a metal-metal scattering pathway at 3.38 Å 
improved the fit to the data by 37% (compare Table 3.1, Fit 1-3 to Fit 1-4, Figure 3.2). Together 
these data are consistent with a metal binding site in NDM-1 that coincides with a fully-loaded B1 
  
Figure 3.2. Fourier transforms (A) of k3-weighted EXAFS (B) for NDM-1, solid lines, and 
best fits (open symbols), corresponding to Table 3.1. 
 
Table 3.1. EXAFS Curve Fitting Results for NDM-1.a 
 
Fit Model Zn-N/O Zn-S Zn-Hisb Zn-Zn Rfc Ruc 
1-1 5 N/O 2.01 (6.8)    104 227 
1-2 4 N/O + 0.5 S 1.98 (4.3) 2.26 (4.1)    55 207 
1-3 4 N/O (2His)  
+ 0.5 S 
1.99 (4.2) 2.26 (3.7) 2.89(1.5) 3.15(0.1) 
4.07(15) 4.40(15) 
 112  96 
1-4 4 N/O (2His)  
+ 0.5 S + Zn-
Zn 
1.98 (4.5) 2.25 (4.5) 2.88(2.2) 3.12(0.3) 
4.13(9.1) 4.37(17) 
3.38(7.6)  71  78 
1-5d 4 N/O (2His)  
+ 0.5 S + Zn-
Zn 
2.00 (6.3) 2.30 (9.3) 2.88 (18.5) 3.32 (0) 
4.12 (9.2) 4.35 (28) 
3.36(5.0) 59 65 
 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fits 1-2), 0.2-4.2 Å (fits 3-
5)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
c  Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
d This fit used the same starting parameters as S1-4, but allowed ∆E0, and the Zn-N and Zn-S Sc to float. They 
refined from -21 to -20.2 eV (∆E0), from 0.78 to 0.93 Sc (Zn-N) and from 0.85 to 0.98 Sc (Zn-S). 
 
0
5
10
15
20
0 1 2 3 4 5 6 7
F
T
 M
ag
n
it
u
d
e
R+  (Å)
S1-3: 4 N/O (2His) +0.5S
S1-4: 4 N/O (2His) +0.5 S
             +Zn-Zn
S1-1: 5 N/O
S1-2: 4 N/O +0.5 S
A
-5
0
5
10
15
20
25
30
2 4 6 8 10 12
B
k3
 
 (
k)
k (Å
-1
)
    
    





N
i
ii
N
i
ii
obsobs
calccalc
1
22
1
22
)Im()Re(
)Im()Re(


72 
 
MBL, with one Zn(II) coordinated by 3 histidines (in the Zn1 or 3H site) and solvent, and the other 
Zn(II) coordinated by a single histidine (to give an average of 2 His per Zn), and three low-Z 
(atomic number) donors, most likely oxygens from water and/or carboxylates, and a metal-metal 
separation of ca. 3.4 Å.[40-45]  
Determining the fidelity of the heterometallic forms of NDM-1. Lack of unpaired electrons 
in the valence shell of Zn(II) restricts the use of optical and most spectroscopic techniques to gain 
information about the active site/metal center in Zn(II)-metalloproteins. Previous studies showed 
that cobalt can readily replace zinc (due to similar ionic radii), and Co(II)-substituted enzymes 
retain catalytic activities similar to those of the corresponding Zn(II) analogs.[19, 21, 36, 37, 42, 
46-50] To study substrate/inhibitor binding to the metal ions in NDM-1, several Co(II)-substituted 
analogs (Figure 3.3) of NDM-1 were prepared and characterized using steady-state kinetics, UV-
Vis, EPR, and 1H NMR.[51] 
EXAFS spectroscopy was used to verify the fidelity of the metal substitutions, including 
the presence of an intact binuclear center, and to probe the metal-metal distances. Fourier-
transformed Co K-edge EXAFS data for CoCo-NDM-1 are shown at the top of Figure 3.4. Detailed 
fitting results for the three metal-substituted variants are presented in Figures 3.5 - 3.8 and Tables 
3.2 - 3.6. Pertinent “best” fitting details are summarized in Table 3.2. The best fit to the CoCo-
NDM-1 data indicated a first shell of 4 N/O and 0.5 S donors per Co. Inclusion of the sulfur in the 
fit is critical, based on a 47% improvement in the first-shell fit residual (see Figure 3.5 and Table 
3.3, compare fits 1-1 and 1-2). Multiple scattering analyses indicate an average of 2 histidines per 
Co, while the addition of a Co-Co interaction at 3.51 Å resulted in a 66% improvement of the fit 
residual (Table 3.3, compare fits 1-3 and 1-4). This metal-metal distance is 0.13 Å longer than the 
3.38 Å Zn-Zn separation in ZnZn-NDM-1,[52] reflecting the larger covalent radius of Co(II). The 
 
Figure 3.3. Active site structures of metal substituted analogous of NDM-1. A. CoCo NDM-
1, B. ZnCo NDM-1, C. CoCd NDM-1. 
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EXAFS data clearly show that the addition of two equivalents of Co(II) to apo-NDM-1 results in 
the formation of an intact, singly-bridged binuclear center. 
 XAS of ZnCo-NDM-1 affords the unique opportunity to examine both metal sites 
independently. The best fits of the Fourier-transformed Zn K-edge and Co K-edge EXAFS data 
for ZnCo-NDM-1 are shown in Figure 3.4; detailed fitting results are shown in Figures 3.5 and 3.6 
and Tables 3.4 and 3.5, respectively. The Zn K-edge EXAFS data were best fitted with a first shell 
of 4 N/O donors, including 3 histidines per Zn(II). Addition of a Co-Zn interaction at 3.45 Å 
improved the fit residual by 30% (Table 3.4, compare fits 2-2 and 2-3). Inspection of the 
corresponding fits (Figure 3.6) shows that the metal-metal vector dramatically improved the fit at 
R +  > 2.8 Å, but a shorter distance interaction near R +  ~ 2.1 Å remains unmatched. We 
initially attempted to fit this part of the spectrum with a Zn-S interaction, on the assumption that 
perhaps it represented a small amount of scrambling between the two metal sites and would thus 
give us a semi-quantitative measure of the homogeneity of the enzyme. However, all attempts to 
fit this interaction as a Zn-S were visually unsatisfactory, leading to only marginal improvements 
in the fit residuals and mostly unreasonable metal-ligand distances (Table 3.4, compare fits 2-3 
and 2-5). The largest Zn-S contribution that gave reasonable parameters suggests no more than 
20% of the total enzyme held Zn(II) in the Zn2 site. In contrast, inclusion of a Zn-CCO2- interaction 
at 2.51 Å nicely reproduced this feature and reduced the fit residual by a remarkable 73% (compare 
fits Table 3.4, 2-3 and 2-4). The requirement that this feature be a part of the final fit suggests a 
more intimate connection to Asp124 than expected for metal bound at the Zn1 site, but the presence 
of an additional carboxylate bridge would be expected to lead to substantially shorter metal-metal 
separations than observed.[38, 53]  
 The corresponding Co K-edge EXAFS were best fitted with a first shell of 4 N/O and 1 S 
donor (inclusion of the cobalt-sulfur path improved the fit by 46%; compare fits Table 3.5, 3-1 and 
3-2). Multiple scattering analyses indicate only one histidine, while inclusion of an additional Co-
Zn scattering pathway at 3.47 Å improved the fit by 26% (compare fits 3-3 and 3-4 in Table 3.5,). 
In this case, inclusion of a Co-CCO2- scattering pathway at 2.47 Å further lowered the fit residual 
by another 44%. The two metal-metal fits are in excellent agreement, and the set shows a smooth 
progression, from 3.38 (Zn-Zn) to 3.45 (CoZn) to 3.51 Å (CoCo). Taken together, the EXAFS data 
on ZnCo-NDM-1 indicate a highly homogeneous enzyme, with Zn(II) binding at the Zn1 site and 
Co(II) binding at the Zn2 site in a heterodimetallic center.  
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Fourier-
transformed Co 
K-edge EXAFS 
data for CoCd-
NDM-1 are 
shown at the 
bottom of Figure 
3.4. Detailed 
fitting results are 
shown in Figure 
3.8 and Table 3.6. 
The best fit was 
obtained with a 
first shell of 4 N/O donors. The addition of a sulfur scatterer in the first shell resulted in a poorer 
fit (not shown). Multiple scattering analyses indicate 3 histidines per Co ion. Inclusion of a Co-Cd 
vector at 3.56 Å improved the fit by about 26%. A second shallow minimum is observed with a 
3.79 Å Co-Cd vector, and a fit that includes both distances, refining the respective coordination 
numbers, suggests no more than an 80/20 distribution between the two distances. Overall, these 
data are again consistent with the description above, with Co occupying the Zn1 site and Cd 
occupying the Zn2 site in CoCd-NDM-1, in an intact binuclear center. 
Table 3.2. EXAFS fitting results (best fit) for metal-substituted NDM-1.a  
 
Species Model M-N/O M-S M-M  
ZnZn 4 N/O (2 His) + 0.5 S 1.98 (4.5) 2.25 (4.5) 3.38 (7.6)  
CoCo 4 N/O (2 His) + 0.5 S 2.06 (5.3) 2.29 (5.1) 3.51 (6.9)  
ZnCo (Zn) 4 N/O (3 His) 2.01 (6.5)  3.45 (11)  
     (Co) 4 N/O (1 His) + 1 S 2.03 (4.7) 2.32 (5.1) 3.45 (15)  
CoCd (Co) 4 N/O (3 His) 2.01 (3.4)  3.56 (13)  
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)). Fits correspond to those 
shown in Figure 3.4.  
 
 
Figure 3.4. Fourier-transformed EXAFS spectra (solid lines) for metal-
substituted forms of NDM-1 and best fits (open symbols). From top to 
bottom: CoCo-NDM-1 (Co K-edge), ZnCo-NDM-1 (Zn K-edge), ZnCo-
NDM-1 (Co K-edge), CoCd-NDM-1 (Co K-edge).  
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Figure 3.5. Fourier transforms (A) of Co K-edge EXAFS (B) for CoCo-NDM-1. The solid 
lines represent the data, the open symbols represent the various fits, corresponding to Table 
3.3. 
 
Table 3.3. Fitting results for Co K-edge EXAFS of CoCo-NDM-1.a 
 
Fit Model Co-N/O Co-S Co-His b Co-Co Rf c Ru c 
1-1 4.5 N/O 2.07 (4.6)    47 172 
1-2 4 N/O + 0.5 S 2.06 (5.2) 2.30 (2.4)   25 152 
1-3 4 N/O (2 His)  
+ 0.5 S 
2.06 (5.7) 2.28 (5.0) 3.00 (4.8)  3.16 (5.0)   
4.54 (0.1)  4.63 (9.5) 
 64   90 
1-4 4 N/O (2 His)  
+ 0.5 S + Co-Co 
2.06 (5.3) 2.29 (5.1) 3.00 (3.9)  3.15 (0.1) 
3.96 (5.6)  4.59 (15) 
3.51 (6.9)  22   76 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.3 Å (fits 1-2), 0.3-4.0 Å 
(fits 3-4)]. 
b Imidazole multiple scattering paths represent combined paths (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Figure 3.6. Fourier transforms (A) of Zn K-edge EXAFS (B) for ZnCo-NDM-1. The solid 
lines represent the data, the open symbols represent the various fits, corresponding to Table 
3.4. 
 
Table 3.4. Fitting results for Zn K-edge EXAFS of ZnCo-NDM-1.a 
 
Fit Model Zn-N/O Zn-Hisb Zn-C Zn-Co Rfc Ruc 
2-1 4 N/O 2.01 (6.5)    46 222 
2-2 4 N/O (3 His) 2.00 (6.4) 2.91 (5.1)  3.14 (3.8) 
4.11 (15)   4.30 (18) 
   91    88 
2-3 4 N/O (3 His)  
+ 1 Co 
2.00 (6.4) 2.91 (6.0)  3.12 (3.1) 
4.16 (14)   4.41 (18) 
 3.45 (9.4) 73   71 
2-4 4 N/O (3 His) 
+ 1 C + Zn-Co 
2.01 (6.5) 2.92 (5.2)  3.13 (5.7) 
4.16 (13)   4.41 (18) 
2.51 (0.2) 3.45 (11) 20   42 
2-5 d 4 N/O (3 His) 
+ 0.2 S + Zn-Co 
2.01 (6.5) 2.94 (6.0)  3.22 (12) 
4.16 (12)   4.41 (23) 
 3.45 (10) 54   57 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-
integer coordination number fits to filtered EXAFS data [k = 1.5-13.5 Å-1; R = 0.5 – 2.3 Å (fit 1), 
0.3-4.0 Å (fits 2-5)]. 
b Imidazole multiple scattering paths represent combined paths (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
d Not shown. The Zn-S distance, Debye-Waller factor, and coordination number were refined for this fit, 
in addition to the distance and Debye-Waller factor for all other shells. The Zn-S distance (Debye-
Waller) refined to 2.31 Å (0.1), while the coordination number refined to 0.2. 
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Figure 3.7. Fourier transforms (A) of Co K-edge EXAFS (B) for ZnCo-NDM-1. The solid 
lines represent the data, the open symbols represent the various fits, corresponding to Table 
3.5. 
Table 3.5. Fitting results for Co K-edge EXAFS of ZnCo-NDM-1.a 
 
Fit Model Co-N/O Co-S Co-His b Co-C Co-Zn Rf c Ru c 
3-1 5 N/O 2.06 (7.6)     133 270 
3-2 4 N/O + 1 S 2.03 (5.3) 2.32 (6.7)      72 235 
3-3 4 N/O (1 His)  
+ 1 S 
2.03 (4.6) 2.32 (5.6) 3.00 (0.1)  3.19 (0.1) 
4.14 (5.7)  4.59 (8.8) 
  119 136 
3-4 4 N/O (1 His)  
+ 1 S + Co-
Zn 
2.03 (4.7) 2.32 (5.6) 2.99 (1.0)  3.19 (1.0) 
4.14 (4.2)  4.60 (8.2) 
 3.47 
(14) 
  88 123 
3-5 4 N/O (1 His)  
+ 1 S + Co-
Zn + 1 C 
2.04 (4.0) 2.32 (5.1) 2.99 (1.0)  3.19 (0.1) 
4.14 (4.2)  4.60 (8.2) 
2.47 
(1.0) 
3.45 
(15) 
  49   87 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11.8 Å-1; R = 0.5 – 2.3 Å (fits 1-2), 0.3-4.0 Å (fits 
3-5)]. 
b Imidazole multiple scattering paths represent combined paths (see Materials and Methods).  
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Figure 3.8. Fourier transforms (A) of Co K-edge EXAFS (B) for CoCd-NDM-1. The solid 
lines represent the data, the open symbols represent the various fits, corresponding to Table 
3.6. 
 
Table 3.6. Fitting results for Co K-edge EXAFS of CoCd-NDM-1.a 
 
Fit Model Co-N/O Co-His b Co-Cd Rf c Ru c 
4-1 4 N/O 2.01 (3.4)   51 230 
4-2 4 N/O (3His) 2.01 (3.4) 3.00 (5.3)  3.20 (7.5) 
4.19 (3.2)  4.58 (2.0) 
 68 115 
4-3 4 N/O (3His)  
+ Co-Cd 
2.01 (3.4) 2.97 (5.0)  3.19 (8.4) 
4.19 (3.2)  4.60 (16) 
3.56 (13) 50   98 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from 
integer or half-integer coordination number fits to filtered EXAFS data [k = 1.5-12 Å-
1; R = 0.5 – 2.3 Å (fit 1), 0.3-4.0 Å (fits 2-3)]. 
b Imidazole multiple scattering paths represent combined paths (see Materials and 
Methods).  
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Probing the reaction mechanism of BcII, SfhI, and GOB-18. BcII was first identified and 
isolated in 1974, and it belongs to the B1 subclass, which often contains two Zn(II) ions in the 
active site, although there have been reports of analogs of BcII with fewer than 2 equivalents of 
Zn(II).[54-57] There are 14 BcII crystal structures reported in the Protein Data Bank 
(PDB.ORG).[54-56] The first reported crystal structure of BcII contained only one Zn(II); 
however, the crystals for this structure were grown at low pH.[24] Subsequent structures have 
confirmed a dinuclear Zn(II) site in BcII.[54-56] Previous EXAFS studies on BcII showed good 
agreement with the crystallographic data.[50] EXAFS spectra of resting ZnZn-BcII were 
previously reported and were fitted with an average first shell of 4 N/O and 0.5 S scatterers, with 
an average of 2 imidazoles per Zn(II) and a Zn-Zn separation of 3.42 Å. SfhI was first identified 
from environmental drinking waters in northeast Portugal, and it belongs to the B2 class.[58, 59] 
Crystal structures indicate that SfhI contains one Zn(II) ion in the active site and that the metal ion 
is coordinated by Asp, Cys, and His.[32], which is the consensus Zn2 site. GOB-18 was isolated 
from the Gram negative opportunistic pathogen, Elizabethkingia meningoseptica, and 
interestingly, GOB-18 binds one Zn(II) at the Zn2 site even though it belongs to the B3 MBL 
subclass.[33] The metal binding sites of these enzymes are shown in Figure 3.9.  
To probe the catalytic mechanism of MBLs, presteady-state kinetic experiments were 
performed using chromogenic (nitrocefin/chromacef) substrates. A ring-opened, nitrogen anionic 
intermediate was detected in diode array UV-Vis spectroscopic studies on L1,[21, 37, 60] 
CcrA,[61, 62] NDM-1[10] and VIM-2;[19] however, a similar intermediate was not detected in 
studies on GOB,[33] ImiS,[36] Bla2,[47] BcII,[63, 64] or IMP-1.[42] In this study having one 
enzyme from each of the distinct MBL classes allowed us to address mechanistic/structural 
similarities of the enzymes using EXAFS. Nitrocefin is not an approved drug,[65] and its 
 
Figure 3.9. Active sites of the A: BcII[50]; B: SfhI[32]; and C: GOB-18[33]. W indicates a 
water molecule or hydroxyl group. 
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styrylbenzene substituent, with an extended π-delocalized system, has been implicated in the 
formation/stabilization of the anionic species.[10] Other -lactam containing substrates do not 
have this substituent, suggesting that this anionic intermediate may not be formed when other 
substrates, including clinically-relevant ones, are hydrolysed. Imipenem, which is one of the most 
employed antibiotics clinically and does not contain the styrylbenzene substituent, is a substrate 
of B1, B2, and B3 lactamases and was used in these RFQ-EXAFS studies.[66, 67] 
Vila and co-workers monitored imipenem hydrolysis by GOB-18 and SfhI (Zn(II) in the Zn2 site 
only) using presteady-state kinetic studies with photodiode-array UV-Vis detection, and the 
analysis of their progress curves was consistent with both enzymes utilizing a kinetic mechanism 
in which a shorted-lived intermediate (called EI1) was formed during early steps of the reaction 
and a second intermediate (called EI2) subsequently accumulated. Vila and co-workers proposed 
that EI1 is an anionic species with a negatively-charged nitrogen atom, which is stabilized by the 
metal ion in the consensus Zn2 site (Vila and coworkers, unpublished results). The formation of 
this intermediate resulted in an increase in the coordination number of Co(II) in Co(II)-substituted 
GOB-18; however, similar studies on Co(II)-SfhI were not reported. Best fits of the stopped-flow 
kinetic data required that there were two fates of EI1: this intermediate could breakdown and 
directly form product (called branch) or this intermediate could convert to the second intermediate 
EI2. Previously in studies on BcII, Vila speculated that EI2, which absorbs strongly at 340 nm when 
imipenem is used as substrate, has a carbanion at position 3 in the 5-membered ring of imipenem, 
which would be in resonance with the imipenem substituent at position 3 (thio 2-[(iminomethyl) 
amino] ethyl). A similar carbanion has been proposed for NDM-1 based on crystallographic 
studies.[18] The two reported intermediates are similar to those described for imipenem hydrolysis 
by di-Zn(II) BcII, and correspond to species in which the C-N bond of the β-lactam ring has already 
been cleaved.[68] Under various substrate/enzyme concentration conditions, the lifetime of EI1 
was on the order of tens to hundreds of milliseconds and the formation of EI2 was on the order of 
seconds. Both of these intermediates could be interrogated with RFQ-EXAFS studies. 
EXAFS spectra were obtained on resting GOB-18 (Zn(II)-GOB-18), a reaction mixture of 
Zn(II)-GOB-18 and imipenem rapid freeze quenched after 10 ms of reaction, and the final GOB-
18/hydrolyzed imipenem complex. Best fits of the Zn K-edge EXAFS spectra of resting Zn(II)-
GOB-18 were consistent with a first shell of 4 N/O at 2.01 Å (including 2 histidines), in agreement 
with previous crystallographic studies.[33] Upon reaction with imipenem for 10 ms, the average 
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Zn-N/O bond length increased to 2.07 Å, consistent with an increase in the coordination number 
of Zn(II) (Figure 3.10 and Table 3.7). This result is consistent with stopped-flow UV-Vis studies 
on Co(II)-substituted GOB-18, which showed a decrease in the absorbance of the d-d bands of 
Co(II) during substrate binding and catalysis (Vila, unpublished results). The lifetime of the EI1 
species, as predicted by previous stopped-flow UV-Vis studies (Vila and coworkers, unpublished), 
suggests that the predominant species in our RFQ-EXAFS sample was EI1. However, the first shell 
bond length in the product complex remained substantially longer than that in the resting enzyme 
at 2.08 Å (Figure 3.11 and Table 3.8), suggesting that the Zn(II) ion progressed from four-
coordinate in the resting state to five-coordinate in the 10 ms intermediate and product complexes. 
This result is not consistent with the stopped-flow studies because the aforementioned stopped 
flow studies demonstrated an increase in the absorbance of the d-d bands after the reaction was 
complete (the concentration of enzyme and substrate used in the stopped-flow studies would have 
resulted in a sample containing primarily EP)(Vila and workers unpublished). The XANES spectra 
of the RFQ sample (Figure 3.12) showed a dramatic increase in the white line intensity that was 
retained in the product complex, which is also consistent with an increase in the coordination 
number in the EP complex. We do acknowledge that the Co(II) in Co(II)-substituted GOB-18 may 
not behave identically as Zn(II) in the native enzyme. 
RFQ-EXAFS studies were also used to probe the mechanism of SfhI. On progression from 
resting enzyme to the 10 ms intermediate to the enzyme-product complex, the XANES spectra for 
SfhI were nearly superimposable (Figure 3.12), indicating a lack of appreciable rearrangement at 
the metal sites during catalysis. This result is supported by a comparison of the EXAFS data in 
Figure 3.13 - 3.15. Best fits of the Zn-K edge EXAFS data of resting SfhI demonstrate 4 N/O 
scatterers at 2.02 Å and 1 S at 2.29 Å, and multiple scattering analyses suggest coordination of 1 
His (Figure 3.13 and Table 3.9). Best fits of the EXAFS spectra for the sample containing SfhI 
and imipenem quenched at 10 ms indicate 3 N/O scatterers at 2.02 Å and 1 S at 2.29 Å in the first 
shell, and multiple scattering analyses suggest one His (Figure 3.14 and Table 3.10). EXAFS 
spectra of the SfhI/product complex were almost identical with those of the 10 ms quenched 
sample (Figure 3.15 and Table 3.11). The only appreciable difference is a slight enhancement of 
the Zn-S scattering in the 10 ms sample, and some complex outer shell contributions in the sample 
quenched at 10 ms that disappear in the product complex. The curve fits showed similar behavior, 
with a lack of appreciable changes across the set of SfhI samples, aside from some difficultly in 
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fitting the outer shells in the spectra of the 10 ms intermediate (see Figure 3.13 - 3.15). Stopped-
flow UV-Vis studies on Co(II)-substituted SfhI were not completed; therefore, it is not clear if 
those studies would have predicted a change in coordination number of the metal ion during 
substrate binding or catalysis. However, the EXAFS data on SfhI demonstrate no change in 
coordination number of Zn(II) during catalysis at 10 ms or in the enzyme/product complex. Given 
the stopped-flow data on SfhI, the predominant species in the 10 ms sample was EI1, and our data 
clearly show that substrate/intermediate binding does not change coordination. It is possible that 
substrate replaced the terminally-bound water, but the EXAFS data cannot address this possibility.  
 Imipenem hydrolysis by the B1 enzyme, ZnZn-BcII, takes place via a branched kinetic 
mechanism, with accumulation of an anionic intermediate stabilized by the Zn2 ion.[68] We probed 
imipenem hydrolysis by using RFQ-EXAFS. The XANES spectra for ZnZn-BcII displayed little 
change on progression from resting enzyme to intermediate or to enzyme-product complex, aside 
from a sharpening of the first feature above the white line signal (see Figure 3.12). The EXAFS 
spectrum of resting ZnZn-BcII was previously reported and was fitted with an average first shell 
of 4 N/O and 0.5 S scatterers, with an average of 2 imidazoles per Zn(II) and a Zn-Zn separation 
of 3.42 Å.[50] After 10 ms of reaction with imipenem, the first shell peak in the Fourier-transform 
diminished and broadened. However, the best fit was still obtained with 4 N/O + 0.5 S scatterers 
per Zn(II) ion (see Figure 3.17 and Table 3.12). The changes in the Fourier-transform could only 
be attributed to a small increase in the Zn-S distance (+ 0.02 Å) and to a two-fold decrease in its 
Debye-Waller factor. The inclusion of a Zn-Zn interaction at 3.82 Å resulted in a 60% 
improvement in the fit residual (compare fits Table 3.12, fits 10-5 and 10-6 in Figure 3.17). A fit 
that included two Zn-Zn sub-populations refined to 90% at 3.82 Å and 10% at 3.51 Å resulted in 
a further 28% improvement in the fit residual. The EXAFS spectrum of the corresponding product 
complex of ZnZn-BcII and imipenem was best fitted with the same parameters, including a 4 N/O 
+ 0.5 S first shell and an average of 2 histidine ligands per Zn(II) (Figure 3.18). The Zn-Zn distance 
was refined to 3.51 Å, giving a 60% improvement in fit residual (compare fits Table 3.13, 10-9 
and 10-10). This distance suggested that the 10% sub-population at 10 ms can be accounted for by 
a small amount of enzyme-product complex. 
 Briefly, EXAFS results on SfhI and BcII indicate no change in coordination number of Zn(II) 
upon binding of substrate, intermediate, or product, while the results on GOB-18 suggest an 
increase in coordination number of Zn2 upon substrate, intermediate, and product binding.  
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3.5. Discussion 
X-ray absorption spectroscopy has been a reliable technique to study metalloprotein active 
sites since the early 1970s.[69] This technique offers two major advantages over X-ray 
crystallography: 1) XAS does not require crystalline material and can be applied on frozen 
solutions, which means that frozen reaction intermediates can be investigated, and 2) XAS is 
element-specific, which allows researchers to study multiple metal centers in a single sample as 
long as the metal ions are different (as in heterobimetallic enzymes).[70] In our research XAS is a 
critical technique because it is the only common spectroscopic technique that can be used to 
interrogate Zn(II) metalloproteins. Our group has used XAS to probe the metal binding site in 
several proteins.[10, 19, 22, 33, 42, 47, 48, 50, 51, 71] Recently, our lab developed strategies to 
prepare heterobimetallic forms of the MBLs,[22, 42, 47, 48, 72, 73], allowing us to probe both 
metal centers in the same sample independently. In this chapter, we used XAS to address three 
distinct, but related, issues involving MBLs: (1) we probed the metal binding site of NDM-1 to 
address controversies about metal binding to these enzymes, (2) we used EXAFS to confirm the 
metal centers in heterobimetallic analogs of NDM-1, and (3) we used XAS and RFQ-XAS to probe 
the reaction mechanism of a MBL from each of the representative MBL classes.  
Several groups have reported purification, characterization, and crystal structures of 
recombinant NDM-1; however, there are conflicting data on NDM-1 regarding metal binding and 
catalytic activity.[12-18, 74-76] There are significantly different steady-state constants reported 
for NDM-1 by different groups.[13, 74] For the articles that report metal content, there are different 
values for metal ion:enzyme stoichiometries presented.[12-18] A few studies reported that NDM-
1 binds to one Zn(II),[12, 13] while other studies showed NDM-1 binds tightly to two Zn(II) 
ions.[10, 15, 16, 51] One group reported that NDM-1 binds one Zn(II) tightly and one Zn(II) more 
loosely.[74] Metal-metal distances in NDM-1 containing two equivalents of metal have been 
reported to range between 3.29 Å and 4.8 Å.[19] Recently, crystal structures of NDM-1 bound to 
a reaction intermediate were published, and the metal-metal distances were reported to be 3.8 Å 
and 4.5 Å (4RL0 and 4RL2).[18] In our work, we proposed to address some of the reported 
differences in NDM-1 by using EXAFS spectroscopy.[70] 
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Figure 3.10. Fourier transforms (left) of k3-weighted EXAFS spectra (right) for GOB freeze-
quenched after 10 ms of reaction with imipenem (solid lines) and corresponding curve fits 
(open symbols).  
 
Table 3.7. Detailed EXAFS curve fitting results for GOB freeze-quenched after 10 ms of 
reaction with imipenem.a 
 
Fit Model Zn-O Zn-N Zn-CCO2- Zn-His 
b Rf c Ru c 
3-1 5 N/O  2.07 (6.4)   84 321 
3-2 3 N + 2 O 1.97 (0.9) 2.13 (4.8)   33 286 
3-3 3 N (2 His) + 2 O 1.96 (2.9) 2.14 (11)  
2.94 (2.6) 3.12 (0.1) 
4.17 (17) 4.44 (15) 
223 237 
3-4 3 N (2 His) + 2 O 1.96 (4.3) 2.14 (9.6) 2.50 (1.6) 
2.95 (1.3) 3.11 (6.1) 
4.18 (13) 4.43 (19) 
183 200 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.1-4.2 Å (fits 3-
4)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Figure 3.11. Fourier transforms (left) of k3-weighted EXAFS spectra (right) for the GOB-
imipenem product complex (solid lines) and corresponding curve fits (open symbols).  
 
Table 3.8. Detailed EXAFS curve fitting results for the GOB-imipenem product complex.a 
 
Fit Model Zn-O Zn-N Zn-CCO2- Zn-His 
b Rf c Ru c 
3-5 5 N/O  2.08 (9.2)   68 310 
3-6 3 N + 2 O 1.99 (1.9) 2.15 (1.8)   33 281 
3-7 3 N (2 His) + 2 O 1.99 (1.1) 2.14 (3.2)  
2.86 (5.0) 2.94 (2.1) 
3.93 (3.9) 4.50 (20) 
96 237 
3-8 3 N (2 His) + 2 O 1.99 (1.3) 2.15 (1.9) 2.65 (0.6) 
2.84 (4.9) 3.19 (1.6) 
4.02 (7.3) 4.50 (21) 
72 182 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.1-4.2 Å (fits 3-
4)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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EXAFS spectra of our recombinant NDM-1, which tightly binds 2 equivalents of Zn(II),[10] 
were best fitted with an average Zn(II) coordination sphere that matches nicely those of other B1 
MBLs, with an average ligand environment of 2 His, 0.5 Cys and 2.5 other low-Z ligands, 
presumably solvent molecules and or carboxylate oxygens. The metal-metal distance was 3.38 Å 
for NDM-1, which is in between the crystallographically-determined distance of 3.2 Å[74] and the 
QM/MM modeling-determined distance of 3.58 Å[74] but significantly shorter than metal-metal 
distances reported for a NDM-1/product complex (4.59 Å)[15] and a Zn-Cd analog (3.64 Å)[77]. 
While there are conflicting data on the metal-metal distances in NDM-1 from crystallographic 
studies, our EXAFS data on NDM-1 are consistent with previous data on other MBLs. These data 
nicely show how NDM-1 fits into the B1 subclass and that our recombinant enzyme can be used 
for future rapid-freeze quench spectroscopic studies. 
 
Figure 3.12. Normalized XANES spectra for BcII (top), SfhI (center), and GOB-18 (bottom) 
in the resting state (black line), freeze-quenched after 10 ms of reaction with imipenem (red 
lines), and the corresponding product complexes (gray lines). 
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Figure 3.13. Fourier transforms (left) of k3-weighted EXAFS spectra (right) for resting SfhI 
(solid lines) and corresponding curve fits (open symbols).  
 
Table 3.9. Detailed EXAFS curve fitting results for resting SfhI.a 
 
Fit Model Zn-N/O Zn-S Zn-His b Rf c Ru c 
9-1 6 N/O 2.05 (7.7)   159 191 
9-2 4 N/O + 1 S 2.02 (5.2) 2.28 (3.6)  11 97 
9-3 4 N/O (1 His) + 1 S 2.02 (4.8) 2.29 (3.5) 
2.82 (11) 3.19 (0.1) 
4.11 (17) 4.47 (12) 
45 52 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derived from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.1-4.2 Å (fit 3)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Figure 3.14. Fourier transforms (left) of k3-weighted EXAFS spectra (right) for SfhI freeze-
quenched after 10 ms of reaction with imipenem (solid lines), and corresponding curve fits 
(open symbols).  
 
Table 3.10. Detailed EXAFS curve fitting results for resting SfhI freeze-quenched after 10 ms 
of reaction with imipenem.a 
 
Fit Model Zn-N/O Zn-S Zn-His b Rf c Ru c 
9-4 6 N/O 2.06 (8.6)   200 350 
9-5 3 N/O + 1 S 2.02 (3.7) 2.28 (3.3)  28 253 
9-6 3 N/O (1 His) + 1 S 2.02 (2.3) 2.29 (3.0) 
2.84 (11) 3.61 (0.1) 
4.26 (2.1) 4.37 (1.1) 
196 209 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derived from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.1-4.2 Å (fit 3)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
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Figure 3.15. Fourier transforms (left) of k3-weighted EXAFS (right) for the SfhI-imipenem 
product complex (solid lines), and corresponding curve fits (open symbols).  
 
Table 3.11. Detailed EXAFS curve fitting results for the SfhI-imipenem product complex.a 
 
Fit Model Zn-N/O Zn-S Zn-His b Rf c Ru c 
9-7 6 N/O 2.05 (8.2)   117 176 
9-8 3 N/O + 1 S 2.01 (3.3) 2.28 (3.9)  13 97 
9-9 3 N/O (1 His) + 1 S 2.02 (3.1) 2.29 (4.3) 
2.82 (6.8) 3.17 (0.1) 
4.08 (14) 4.47 (14) 
55 67 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derived from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.1-4.2 Å (fit 3)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
 
          
     





N
i
obsiobsi
N
i
calcicalciobsiobsi
1
2
,
2
,
1
2
,
2
,
2
,
2
,
ImRe
ImReImRe


90 
 
 
 
Figure 3.16. Fourier-transforms (left) of k3-weighted EXAFS (right) for BcII freeze-quenched 
after 10 ms of reaction with imipenem (solid lines), and corresponding curve fits (open 
symbols).  
 
Table 3.12. Detailed EXAFS curve fitting results for BcII freeze-quenched after 10 ms of 
reaction with imipenem.a 
 
Fit Model Zn-N/O Zn-S Zn-His b Zn-Zn Rf c Ru c 
10-1 5 N/O 2.04 (10)    197 366 
10-2 2 N + 2 O 
1.96 (2.5) 
2.12 (1.3) 
   136 325 
10-3 4 N/O + 0.5 S 2.02 (4.1) 2.29 (2.9)     90 322 
10-4 2 N + 2 O + 0.5 S 
1.91 (1.6) 
2.06 (3.9) 
2.31 (2.0)     66 309 
10-5 
2 N + 2 O (2 His)  
       + 0.5 S 
1.97 (5.4) 
2.12 (9.4) 
2.29 (5.2) 
2.92 (4.4) 3.16 (0.1) 
4.15 (16)  4.45 (17) 
   96 193 
10-6 
2 N + 2 O (2 His)  
   + 0.5 S + Zn-Zn d 
1.97 (5.2) 
2.13 (8.2) 
2.29 (5.3) 
2.92 (4.6) 3.16 (0.1) 
4.24 (15)  4.45 (17) 
3.82 (7.1)   39 143 
a 
Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derived from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-4) or 0.1-4.2 Å (fits 5-
6)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
c Goodness of fit (Rf for fits to filtered data; Ru for fits to unfiltered data) defined as 1000*
, where N is the number of data points. 
d Inclusion of two Zn-Zn populations yielded a maximum reduction in fit residual to 28, with 0.1 Zn at 3.51 Å 
and 0.9 Zn at 3.82 Å. 
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Figure 3.17. Fourier transforms (A) of k3-weighted EXAFS (B) for the BcII-imipenem product 
complex (solid lines), and corresponding curve fits (open symbols).  
 
Table 3.13. Detailed EXAFS curve fitting results for the BcII-imipenem product complex.a 
 
Fit Model Zn-N/O Zn-S Zn-His b Zn-Zn Rf c Ru c 
10-7 5 N/O 
2.03 
(7.8) 
   89 243 
10-8 4 N/O + 0.5 S 
2.02 
(5.6) 
2.29 
(4.5) 
  48 225 
10-9 4 N/O (2 His) + 0.5 S 
2.02 
(5.9) 
2.28 
(5.6) 
2.93 (2.9)  3.15 (1.0) 
4.14 (18)   4.44 (24) 
 95 76 
10-10 
4 N/O (2 His) + 0.5 S 
+ Zn-Zn 
2.02 
(6.0) 
2.28 
(6.0) 
2.94 (3.3)  3.13 (0.8) 
4.16 (17)   4.44 (15) 
3.51 
(7.9) 
34 57 
10-11 
4 N/O (2 His) + 0.5 S 
+ 0.5 C + Zn-Zn d 
2.02 
(6.0) 
2.30 
(7.3) 
2.94 (3.3)  3.13 (0.9) 
4.17 (14)   4.44 (21) 
3.51 
(8.1) 
26 44 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derived from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12.5 Å-1; R = 0.7-2.2 Å (fits 1-2) or 0.2-4.2 Å (fits 3-
5)]. 
b Multiple scattering paths represent combined paths, as described previously (see Materials and Methods). 
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RFQ-EXAFS studies on the ZnZn-analog of NDM-1 would be very difficult to interpret 
because it would be almost impossible to interrogate one metal binding site upon substrate binding 
without overlapping signals from the other metal binding site. Fortunately, Co(II)-substituted 
analogs (CoCo, ZnCo, and CoCd) of NDM-1 have been prepared and characterized,[51] and the 
use of these analogs in RFQ-EXAFS allowed for us to probe the reaction mechanism and attribute 
metal binding site changes upon substrate binding to a specific site. EXAFS spectroscopy has been 
used in past to study the heterobimetallic forms MBLs to study the fidelity of metal ions and 
investigate the catalytic mechanism.[19, 42, 47, 48, 50, 70] 
EXAFS spectra were obtained and analyzed on two heterodimetallic analogs of NDM-1. 
The data confirm the fidelity of the heterodimetallic centers in the analogs, with zinc present at the 
Zn1 site and cobalt present at the Zn2 site in the ZnCo analog of NDM-1 and cobalt present at the 
Zn1 site and cadmium present at the Zn2 site in the CoCd analog of NDM-1. The EXAFS-derived 
metal-metal separations (Table 3.2) track with the covalent radii of the metal ions (3.38 Å (Zn-Zn) 
to 3.45 Å (Zn-Co) to 3.51 Å (Co-Co) to 3.56 Å (Co-Cd)), suggesting there is only minimal 
modulation of the metal-oxygen-metal angles, which we would expect to translate into only minor 
differences in reaction rates, as was seen. The metal-metal distances of these heterobimetallic 
forms of NDM-1 were slightly longer than that of Zn-Zn NDM-1; a result that is similar to results 
on metal-substituted forms of other MBLs.[19] Previous RFQ-EXAFS studies on MBL L1 
demonstrated that the metal-metal distance increased during catalysis; however, no information 
about specific sites was possible because the Zn1 and Zn2 sites both contained Zn(II) and EXAFS 
data described information that was an average of the two sites.[71] The work described in this 
study now allow for each metal binding site to be examined separately. These studies will be 
completed in the future. 
We also used RFQ-EXAFS to study the mechanism of imipenem hydrolysis by three 
different MBLs: a di-Zn(II) B1 enzyme (BcII), a mono-Zn(II) B2 carbapenemase (Sfh-I), and an 
atypical B3 enzyme that contained only one Zn(II) in the Zn2 site (GOB-18). Direct monitoring of 
the Zn(II) coordination sphere by RFQ-XAS showed that the accumulation of intermediate species 
involves no change in the coordination number of either Zn(II) in BcII. For the dinuclear Zn(II)-
containing BcII, formation of intermediate species was accompanied by a significant lengthening 
of the Zn(II)-Zn(II) distance, and this distance decreases, albeit not to distance in the resting 
enzyme, to 3.51 Å in the enzyme-product adduct. This behaviour is analogous to that reported for 
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nitrocefin hydrolysis by the dinuclear B3 enzyme L1.[71] The RFQ-EXAFS results on the 10 ms 
intermediate of GOB-18 and imipenem showed an increased average Zn-N/O bond length, and 
this increased bond length remained the same in the GOB-18/product complex. This increased 
bond length suggests five-coordinate Zn(II) in the 10 ms and product samples, and the EXAFS 
data supports four-coordinate Zn(II) in the resting form of the enzyme. In addition, the XANES 
spectrum of the 10 ms sample showed a significant increase in the white line intensity that was 
retained in the spectrum of the product complex, which is consistent with an increase in the 
coordination number of Zn(II) in both samples. As discussed above, the result on the EP complex 
of GOB-18 and imipenem are not consistent with previous stopped-flow UV-Vis studies (Vila and 
co-workers, unpublished). Finally, the EXAFS data on mono-Zn(II) B2 enzyme SfhI were not 
consistent with changes in the coordination geometry of Zn(II) during turnover.  
Vila’s stopped-flow UV-Vis with diode-array detection studies support the presence of two 
intermediates in the active sites in all three enzymes, despite the enzymes having different active 
sites, metal/enzyme stoichiometries, and changes in coordination number during catalysis (Vila 
and co-workers, unpublished). The stopped-flow studies suggest mechanistic convergent evolution 
for these enzymes. However, the EXAFS data indicate that catalysis is achieved differently by the 
metal centers in these enzymes, suggesting structural divergent evolution. This point is important 
because it suggests that an inhibitor that targets the Zn2 site in the MBLs may not be a universal 
inhibitor. 
 
3.6. Summary  
In summary, this chapter described three separate questions about the MBLs and how XAS 
spectroscopy could be used to address these questions. Clearly, EXAFS is a very sensitive 
technique that allows for detailed information about the environment of the metal ion(s) to be 
gleaned. The coupling of RFQ techniques with XAS allows for interrogation of enzymatic 
reactions during catalysis. It would be interesting to probe the reaction mechanisms of several of 
the heterobimetallic forms of MBLs at faster time points, which would require the construction 
and optimization of a different RFQ instrument. The studies herein most likely involved 
enzyme/intermediate or enzyme/product complexes. Freeze quenching a reaction at 100 
microseconds may allow for information about the enzyme/substrate complex. An RFQ system 
that would allow for faster freeze quench times is currently being developed in the lab.  
94 
 
3.7. References 
1 K. K. Kumarasamy, M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. 
Chaudhary, M. Doumith, C. G. Giske, S. Irfan, P. Krishnan, A. V. Kumar, S. Maharjan, S. 
Mushtaq, T. Noorie, D. L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J. B. 
Sarma, M. Sharma, E. Sheridan, M. A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, 
W. Welfare, D. M. Livermore and N. Woodford (2010) Lancet Infect Dis 10:597-602 
2 C. S. Lee and Y. Doi (2014) Infect Chemother 46:149-164 
3 Antibiotic Resistance Threats in the United States (2013) Eurosurveillance 18:28-28 
4 M. W. Crowder, J. Spencer and A. J. Vila (2006) Acc Chem Res 39:721-728 
5 P. Nordmann, L. Poirel, T. R. Walsh and D. M. Livermore (2011) Trends Microbiol 
19:588-595 
6 R. A. Bonomo (2011) Clin Infect Dis 52:485-487 
7 T. H. Koh, C. T. Khoo, L. Wijaya, H. N. Leong, Y. L. Lo, L. C. Lim and T. Y. Koh (2010) 
Lancet Infect Dis 10:828 
8 J. M. Rolain, P. Parola and G. Cornaglia (2010) Clin Microbiol Infect 16:1699-1701 
9 C. Lascols, M. Hackel, S. H. Marshall, A. M. Hujer, S. Bouchillon, R. Badal, D. Hoban 
and R. A. Bonomo (2011) J Antimicrob Chemother 66:1992-1997 
10 H. Yang, M. Aitha, A. M. Hetrick, T. K. Richmond, D. L. Tierney and M. W. Crowder 
(2012) Biochemistry 51:3839-3847 
11 K. Bush, T. Palzikill, G. Jacoby http://www.lahey.org/studies/other.asp#table1. Jürgen 
Pleiss,  
12 V. L. Green, A. Verma, R. J. Owens, S. E. Phillips and S. B. Carr (2011) Acta Crystallogr, 
Sect F: Struct Biol Cryst Commun 67:1160-1164 
13 Y. Kim, C. Tesar, J. Mire, R. Jedrzejczak, A. Binkowski, G. Babnigg, J. Sacchettini and 
A. Joachimiak (2011) PLoS One 6:e24621 
14 D. King and N. Strynadka (2011) Protein Sci 20:1484-1491 
15 H. Zhang and Q. Hao (2011) FASEB J 25:2574-2582 
16 Y. Guo, J. Wang, G. Niu, W. Shui, Y. Sun, H. Zhou, Y. Zhang, C. Yang, Z. Lou and Z. 
Rao (2011) Protein & cell 2:384-394 
17 D. T. King, L. J. Worrall, R. Gruninger and N. C. Strynadka (2012) J Am Chem Soc 
134:11362-11365 
95 
 
18 H. Feng, J. Ding, D. Zhu, X. Liu, X. Xu, Y. Zhang, S. Zang, D. C. Wang and W. Liu (2014) 
J Am Chem Soc 136:14694-14697 
19 M. Aitha, A. R. Marts, A. Bergstrom, A. J. Moller, L. Moritz, L. Turner, J. C. Nix, R. A. 
Bonomo, R. C. Page, D. L. Tierney and M. W. Crowder (2014) Biochemistry 53:7321-
7331 
20 E. G. Orellano, J. E. Girardini, J. A. Cricco, E. A. Ceccarelli and A. J. Vila (1998) 
Biochemistry 37:10173-10180 
21 Z. Hu, G. Periyannan, B. Bennett and M. W. Crowder (2008) J Am Chem Soc 130:14207-
14216 
22 Z. Hu, L. J. Spadafora, C. E. Hajdin, B. Bennett and M. W. Crowder (2009) Biochemistry 
48:2981-2989 
23 W. Humphrey, A. Dalke and K. Schulten (1996) J Mol Graphics 14:33-38 
24 A. Carfi, S. Pares, E. Duee, M. Galleni, C. Duez, J. M. Frere and O. Dideberg (1995) 
EMBO J 14:4914-4921 
25 S. M. Fabiane, M. K. Sohi, T. Wan, D. J. Payne, J. H. Bateson, T. Mitchell and B. J. Sutton 
(1998) Biochemistry 37:12404-12411 
26 G. Garau, C. Bebrone, C. Anne, M. Galleni, J. M. Frere and O. Dideberg (2005) J Mol Biol 
345:785-795 
27 I. Garcia-Saez, P. S. Mercuri, C. Papamicael, R. Kahn, J. M. Frere, M. Galleni, G. M. 
Rossolini and O. Dideberg (2003) J Mol Biol 325:651-660 
28 N. O. Concha, B. A. Rasmussen, K. Bush and O. Herzberg (1996) Structure 4:823-836 
29 J. M. Frere, M. Galleni, K. Bush and O. Dideberg (2005) J Antimicrob Chemother 55:1051-
1053 
30 J. H. Ullah, T. R. Walsh, I. A. Taylor, D. C. Emery, C. S. Verma, M. Galleni and J. Spencer 
(1998) J Mol Biol 284:125-136 
31 J. D. Docquier, M. Benvenuti, V. Calderone, M. Stoczko, N. Menciassi, G. M. Rossolini 
and S. Mangani (2010) Antimicrob Agents Chemother 54:4343-4351 
32 F. Fonseca, E. H. Bromley, M. J. Saavedra, A. Correia and J. Spencer (2011) J Mol Biol 
411:951-959 
96 
 
33 J. Moran-Barrio, J. M. Gonzalez, M. N. Lisa, A. L. Costello, M. D. Peraro, P. Carloni, B. 
Bennett, D. L. Tierney, A. S. Limansky, A. M. Viale and A. J. Vila (2007) J Biol Chem 
282:18286-18293 
34 J. M. Gonzalez, M. R. Meini, P. E. Tomatis, F. J. Medrano Martin, J. A. Cricco and A. J. 
Vila (2012) Nat Chem Biol 8:698-700 
35 L. J. Gonzalez, D. M. Moreno, R. A. Bonomo and A. J. Vila (2014) PLoS Pathog 
10:e1003817 
36 N. P. Sharma, C. Hajdin, S. Chandrasekar, B. Bennett, K. W. Yang and M. W. Crowder 
(2006) Biochemistry 45:10729-10738 
37 J. D. Garrity, B. Bennett and M. W. Crowder (2005) Biochemistry 44:1078-1087 
38 P. W. Thomas, E. M. Stone, A. L. Costello, D. L. Tierney and W. Fast (2005) Biochemistry 
44:7559-7565 
39 A. L. Ankudinov, B. Ravel, J. J. Rehr and S. D. Conradson (1998) Phys Rev B 58:7565-
7576 
40 L. A. Abriata, L. J. Gonzalez, L. I. Llarrull, P. E. Tomatis, W. K. Myers, A. L. Costello, D. 
L. Tierney and A. J. Vila (2008) Biochemistry 47:8590-8599 
41 J. M. Gonzalez, F. J. Medrano Martin, A. L. Costello, D. L. Tierney and A. J. Vila (2007) 
J Mol Biol 373:1141-1156 
42 D. H. Griffin, T. K. Richmond, C. Sanchez, A. J. Moller, R. M. Breece, D. L. Tierney, B. 
Bennett and M. W. Crowder (2011) Biochemistry 50:9125-9134 
43 M. J. Hawk, R. M. Breece, C. E. Hajdin, K. M. Bender, Z. Hu, A. L. Costello, B. Bennett, 
D. L. Tierney and M. W. Crowder (2009) J Am Chem Soc 131:10753-10762 
44 G. Periyannan, A. L. Costello, D. L. Tierney, K. W. Yang, B. Bennett and M. W. Crowder 
(2006) Biochemistry 45:1313-1320 
45 V. A. Campos-Bermudez, J. M. Gonzalez, D. L. Tierney and A. J. Vila (2010) J Biol Inorg 
Chem 15:1209-1218 
46 Z. Hu, G. R. Periyannan and M. W. Crowder (2008) Anal Biochem 378:177-183 
47 M. J. Hawk, R. M. Breece, C. E. Hajdin, K. M. Bender, Z. X. Hu, A. L. Costello, B. 
Bennett, D. L. Tierney and M. W. Crowder (2009) J Am Chem Soc 131:10753-10762 
48 G. R. Periyannan, A. L. Costello, D. L. Tierney, K. W. Yang, B. Bennett and M. W. 
Crowder (2006) Biochemistry 45:1313-1320 
97 
 
49 H. Yang, M. Aitha, A. R. Marts, A. M. Hetrick, B. Bennett, M. W. Crowder and D. L. 
Tierney (2014) J Am Chem Soc 136:7273-7285 
50 R. M. Breece, L. I. Llarrull, M. F. Tioni, A. J. Vila and D. L. Tierney (2012) J Inorg 
Biochem 111:182-186 
51 H. Yang, M. Aitha, A. R. Marts, A. Hetrick, B. Bennett, M. W. Crowder and D. L. Tierney 
(2014) J Am Chem Soc 136:7273-7285 
52 H. Yang, M. Aitha, A. M. Hetrick, T. K. Richmond, D. L. Tierney and M. W. Crowder 
(2012) Biochemistry 51:3839-3847 
53 J. Momb, P. W. Thomas, R. M. Breece, D. L. Tierney and W. Fast (2006) Biochemistry 
45:13385-13393 
54 A. I. Karsisiotis, C. F. Damblon and G. C. Roberts (2013) Biochem J 456:397-407 
55 J. Brem, S. S. van Berkel, W. Aik, A. M. Rydzik, M. B. Avison, I. Pettinati, K. D. Umland, 
A. Kawamura, J. Spencer, T. D. Claridge, M. A. McDonough and C. J. Schofield (2014) 
Nat Chem 6:1084-1090 
56 A. M. Davies, R. M. Rasia, A. J. Vila, B. J. Sutton and S. M. Fabiane (2005) Biochemistry 
44:4841-4849 
57 R. B. Davies (1975) Biochem J 145:409-411 
58 M. J. Saavedra, L. Peixe, J. C. Sousa, I. Henriques, A. Alves and A. Correia (2003) 
Antimicrob Agents Chemother 47:2330-2333 
59 F. Fonseca, A. C. Sarmento, I. Henriques, B. Samyn, J. van Beeumen, P. Domingues, M. 
R. Domingues, M. J. Saavedra and A. Correia (2007) Antimicrob Agents Chemother 
51:4512-4514 
60 S. McManus-Munoz and M. W. Crowder (1999) Biochemistry 38:1547-1553 
61 Z. G. Wang and S. J. Benkovic (1998) J Biol Chem 273:22402-22408 
62 Z. G. Wang, W. Fast and S. J. Benkovic (1998) J Am Chem Soc 120:10788-10789 
63 R. M. Rasia and A. J. Vila (2003) ARKAT USA, Inc:507-516 
64 L. I. Llarrull, M. F. Tioni, J. Kowalski, B. Bennett and A. J. Vila (2007) J Biol Chem 
282:30586-30595 
65 M. T. Rehman, M. Faheem and A. U. Khan (2013) Lett Appl Microbiol 57:325-329 
66 S. P. Clissold, P. A. Todd and D. M. Campoli-Richards (1987) Drugs 33:183-241 
98 
 
67 K. M. Papp-Wallace, A. Endimiani, M. A. Taracila and R. A. Bonomo (2011) Antimicro 
Agents Chemother 55:4943-4960 
68 M. F. Tioni, L. I. Llarrull, A. A. Poeylaut-Palena, M. A. Marti, M. Saggu, G. R. Periyannan, 
E. G. Mata, B. Bennett, D. H. Murgida and A. J. Vila (2008) J Am Chem Soc 130:15852-
15863 
69 R. A. Scott (1985) Methods Enzymol 117:414-459 
70 D. L. Tierney and G. Schenk (2014) Biophys J 107:1263-1272 
71 R. M. Breece, Z. Hu, B. Bennett, M. W. Crowder and D. L. Tierney (2009) J Am Chem 
Soc 131:11642-11643 
72 H. Yang, M. Aitha, A. R. Marts, A. Hetrick, B. Bennett, M. W. Crowder and D. L. Tierney 
(2014) J Am Chem Soc 136:7273-7285 
73 M. Aitha, A. R. Marts, A. Bergstrom, A. J. Moller, L. Moritz, L. Turner, J. C. Nix, R. A. 
Bonomo, R. C. Page, D. L. Tierney and M. W. Crowder (2014) Biochemistry 53:7321-
7331 
74 P. W. Thomas, M. Zheng, S. Wu, H. Guo, D. Liu, D. Xu and W. Fast (2011) Biochemistry 
50:10102-10113 
75 B. Zheng, S. Tan, J. Gao, H. Han, J. Liu, G. Lu, D. Liu, Y. Yi, B. Zhu and G. F. Gao (2011) 
Protein Cell 2:250-258 
76 Z. Liang, L. Li, Y. Wang, L. Chen, X. Kong, Y. Hong, L. Lan, M. Zheng, C. Guang-Yang, 
H. Liu, X. Shen, C. Luo, K. K. Li, K. Chen and H. Jiang (2011) PLoS One 6:e23606 
77 V. L. Green, A. Verma, R. J. Owens, S. E. Phillips and S. B. Carr (2011) Acta 
Crystallographica, Sect F: Struct Biol Cryst Commun 67:1160-1164 
 
3.8. Acknowledgment 
This work was supported by the National Institutes of Health (GM093987 to MWC and 
DLT; EB001980 to BB; P30-EB-009998 to the Center for Synchrotron Biosciences from the 
NIBIB, which supports beamline X3B at the NSLS) and the National Science Foundation (CHE-
1151658 to MWC and DLT; CHE-1152755 to DLT). MBL samples used in this study (BcII, SfhI, 
and GOB-18) were supplied by Alejandro M. Vila, and NDM-1 was supplied by Hao Yang.  
 
 
99 
 
Chapter 4 
 
 
 
 
 
 
 
 
 
Probing substrate binding to the metal binding sites in metallo--
lactamase L1 during catalysis 
 
 
 
 
 
 
 
100 
 
Probing substrate binding to the metal binding sites in metallo--
lactamase L1 during catalysis 
Mahesh Aitha,1 David L. Tierney,1* Michael W. Crowder,1* 
 
†Department of Chemistry and Biochemistry, Miami University, 650 East High Street, Oxford, 
Ohio 45056, USA 
 
 
 
 
 
 
 
 
*Corresponding authors: David L. Tierney and Michael W. Crowder 
Phone: (513) 529-2813; Fax: (513) 529-5715; e-mail: tiernedl@miamioh.edu; 
crowdemw@MiamiOH.edu 
 
 
 
 
Contributions of the chapter. Samples prepared and data collected and analyzed by Mahesh 
Aitha under the supervision of David Tierney and Michael Crowder. This chapter was written by 
Mahesh Aitha and edited by Michael Crowder. 
 
This chapter will be submitted for publication later in the year. 
101 
 
4.1. Abstract 
 Metal ions in metallo--lactamases (MBLs) play a major role in catalysis. In this study we 
investigated the role of the metal ions in the Zn1 and Zn2 sites of MBL L1during catalysis. A ZnCo 
(with Zn(II) in the invariant Zn1 site and Co(II) in the Zn2 site) analog of MBL L1 was prepared 
by using a biological incorporation method. Extended X-ray Absorption Fine Structure (EXAFS) 
spectroscopic studies were used to confirm that the ZnCo analog was prepared. To study the roles 
of the Zn(II) and Co(II) ions during catalysis, rapid freeze quench (RFQ)-EXAFS studies were 
used to probe the reaction of the ZnCo-L1 analog with chromacef when quenched at 10 ms, 50 ms, 
and 100 ms. The L1-product complex was also analyzed with EXAFS spectroscopy. The data show 
that the Zn-Co distance is 3.49 Å in the resting enzyme and that this distance increases by 0.3 Å 
in the sample that was quenched at 10 ms. The average Zn-Co distance decreases at the other time 
points until reaching a distance of 3.58 Å in the L1-product complex. Results from EXAFS data 
suggest that the -lactam carbonyl interacts with the metal ion in the Zn1 site. The data also show 
that a Co-S interaction is present in the 100 ms quenched sample and in the L1-product complex, 
which suggests that there is a significant rearrangement of product in the active site. 
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4.2. Introduction 
A recent study conducted by the British Government speculated that antibiotic resistance 
will directly lead to world health care costs up to $100 trillion by year 2050 and result in 10 million 
deaths per year.[1] The β-lactamases are a class of enzymes, which inactivate -lactam-containing 
inhibitors of bacterial tranpeptidases by hydrolyzing the amide bond in these compounds.[2, 3] 
Transpeptidases catalyze the crosslinking of the building blocks of the bacterial peptidoglycan 
layer, resulting in a cell wall that imparts shape and rigidity to the cell.[4] -Lactam containing 
antibiotics, such as penicillins, cephalosporins, and carbapenems, react with transpeptidases and 
form covalently-bound intermediates, which are slowly hydrolyzed or not hydrolyzed at all.[4] 
The resulting bacterial cell walls are not as extensively crosslinked and are more susceptible to 
osmotic lysis. By the end of 2013, over 1,300 -lactamases have been identified and classified into 
4 major groups, A to D, based on their sequence homologies.[5-8] Class A, C, and D enzymes are 
called serine -lactamases (SBLs), because they use an active site serine as a nucleophile during 
-lactam hydrolysis.[9] Several clinical inhibitors, such as clavulanic acid, sulbactam, tazobactam, 
and avibactam, are available to inhibit many of the SBLs. Class B enzymes are called MBLs 
because they require one or two Zn(II) ions for full catalytic activity.[10] MBLs have been further 
classified into three subgroups (B1-B3) based on their sequence homologies and number of metal 
ions in their active sites.[10] Most of the B1 and B3 enzymes bind 2 equivalents of Zn(II) at the 
Zn1 and Zn2 sites. One major difference between B1 and B3 enzymes is the Zn2 site: in the B1 
enzymes Zn(II) is coordinated by 1 His, 1 Cys, 1 Asp, a terminally-bound water, and a bridging 
solvent molecule, while in most of the B3 enzymes, the Cys is replaced by a second His. The B2 
enzymes bind 1 Zn(II) ion at the Zn2 site, and binding of Zn(II) at the Zn1 site is inhibitory.[10] 
Several clinically-important bacterial strains have been identified that produce chromosomally-
encoded MBLs, such as Bacillus cereus (BcII),[11] Bacteroides fragilis (CcrA),[12] 
Elizabethkingia meningoseptica (BlaB),[13] and Stenotrophomonas maltophilia (L1),[14] and 
plasmid-encoded MBLs, such as IMP,[15] VIM,[16] and NDM[17] variants, have recently been 
reported and are causing concern among clinicians. The MBLs hydrolyze all known penicillins, 
carbapenems, and cephalosporins, and to date, there are no clinical inhibitors available. The long-
term goal of our group is to develop MBLs inhibitors. One design strategy that we are using is to 
develop inhibitors that target specific steps in the reaction mechanism. This strategy requires that 
we carefully probe the mechanism and identify any reaction intermediates.  
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A few studies have addressed the active sites in L1 during catalysis.[18-20] A crystal 
structure of hydrolyzed moxalactam bound to L1 was reported.[21] In this structure, the metal ion 
in the Zn1 site was five-coordinate, with one oxygen from the newly generated carboxylate 
(initially the -lactam carbonyl) bound to the metal ion and the other oxygen pointing towards 
Pro228. It is not clear if the bound carboxylate oxygen originated from the moxalactam or from 
the bridging solvent molecule. The Zn2 site was six-coordinate, with the β-lactam nitrogen and one 
of the oxygens from the invariant carboxylate at the 2 position on substrate bound to the metal ion 
(in addition to two His, one Asp, and one terminally-bound solvent molecule). The metal-metal 
distance in the L1-product complex was found to be 3.68 Å, which was greater than that of the 
resting enzyme (3.68 vs 3.50 Å). This study was the first of its kind to show the orientation of 
substrate relative to the dinuclear Zn(II) center and supported previous computational studies on 
L1 by the same group.[14] However, this structure did result in a number of questions about the 
mechanism. (1) Does this structure show the product of the reaction as the substrate is hydrolyzed 
or is this model a structure of the enzyme that bound a product molecule from solution? (2) Did 
the oxygen bound to Zn1 originate from the bridging solvent molecule or from the substrate β-
lactam carbonyl?  
To date, no crystal structure of an enzyme-substrate or –intermediate complex of L1 has 
been reported; however, recent crystal structures of NDM-1 and ring opened intermediate 
complexes (hydrolyzed cefuroxime and cephalexin) have been reported.[22] One of the structures 
showed that one oxygen of the newly formed carboxylate of the β-lactam ring interacts with Zn1 
and Asn233. The other structure showed no interaction of intermediate with Zn1 but showed a 
bridging solvent molecule. The metal ion in the Zn2 site coordinated the nitrogen, which was part 
of the β-lactam ring, and one of the oxygens from the invariant carboxylate on substrate. The 
metal-metal distances in these two crystal structures were found to be 3.8 Å (in the cefuroxime 
complex) and 4.5 Å (in the cephalexin complex). It is surprising that two similar intermediates 
bound so differently to NDM-1. 
Previously, rapid freeze quench (RFQ)-spectroscopic studies have been used to trap 
catalytic intermediates in the millisecond timescale.[19, 23-27] Previous RFQ-EXAFS and RFQ-
EPR studies have reported different coordination numbers for metal ions in L1 samples freeze 
quenched at 10 ms.[19, 23] RFQ-EPR studies on ZnCo-L1 demonstrated that Co(II) (Zn2 site) is 
five-coordinate in the resting state, proceeds through a four-coordinate species during the reaction, 
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and is five-coordinate in the enzyme product complex.[28] In contrast, RFQ-EXAFS studies on 
ZnZn-L1 indicate an increase in the average coordination number of Zn(II) in the sample freeze 
quenched at 10 ms and in the product complex, as compared to the resting enzyme.[23] Breece et 
al. observed an increase in the metal-metal distance in the sample of L1 and nitrocefin quenched 
at 10 ms, as compared to that of the resting and product-bound forms of the enzyme. The analysis 
of the EXAFS data on the L1-product complex revealed an improved fit residual when a Zn-sulfur 
interaction was included in the fit.[23, 29] This result strongly suggested that there is a rotation 
around the C6-C7 bond in product, which positioned the ring sulfur in product bound to one of the 
metal ions in the active site. Since the ZnZn-L1 analog was used in this study, and it was not 
possible to unambiguously probe the role of each metal ion site during catalysis. In addition, the 
enzyme-product complex was prepared by incubating substrate with enzyme and freezing the 
sample. As discussed before with the crystal structure of L1 bound to product, it was not possible 
to determine if the enzyme-product complex was catalytically-competent (i.e., if the rotated 
product was produced when the product was in the active site or if the product released, rotated, 
and rebound in this conformation). With the previous X-ray crystallographic and spectroscopic 
studies on L1, it was also not possible to determine the orientation of substrate in the active site 
(does the -lactam carbonyl oxygen bind to Zn1 or Zn2?). To address these issues, we proposed to 
use the heterobimetallic analog of L1 (ZnCo-analog), which was previously shown to 
predominantly have Zn(II) in the Zn1 site and Co(II) in the Zn2 site,[19] and RFQ-EXAFS to probe 
each metal site independently. 
 
4.3. Methods 
 Over-expression and purification of L1. Heterobimetallic (ZnCo) L1 was prepared as 
previously described.[30] Briefly, four liters of minimal medium were inoculated with 50 ml of an 
overnight culture, and the cultures were shaken at 37 oC until the OD600 reached 0.6-0.8. Cells 
were cooled to 18 °C for 15 mins, and protein production was induced by making the cultures 0.5 
mM in IPTG. After the cultures were shaken overnight (16 hrs), cells were harvested by 
centrifugation at 7,000 RPM for 10 mins in a GS3 rotor. The bacterial pellet was resuspended in 
30 ml of Chelex100-treated 50 mM HEPES, pH 6.8, containing 500 mM NaCl. Cells were ruptured 
by passing the suspension two times through a French press at 1,000 psi. The lysed cells were 
centrifuged at 15,000 RPM for 25 mins to clear the mixture, which was dialyzed overnight against 
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2 L of Chelex100-treated 50 mM HEPES, pH 6.8, to remove the NaCl. After centrifugation the 
resulting supernatant was loaded on a (1.5 X 20 with a 28 ml bed volume) SP-Sepharose column, 
which was equilibrated with 50 mM HEPES, pH 6.8, and protein was eluted with a 0-500 mM 
NaCl linear gradient in the same buffer. Protein purity was confirmed by SDS-PAGE, and protein 
concentration was determined by using a Nanodrop.[31]  
Metal analyses. A Perkin-Elmer Optima 7300 DV Inductively Coupled Plasma 
spectrometer with Optical Emission Spectroscopy detection (ICP-OES) was used to determine the 
metal content of the L1 samples. Protein samples were diluted to 1 M by using 50 mM Tris, pH 
7.6. Standard calibration curves were generated with correlation coefficients greater than 0.999 by 
using Zn and Co metal standard solutions.[32] 
Steady state kinetics. All steady state kinetic studies were conducted on an Agilent 8453 
UV-Vis diode array spectrophotometer at 25 oC. Michaelis constants (Km) and turnover numbers 
(kcat) were determined by monitoring product formation at 442 nm using chromacef as substrate in 
50 mM cacodylate, pH 7.0. Rate data were converted to concentration data using the extinction 
coefficient of hydrolyzed chromacef (ε442nm = 18,600 M-1cm-1).[32, 33] Concentration versus time 
data were then fitted to the Michaelis-Menton equation, as previously reported.[32]  
Sample preparation. EXAFS samples (approximately 1 mM in protein) were prepared 
with 20% (v/v) glycerol as a glassing agent. Product samples were prepared by incubating an equal 
amount of 1 mM enzyme and 5 mM chromacef for one hour on ice. All EXAFS samples of resting 
L1 or the L1-product complex were loaded in Lucite cuvettes with 6 µm polypropylene windows, 
frozen rapidly, and stored in liquid nitrogen.  
Freeze-quenched EXAFS samples were generated using a modified Update Instruments 
(Madison, WI) rapid-freeze-quench (RFQ) system. All enzyme and substrate starting 
concentrations were 1 mM and 5 mM, respectively, prepared in metal-free (Chelex100, Bio-Rad) 
50 mM HEPES, pH 7.0, containing 20% v/v glycerol. A model 715 Update Instruments ram 
controller was used to drive a PMI-Kollmorgen stepping motor (model 00D12F-02001-1) 
connected to a ram that in turn drove the Update Instrument syringes. The syringes, mixer, and 
tubing were all contained in a watertight bath that was maintained at 2 °C.[18, 34] Immediately 
prior to sample collection, the nozzle (and, for the shortest reaction times, the attached mixer) was 
removed from the bath and held 5 mm above the surface of 2-methylbutane contained in a 
collecting funnel and maintained at -130 °C by a surrounding bath (Update Instruments) of liquid 
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nitrogen cooled 2-methylbutane. Samples were packed into home-designed EXAFS sample 
holders at -130 °C; excess 2-methylbutane was decanted, and samples were stored in liquid 
nitrogen until data collection. The RFQ system was calibrated by comparing the development of a 
low-spin Fe(III) EPR signal and the disappearance of a high-spin Fe(III) EPR signal with the 
associated optical changes at 636 nm using stopped-flow spectrophotometry, upon mixing 
myoglobin with an excess of sodium azide. The shortest, total effective reaction time that could be 
achieved with the RFQ system was 10 ms.[18, 24] 
EXAFS spectroscopy. X-ray absorption spectra were measured at the National 
Synchrotron Light Source (NSLS), beamline X3B, using a Si (111) double-crystal 
monochromator; harmonic rejection was accomplished with a Ni mirror. Fluorescence excitation 
spectra for all samples were measured with a 31-element solid-state Ge detector array. Samples 
were held at approximately 15 K in a Displex cryostat. EXAFS data collection and reduction were 
performed according to published procedures.[35] Data were measured in duplicate, six scans each 
on two independently-prepared samples. Fits to the two data sets were equivalent. The 
experimental spectra presented here are the averaged data sets (12 scans per sample). The data 
were converted from energy to k-space using E0 = 9,680 eV and 7,730 eV for Zn and Co, 
respectively)  
Fourier-filtered EXAFS data were fitted using the nonlinear least-squares engine of 
IFEFFIT, which is distributed with SixPack (SixPack is available free of charge from http://www-
ssrl.slac.stanford.edu/exafspak.html; IFEFFIT is open source software available from 
http://cars9.uchicago.edu/ifeffit/Ifeffit). Theoretical amplitude and phase functions were 
calculated with FEFF v. 8.00.[36] Zinc-nitrogen single-scattering and zinc-imidazole multiple-
scattering was calibrated to the experimental EXAFS of zinc tetrakis-1-methylimidazole Zn(II) 
perchlorate, [Zn(MeIm)4][ClO4]2. Zinc-sulfur scattering was calibrated to the experimental 
EXAFS of tetrabutylammonium zinc tetramesitylthiolate, [Bu4N]2[Zn(Smes)4]. Optimum scale 
factors (Sc) and ∆E0 were derived from fits to the model data (Sc = 0.78 (Zn-N) or 0.91 (Zn-S); 
∆E0= -21 eV), and they were held fixed at these values for fits to metalloprotein data. The models 
used for the calibration of cobalt-nitrogen (and cobalt-imidazole) and cobalt-sulfur scattering were, 
respectively, hexakis-imidazole cobalt(II) perchlorate, [Co(Im)6][ClO4]2 and tetrabutylammonium 
cobalt(II) tetramesitylthiolate, [Bu4N]2[Co(Smes)4], respectively. The resulting Sc and ∆E0 (Sc = 
0.79 (Co-N) or 0.85 (Co-S); ∆E0 = -21 eV) were held fixed at these calibrated values in subsequent 
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fits to metalloprotein data. First shell fits were then obtained for all reasonable coordination 
numbers, including mixed nitrogen/oxygen/sulfur ligation, while allowing the absorber-scattered 
distance, Ras, and the Debye-Waller factor, σas2, to vary. Multiple scattering contributions from 
histidine ligands were fitted according to published procedures.[37] Metal-metal (zinc-cobalt and 
cobalt-cobalt) scattering were modeled with reference to the experimental EXAFS of Zn2 (salpn)2 
and Co2 (salpn)2. 
 
4.4. Results 
 Over-expression and purification. The heterobimetallic (ZnCo) analog of L1 was over-
expressed and purified as previously described.[19, 30] The purified enzyme exhibited a kcat of 23 
+ 1 s-1 and a Km of 2.5 + 0.1 M when using chromacef as substrate and bound 1.0 + 0.1 equivalents 
of Zn(II) and 0.9 + 0.1 equivalents of Co(II). These values are similar to those previously reported 
for wild-type L1 (kcat = 25 + 1 s
-1; Km = 2.9 + 0.1 M).[34]  
EXAFS spectroscopy. Previous crystal structures of L1 showed Zn(II) in the Zn1 site bound 
to the three histidine residues; two of the three at 2.00 Å and the third histidine at 2.01 Å.[14] The 
metal ions in the Zn1 and Zn2 sites were bridged by a solvent (hydroxyl) molecule, which was 
located 1.9 Å from Zn1 and 2.1 Å from Zn2. Zn(II) in the Zn2 site was bound to two histidines, one 
at 2.0 Å and the second one at 2.1 Å, one aspartate at 2.1 Å, and one water molecule at 2.4 Å. The 
distance between the metal ions in the Zn1 and Zn2 sites was 3.5 Å.[14] EXAFS studies on ZnZn-
L1 yielded metal-ligand and metal-metal distances similar to those reported in the crystal 
structures. The analysis of previous EXAFS spectra revealed an average Zn(II) first shell 
coordinated by 4.5 N/O at 2.02 Å, and multiple scattering analyses indicated an average of 2.5 His 
bound to each Zn(II).[23] The inclusion of a metal-metal interaction at 3.42 Å improved fit 
residuals.[23] Best fit results of the EXAFS spectra of CoCo-L1 revealed an average Co(II) first 
shell coordinated by 5 N/O at 2.12 Å, and multiple scattering analyses suggested an average of 2.5 
His per Co. The inclusion of a metal-metal interaction did not improve the fit residual (Table 4.2) 
(unpublished data, Hu, Tierney, and Crowder). 
Fourier-transformed Zn K- and Co K-edge EXAFS spectra of resting ZnCo-L1 are shown 
in Figures 4.3 and 4.4, and fitting data are summarized in Tables 4.3 and 4.4. Nonlinear least square 
regression analyses on the resting ZnCo-L1 sample showed a Zn K-edge first shell consistent with 
4 N/O ligands at 2.01 Å and a second shell coordinated by 3 His; these values are consistent with 
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the published ligand environment of the metal ion in the Zn1 site (Table 4.2).[14] Inclusion of a 
metal-metal (Zn-Co) interaction at 3.48 Å in the model resulted in a 17% improvement in the fit 
residual (Figure 4.3 and Table 4.3). Analyses of the Co K-edge of the resting ZnCo-L1 sample 
were consistent with a first shell coordinated by 5 N/O ligands at 2.08 Å and a second shell 
coordinated by 2 His and 1 carbon at 2.41 Å, possibly from Asp120.[14] The inclusion of a metal-
metal interaction at 3.50 Å (Co-Zn) resulted in an improvement of the fit residual by 30% (Figure 
4.4 and Table 4.4). The Zn K-edge and Co-K-edge EXAFS results showed a metal-metal distance 
of 3.48 Å (Zn-Co) and 3.50 Å (Co-Zn), which are the same within the experimental error. The 
mean distance of 3.49 Å is considered the metal-metal distance in resting ZnCo-L1, which is 0.8 
Å longer than in the ZnZn-analog. These results indicate that the ZnCo-L1 analog has 
predominantly Zn(II) in the Zn1 site and Co in the Zn2 site. The EXAFS data on the ZnCo-L1 
enzyme yielded metal-ligand and metal-metal distances similar to those previously reported in 
crystal structures and EXAFS studies on ZnZn-L1 (Table 4.2). 
To probe the hydrolysis reaction, ZnCo-L1 (ca. 1 mM) was rapidly mixed with chromacef 
(ca. 1 mM), and the reaction was freeze-quenched at 10 ms, 50 ms, and 100 ms. Each sample was 
analyzed with EXAFS spectroscopy (Figures 4.1 and 4.2), and fitting data are summarized in Table 
4.1. 
 
 
Table 4.1. EXAFS fittings results of the Zn K-edge and Co K-edge data of all the samples 
(resting L1, samples freeze quenched at 10 ms, 50 ms, and 100 ms, and L1-product complex). 
 
  T 
(ms) 
Zn-N/O  
 Co-N/O Co-S 
Zn-Co 
Co-Zn 
Zn-K Model 
Co-K Model 
0 2.01 2.10  
3.48 
3.50 
4N/O(3H)+1Zn 
5N/O(2H)+1C+1Zn 
10 2.01 2.06  
3.82 
3.81 
4N/O(3H)+1Zn  
5N/O(2H) +1 Zn 
50 2.00 2.10  
3.70 
3.68 
4N/O(3H)+1Zn 
5N/O(2H)+1C+1Zn 
100 2.01 2.07 2.28 
3.59 
3.58 
4N/O(3H)+1Zn 
4N/O(2H)+1S+1C+1Zn 
Prod. 2.02 2.08 2.29 
3.59 
3.57 
4N/O(3H)+1Zn 
4N/O(2H)+1S+1C+1Zn 
 
109 
 
 
4
8
12
16
20
0 1 2 3 4 5 6
R+  (Å)
F
T
 M
a
g
n
it
u
d
e
Zn
Resting
10 ms
Resting
50 ms
Resting
100 ms
Resting
Product
Resting
0
6
12
18
24
2 4 6 8 10
k (Å
-1
)
k
3
 
 (
k
)
 
Figure 4.1. Comparison of the Fourier-transformed Zn K-edge EXAFS spectra (R-space (left), 
K-space (right)) of the ZnCo-L1 samples. Fourier-transformed EXAFS spectra of resting ZnCo 
L1 (Top), samples freeze-quenched at 10 ms, 50 ms, and 100 ms, and the L1-product complex 
(top to bottom). 
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Figure 4.2. Comparison of the Fourier transformed Co K-edge EXAFS spectra (R-space (left), 
K-space (right)) of the ZnCo-L1 samples. Fourier-transformed EXAFS spectra of resting ZnCo 
L1 (Top), samples freeze-quenched at 10 ms, 50 ms, and 100 ms, and the L1-product complex 
(top to bottom). 
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Best fit results of the ZnCo-L1/chromacef sample freeze-quenched at 10 ms indicated a Zn 
K-edge first shell with 4 N/O ligands at 2.02 Å and a second shell coordinated by 3 His ligands. 
Inclusion of a metal-metal interaction at 3.82 Å improved the fit residual by 14% (Figure 4.5 and 
Table 4.5). Co K-edge fit results of the 10 ms sample revealed a first shell coordinated by 5 N/O 
ligands at 2.06 Å and a second shell coordinated by 2 His. While the inclusion of a Co-C interaction 
in the spectrum of resting ZnCo-L1 improved the fit residual, the inclusion of this same interaction 
in the spectrum of ZnCo-L1/chromacef quenched at 10 ms did not improve the fit and was not 
included in the final model. Inclusion of a metal-metal interaction at 3.81 Å to the model improved 
the fit residual by 34% (Figure 4.6 and Table 4.6). A similar increased metal-metal distance was 
previously observed in the ZnZn-L1/nitrocefin sample quenched at 10 ms.[23] These data strongly 
suggest that there was no change in the coordination number of either metal ion in the sample 
quenched at 10 ms. 
 
 
 
Table 4.2. Metal ligand distances of ZnCo-L1 from these EXAFS data compared with data 
from previous crystal structures and previous EXAFS data on ZnZn-L1 and CoCo-L1. 
 
Zn/Co(II) – ligand Crystal 
Zn-Zn[14] 
EXAFS 
Zn-Zn[23] 
EXAFS 
Co-Coa 
EXAFS 
Zn-Cob 
Metal at Zn1/Zn2 Zn/Zn Zn/Zn Co/Co
 Zn/Co 
Zn1 
His114 
His116 
His160 
O(W1) 
2.0 
2.1 
2.0 
1.9 
2.02 
2.02 
2.02 
2.02 
2.12 
2.12 
2.12 
2.12 
2.01 
2.01 
2.01 
2.01 
Zn2 
His121 
His263 
Asp120 
O(W1) 
O(W2) 
2.0 
2.1 
2.1 
2.1 
2.4 
2.02 
2.02 
2.02 
2.02 
2.02 
2.12 
2.12 
2.12 
2.12 
2.12 
2.08 
2.08 
2.08 
2.08 
2.08 
Zn1 Zn2         3.5 3.42 Not observed 3.49 
a Previous unpublished EXAFS studies (CoCo-L1 was prepared by adding 2 equivalents of Co(II) to the apo-L1, 
(Hu, Tierney, and Crowder)) 
b This study 
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Figure 4.3. Fourier transforms (A) of k3-weighted EXAFS (B) for Zn K-edge of ZnCo-L1 
resting. The solid lines represent the data, the open symbols represent the various fits, 
corresponding to Table 4.3. 
 
Table 4.3. Fitting results for Zn K-edge EXAFS of the resting ZnCo-L1 sample.a 
Fit Model Zn-N/O Zn-Hisb Zn-Co Rfc Ruc 
1-1 4 N/O 2.01 (4.4)   25 142 
1-2 4 N/O (3His) 2.01 (6.1) 2.92 (5.9) 3.17 (4.7) 
4.10 (17) 4.45 (24) 
 27   43 
1-3 4N/O(2His)  
+ Zn-Co 
2.01 (6.1) 2.92 (6.1) 3.17 (5.0) 
4.10 (19) 4.44 (24) 
3.48 (28) 23   38 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.4. Fourier transforms (A) of k3-weighted EXAFS (B) for Co K-edge of ZnCo-L1 
resting. The solid lines represent the data, the open symbols represent the various fits, 
corresponding to Table 4.4. 
 
Table 4.4. Fitting results for Co K-edge EXAFS of the resting ZnCo-L1 sample.a 
 
Fit Model Co-N/O Co-Hisb Co-C Co-Zn Rfc Ruc 
2-1 5 N/O 2.08 (6.8)    41 247 
2-2 5 N/O (2His) 2.08 (6.6) 2.99 (12) 3.28 (1.0) 
4.13 (32) 4.61 (11) 
  61  46 
2-3 5N/O(2His)  
+ Co-Zn 
2.08 (6.6) 3.01 (12) 3.26 (1.0) 
4.24 (8.6) 4.61 (12) 
 3.50 (13) 47  39 
2-4 5N/O(2His)  
+1C + Co-Zn 
2.08 (6.6) 3.01 (12) 3.26 (1.0) 
4.24 (8.6) 4.61 (12) 
2.41 (10) 3.50 (13) 41  35 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11 Å-1; R = 0.5 – 2.2 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.5. Fourier transforms (A) of k3-weighted EXAFS (B) for Zn K-edge of the ZnCo-
L1/chromacef sample quenched at 10 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.5. 
 
Table 4.5. Fitting results for Zn K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 10 ms.a 
 
Fit Model Zn-N/O Zn-Hisb Zn-Co Rfc Ruc 
3-1 4 N/O 2.02 (4.8)   27 135 
3-2 4 N/O (3His) 2.02 (5.0) 2.89 (7.5) 3.13 (4.2) 
4.12 (22) 4.39 (19) 
 49   68 
3-3 4N/O(2His)  
+ Zn-Co 
2.02 (5.0) 2.90 (7.6) 3.13 (4.3) 
4.17 (23) 4.41 (17) 
3.82 (16) 43   59 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.6. Fourier transforms (A) of k3-weighted EXAFS (B) for Co K-edge of the ZnCo-
L1/chromacef sample quenched at 10 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.6. 
 
Table 4.6. Fitting results for Co K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 10 ms.a 
 
Fit Model Co-N/O Co-Hisb Co-Zn Rfc Ruc 
4-1 5 N/O 2.05 (8.0)   85 227 
4-2 5 N/O (2His) 2.06 (7.9) 3.28 (5.6) 3.36 (1.0) 
4.30 (9.8) 4.61 (12) 
 67 121 
4-3 5N/O(2His)  
+ Co-Zn 
2.06 (7.9) 3.28 (5.0) 3.35 (1.0) 
4.29 (15) 4.61 (14) 
3.81 (13) 50 107 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11 Å-1; R = 0.5 – 2.2 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.7. Fourier transforms (A) of k3-weighted EXAFS (B) for Zn K-edge of the ZnCo-
L1/chromacef sample quenched at 50 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.7. 
 
Table 4.7. Fitting results for Zn K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 50 ms.a 
 
Fit Model Zn-N/O Zn-Hisb Zn-Co Rfc Ruc 
5-1 4 N/O 2.01 (4.7)   22 120 
5-2 4 N/O (3His) 2.01 (4.8) 2.89 (6.8) 3.15 (5.9) 
4.16 (21) 4.38 (17) 
 30  50 
5-3 4N/O(2His)  
+ Zn-Co 
2.01 (4.8) 2.90 (6.9) 3.15 (6.2) 
4.16 (16) 4.38 (17) 
3.70 (16) 25  45 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.8. Fourier transforms (A) of k3-weighted EXAFS (B) for Co K-edge of the ZnCo-
L1/chromacef sample quenched at 50 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.8. 
 
Table 4.8. Fitting results for Co K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 50 ms.a 
 
Fit Model Co-N/O Co-Hisb Co-Zn Co-C Rfc Ruc 
6-1 5 N/O 2.09 (8.0)     98 257 
6-2 5 N/O (2His) 2.09 (8.5) 3.02 (6.7) 3.31 (5.3) 
4.13 (1.0) 4.24 (9.2) 
  163 141 
6-3 5N/O(2His)  
+ Co-Zn 
2.10 (8.2) 3.01 (11) 3.31 (1.0) 
4.10 (1.0) 4.21 (14) 
3.68 (6.4)  123 113 
6-4 5N/O(2His) + 
1C + Co-Zn 
2.10 (7.9) 3.01 (8.6) 3.31 (1.2) 
4.10 (1.0) 4.21 (13) 
3.68 (7.5) 
2.41 (5.7) 
103 97 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11 Å-1; R = 0.5 – 2.2 Å (fit 1), 0.3-4.0 Å (fits 2-
4)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.9. Fourier transforms (A) of k3-weighted EXAFS (B) for Zn K-edge of the ZnCo-
L1/chromacef sample quenched at 100 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.9. 
 
Table 4.9. Fitting results for Zn K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 100 ms.a 
 
Fit Model Zn-N/O Zn-Hisb Zn-Co Rfc Ruc 
7-1 4 N/O 2.01 (4.6)   18 147 
7-2 4 N/O (3His) 2.01 (4.8) 2.93 (9.0) 3.16 (6.6) 
4.10 (22) 4.43 (24) 
 53 106 
7-3 4N/O(2His)  
+ Zn-Co 
2.01 (4.8) 2.92 (7.4) 3.14 (4.4) 
4.12 (22) 4.44 (24) 
3.59 (14) 45  97  
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.10. Fourier transforms (A) of k3-weighted EXAFS (B) for Co K-edge of the ZnCo-
L1/chromacef sample quenched at 100 ms. The solid lines represent the data, the open symbols 
represent the various fits, corresponding to Table 4.10. 
 
Table 4.10. Fitting results for Co K-edge EXAFS spectra of the ZnCo-L1/chromacef sample 
quenched at 100 ms.a 
 
Fit Model Co-N/O Co-S Co-Hisb Co-Zn Co-C Rfc Ruc 
8-1 5 N/O 2.07 (7.4)     69 232 
8-2 4 N/O +1 S 2.10 (7.1) 2.23 (9.8)    65 223 
8-3 4 N/O(2His)  
+ 1 S 
2.07 (5.7) 2.28 (17) 3.06 (15) 3.26 (1.0) 
4.16 (3.0) 4.64 (8.5) 
  77 132 
8-4 4 N/O(2His) + 
1 S + Co-Zn 
2.07 (27) 2.27 (16) 3.05 (13) 3.24 (1.0) 
4.12 (7.8) 4.64 (11) 
3.57 (12)  71 122 
8-5 4N/O(2His)+
1S +1C +  
Co-Zn 
2.07 (7.5) 2.28 (13) 3.05 (12) 3.24 (1.0) 
4.12 (6.7) 4.64 (10) 
3.58 (13) 2.40 (4.9) 52 110 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 
3-5)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.11. Fourier transforms (A) of k3-weighted EXAFS (B) for Zn K-edge of the ZnCo-
L1/product complex. The solid lines represent the data, the open symbols represent the various 
fits, corresponding to Table 4.11. 
 
Table 4.11. Fitting results for Zn K-edge EXAFS spectra of the ZnCo-L1/product complex.a 
 
Fit Model Zn-N/O Zn-Hisb Zn-Co Rfc Ruc 
9-1 4 N/O 2.00 (6.0)   62 255 
9-2 4 N/O (3His) 2.00 (5.9) 2.90 (2.5) 3.14 (6.4) 
4.01 (20) 4.44 (14) 
 69 105 
9-3 4N/O(2His)  
+ Zn-Co 
2.00 (5.9) 2.90 (2.4) 3.14 (1.0) 
4.01 (20) 4.45 (14) 
3.59 (11) 45  93  
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-12 Å-1; R = 0.5 – 2.0 Å (fit 1), 0.3-4.0 Å (fits 2-
3)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
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Figure 4.12. Fourier transforms (A) of k3-weighted EXAFS (B) for Co K-edge of the ZnCo-
L1/product complex. The solid lines represent the data, the open symbols represent the various 
fits, corresponding to Table 4.12. 
 
Table 4.12. Fitting results for Co K-edge EXAFS spectra of the ZnCo-L1/product complex.a 
 
Fit Model Co-N/O Co-S Co-Hisb Co-Zn Co-C Rfc Ruc 
10-1 5 N/O 2.08 (7.3)     158 356 
10-2 4 N/O +1 S 2.08 (6.8) 2.30 (8.6)    131 321 
10-3 4 N/O(2His)  
+ 1 S 
2.08 (4.8) 2.29 (5.3) 3.00 (1.0) 3.18 (1.9) 
4.10 (3.5) 4.58 (6.9) 
  238 242 
10-4 4 N/O(2His) 
+ 1S+ Co-Zn 
2.08 (4.8) 2.29 (5.3) 3.00 (1.1) 3.18 (1.9) 
4.10 (3.5) 4.58 (7.1) 
3.57 (9.3)  174 222 
10-5 4N/O(2His)
+1S +1C +  
Co-Zn 
2.08 (4.8) 2.29 (5.3) 3.00 (1.0) 3.18 (1.5) 
4.10 (3.1) 4.58 (6.9) 
3.57 (9.1) 2.47 (0.9) 102 178 
a Distances (Å) and disorder parameters (in parentheses, 2 (10-3 Å2)) shown derive from integer or half-integer 
coordination number fits to filtered EXAFS data [k = 1.5-11 Å-1; R = 0.5 – 2.2 Å (fits 1-2), 0.3-4.0 Å (fits 
3-5)]. 
b Imidazole multiple scattering paths represent combined paths, as described previously (see Materials and 
Methods). 
 
121 
 
 Fitting of the Zn K-edge of the EXAFS spectrum of ZnCo-L1/nitrocefin quenched at 50 
ms suggests a first shell with 4 N/O ligands at 2.01 Å and a second shell coordinated with 3 His. 
Inclusion of a metal-metal interaction at 3.70 Å to the model improved the fit residual by 40% 
(Figure 4.7 and Table 4.7). Fitting of the Co K-edge of the EXAFS spectrum of ZnCo-
L1/chromacef quenched at 50 ms indicates a first shell coordinated by 5 N/O ligands at 2.10 Å and 
a second shell coordinated with 2 His. Inclusion of a metal-metal distance of 3.68 Å improved the 
fit residual by 33%, and inclusion of 1 C interaction at 2.40 Å improved the fit residual by 20% 
(Figure 4.8 and Table 4.8). Inclusion of a Co-C interaction in the second shell resulted in an 
improvement in the fit residual, as observed in the analyses of the EXAFS data on the resting 
ZnCo-L1 sample. The metal-metal distance observed in the fits for the sample quenched at 50 ms 
was 0.12 Å shorter than that determined for the sample quenched at 10 ms. 
 Fitting of the Zn K-edge of the EXAFS spectrum of ZnCo-L1/chromacef quenched at 100 
ms resulted in a first shell coordinated by 4 N/O at 2.01 Å and a second shell coordinated by 3 His. 
Inclusion of a metal-metal interaction at 3.59 Å improved the fit residual by 18% (Figure 4.9 and 
Table 4.9). Best fits of the Co K-edge data for the ZnCo-L1/chromacef sample quenched at 100 
ms showed 5 N/O scatterers at 2.07 Å; however, an improvement in the fit residual of 10% was 
observed when a model with 4 N/O ligands at 2.07 Å and 1 S ligand at 2.28 Å was used to fit the 
first shell data. The best fit of the data revealed a second shell with 2 His, and inclusion of a metal-
metal interaction at 3.58 Å improved the fit residual by 10%. As with fits of the resting enzyme 
and the sample quenched at 50 ms, inclusion of 1 C at 2.40 Å in the second shell improved the fit 
residual by 37% (Figure 4.10 and Table 4.10). Five N/O scatterers in the first shell and 2 His, 1 C, 
and 1 Zn scatterers in second shell were used in the fit model to check the importance of Co-S 
contribution in the fit; however, fit results showed a 32% poorer fit as compared with the fit 
containing 1 S scatterer in the first shell along with 4 N/O scatterers. The observed first shell Co-
S interaction in the spectrum of ZnCo-L1/chromacef quenched at 100 ms is a significant difference 
as compared with the fits of the resting sample and the samples freeze-quenched at 10 ms and 50 
ms. The metal-metal distance observed in the sample quenched at 100 ms is 0.11 Å shorter than 
the metal-metal distance in the sample quenched at 50 ms. 
  Best fits of the Zn K-edge data of the ZnCo-L1/chromacef product complex suggested a 
first shell with 4 N/O scatterers at 2.01 Å and a second shell coordinated by 3 His. Inclusion of a 
metal-metal interaction at 3.59 Å improved the fit residual by 53% (Figure 4.11 and Table 4.11). 
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Best fit results of the Co K-edge showed a first shell coordinated by 4 N/O at 2.08 Å and 1 S at 
2.29 Å, and the inclusion of the sulfur scatterer improved the fit residual by 18%. Multiple 
scattering analysis is consistent with the presence of 2 His scatterers, and inclusion of a metal-
metal interaction at 3.57 Å improved the fit residual by 37%. Inclusion of 1 C interaction at 2.47 
Å to the model improved the fit residual by 70% (Figure 4.12 and Table 4.12). The metal-metal 
distance observed in the ZnCo-L1/chromacef product complex is similar to the metal-metal 
distance in the sample quenched at 100 ms. 
 
4.5. Discussion 
 Several strategies have been used to monitor substrate binding to the MBLs. There are 
more than 200 crystal structures of MBLs available on Protein Data Bank (PDB.ORG) 
(http://www.rcsb.org/pdb/results/results.do?qrid=743BBE07&tabtoshow=Current), and there are 
several structures of enzyme/product or enzyme/inhibitor complexes. However, there are very few 
crystal structures of MBL/intermediate complexes.[22] The main limitation of X-ray 
crystallography to probe substrate binding and/or catalysis is the necessity of diffraction-quality 
crystals of species that react on the millisecond or submillisecond timescale. NMR spectroscopy 
offers information on dynamics; however, the time required to signal average is far too long to 
probe enzymatic reactions that occur on the millisecond timescale.[38] Rapid-freeze quench 
techniques, coupled with spectroscopic methods, afford the ability to monitor these short 
reactions.[19, 23, 25] 
 All known MBLs are zinc-dependent metalloenzymes,[10] and the presence of a metal 
ion(s) affords a “spectroscopic handle” to monitor the structure and mechanism of the enzyme. In 
biology, zinc exists as Zn(II) and is spectroscopically-silent for all spectroscopic techniques except 
EXAFS and 67Zn NMR.[39] In most Zn(II) metalloenzymes zinc can be readily replaced with a 
spectroscopically-active metal ion, like Co(II), yielding catalytically-active enzymes.[18, 19, 24, 
27, 30, 33, 40-43] In this study we chose to utilize L1, which is a B3 class MBL that we have 
extensively studied in the past.[18, 19, 28, 30, 34, 44-46] Previously, RFQ-EPR and –EXAFS have 
been used to probe the metal binding sites in L1 during catalysis.[19, 23] RFQ-EPR studies on 
ZnCo-L1 demonstrated that Co(II) (in the Zn2 site) is 5-coordinate in the resting state, proceeds 
through a 4-coordinate species during the reaction, and is 5-coordinate in the enzyme product 
complex.[19] In contrast, a RFQ-EXAFS study on ZnZn(II)-L1 revealed an average coordination 
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number of 4.5 for Zn(II) in the resting enzyme, in the sample quenched at 10 ms, and in the 
enzyme-product complex.[23, 29] The previous RFQ-EXAFS study suggested that there is a 
rotation around the C6-C7 bond in product, which positioned the ring sulfur in contact with one of 
the metal ions in the active site.[23] However, the ZnZn-L1 analog was used in this study, and it 
was not possible to unambiguously probe the role of each metal ion site during catalysis. In the 
present study the heterobimetallic ZnCo analog of L1 was used, and RFQ-EXAFS spectroscopy 
was used to characterize the reactions of ZnCo-L1 with chromacef freeze-quenched at 10, 50, and 
100 ms. The EXAFS spectra of the resting and product bound forms of the L1 were also analyzed. 
 EXAFS results on the resting ZnCo analog of L1 resting were consistent with data from 
previously-reported crystal structures;[14] Zn(II) was present in the Zn1 site and Co(II) was present 
in the Zn2 site.[19] Zn(II) was coordinated by 4 N/O scatterers in the first shell, which is consistent 
with 3 His and a hydroxyl bridge. Cobalt was coordinated by 5 N/O scatterers in the first shell, 
which is consistent with 2 His, 1 Asp, 1 terminally-bound water, and the hydroxyl bridge as 
ligands. The distance, as determined from EXAFS spectroscopy, between the two metal ions (Zn-
Co) was 3.49 Å, which is longer than the distance of 3.42 Å reported when using ZnZn-L1.[23] 
This result was not surprising because cobalt-substituted enzymes often show slightly increased 
metal-metal distances.[25, 33] Our EXAFS results confirm the fidelity of the heterobimetallic 
(ZnCo) analog of L1 and suggest that information gleaned using RFQ studies on this analog can 
be extrapolated to the naturally-occurring ZnZn analog. This analog also allowed us to address 
some finer points of the reaction mechanism catalyzed by L1. 
There have been several different reaction mechanisms proposed for the MBLs; however, 
two of them are based on large numbers of structural/kinetic studies. Hu et al. proposed a reaction 
mechanism for the hydrolysis of nitrocefin by L1 (Figure 4.13).[19] In this mechanism, the β-
lactam carbonyl oxygen was proposed to interact with the metal ion in the Zn1 site, while the 
nitrogen lone pair on the nitrogen of the β-lactam interacted with the metal ion in the Zn2 site. 
Substrate binding was proposed to result in the loss of the bond between the metal ion in the Zn2 
site and the bridging hydroxide, thereby generating a four-coordinate metal ion in the Zn2 site and 
a five-coordinate metal ion in the Zn1 site. The proposed mechanism showed that the Zn1-bound 
hydroxide is the reactive nucleophile, which was directed for attack on the -lactam carbonyl by 
Asp120. The resulting, short-lived tetrahedral species was converted to a ring-opened, nitrogen 
anionic intermediate (EI) after the loss of the β-lactam bond. The proposed mechanism showed 
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that protonation of the anionic nitrogen occurs during the formation of a new bridging 
hydroxide/water, and it was assumed that this water came from bulk solvent. The resulting EP 
complex was in equilibrium with the resting enzyme, governed by the thermodynamic dissociation 
constant. The metal ion in the Zn2 site was proposed to be five-coordinate in the EP complex and 
in the resting state. The metal ion in the Zn1 site was proposed to be 4-coordinate in the resting 
enzyme and in the EI complex and 5-coordinate in the ES and EP complexes. 
 
Figure 4.13. Proposed reaction mechanism of L1 for the hydrolysis of nitrocefin.[19] 
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A different mechanism was hypothesized by Vila for BcII hydrolysis of imipenem (Figure 
4.14).[47] Upon imipenem binding, the bridging hydroxide becomes terminally-bound to the metal 
ion at the Zn1 site, and the terminally-bound water on the metal ion at the Zn2 site becomes a 
bridging ligand. The main substrate/enzyme contact was proposed to be the carboxylate at the 2 
 
Figure 4.14. Proposed reaction mechanism of BcII for the hydrolysis of imipenem.[47] 
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position on the five-membered ring and possibly a carboxylate/Lys224 interaction (labeled X in 
Figure 4.14). In this ES state, the coordination number for the metal ion in the Zn1 site was 
proposed to be 4, and the coordination number for the metal in the Zn2 site was proposed to be 5. 
The ES complex was proposed to quickly convert to the EI1 complex after the terminally-bound 
hydroxide on the metal ion in the Zn1 site nucleophilically-attacked an unactivated -lactam 
carbonyl. The coordination numbers of the metal ions in the Zn1 and Zn2 sites for the EI
1 complex 
are proposed to be 5 and 5, respectively. There were two fates of the EI1 complex proposed. The 
first fate was a protonation of the nitrogen anion to produce the 1 analog of product (not shown 
in Figure 4.14). A second fate involved a tautomerization of the double bound to generate a carbon 
anion at position 3 in the ring (called EI2 in Figure 4.14). The carbon anion is protonated by the 
bridging water to generate the 1 analog of product. The coordination numbers of both metal ions 
in EI2 were predicted to be 5 (Figure 4.14). Interestingly, all species except the ES complex in the 
Vila mechanism had a bridging solvent molecule.  
Previous presteady-state kinetic studies on ZnCo-L1 with nitrocefin as substrate indicated 
that the predominant species at 10 ms (around 89% of total protein) was intermediate (EI) along 
with small amounts (accounts for less than 12%) substrate (ES complex) and product (EP 
complex).[19] At 50 ms, the predominant species (around 87%) was also intermediate (EI) along 
with small amounts product (EP complex that accounts for less than 15%). At 100 ms, the 
predominant species (around 92%) was product (EP) along with small amounts intermediate. 
Previous stopped-flow photodiode array experiments on CoCo-BcII with imipenem as substrate 
indicated that the predominant species at 10 ms was intermediate EI1.[47] The authors reported 
that the conversion of EI1 into EI2 occurs between 10 ms and 600 ms. The buildup of product (EI3 
or EP) occurred between 0.6 s and 6 s. EXAFS data analysis was carried by considering single 
species present at the each time point (accounts for predominant species). EXAFS data presented 
herein were used to test different aspects of these mechanisms, particularly the reaction mechanism 
of L1.  
 EXAFS results on the ZnCo-L1/chromacef sample freeze quenched at 10 ms (EI is the 
predominant species) showed a coordination number of 4 for Zn(II) and a coordination number of 
5 for Co(II), which are identical to the coordination numbers of the resting enzyme. This result is 
not completely consistent with either reaction mechanism in Figures 4.13 or 4.14. Best fits of the 
EXAFS spectra of this sample demonstrate a large increase in the average metal-metal distance 
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(3.81 vs 3.49 Å), suggesting the loss of the bridging hydroxyl group in this sample, which is 
consistent the proposed structure of EI in the Hu mechanism but inconsistent with the structure of 
EI1 in the Vila mechanism. A similar increase in metal-metal distance was previously reported 
when the ZnZn analog of L1 was used in RFQ-EXAFS studies.[23] There are several possible 
structures for EI that could explain a 4-coordinate metal ion the Zn1 site and a 5-coordinate metal 
ion in the Zn2 site. We favor a structure of EI contains the Zn2 site with 3 enzyme-metal bonds and 
2 substrate-metal bonds and the Zn1 site with 3 enzyme-metal bonds and 1 substrate-metal bond 
(Figure 4.15). This structure is supported by several previous crystallographic studies on enzyme-
product complexes.[21, 22] The binding of substrate resulted in the loss of the Zn2/bridging 
hydroxide bond and the loss of the terminally-bound water molecule. This structure suggests that 
the Zn1-bound hydroxide (previously was the bridging hydroxide) acts as a reactive nucleophile, 
and Asp120 orients the Zn1-bound hydroxide to attack the β-lactam carbonyl. It should be noted 
that we are proposing a 5-coordinate metal ion in the Zn1 site for the ES complex. Our current 
RFQ system has a dead time of 10 ms, and we would not be able to detect this 5-coordinate species. 
We are building a new RFQ system that allows for dead times of 100 s, and we believe that we 
will be able to detect this species with future RFQ-EXAFS studies. The proposed nucleophilic 
attack is believed to result in a tetrahedral intermediate, which decomposes into the ring-opened, 
anionic intermediate (EI). Similar tetrahedral intermediates have been proposed in most, if not all, 
reactions catalyzed by peptidases/amidases.[19, 25, 47] In our mechanism, we propose that attack 
of the Zn(II)-OH on the -lactam carbon results in a “free” hydroxide, which would be expected 
to be more nucleophilic than a Zn(II)-bound hydroxide. We do acknowledge that this part of the 
mechanism is not common for metallopeptidases, but we had to either have the -lactam bond 
bound to the metal ion or the hydroxide bound to the metal ion to maintain the coordination number 
of 4. A reaction mechanism that does not contain a metal ion activated carbonyl is not precedented 
in the literature and does not make chemical sense. Currently, we have no direct evidence for an 
interaction between the Zn1 and the oxygen of the -lactam carboxylate. If a substrate with a thiono 
group[48] is used in RFQ-EXAFS studies, one could address whether the -lactam carbonyl 
oxygen interacts with the metal ion in the Zn1 site. In addition, if an analog of L1 could be 
generated with a bridging sulfhydryl, RFQ-EXAFS could unambiguously determine whether the 
bridging hydroxide becomes terminally-bound in the EI complex. These studies are planned for 
the future.  
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 EXAFS results on the ZnCo-L1/chromacef sample freeze quenched at 50 ms also 
suggested a coordination number of 4 for Zn(II) and a coordination number of 5 for Co(II), which 
are identical to those of the resting enzyme and of the sample quenched at 10 ms. The metal-metal 
distance of this sample was found to be 3.69 Å, which is 0.12 Å smaller than the metal-metal 
distance of the sample quenched at 10 ms. We offer two possibilities to explain the decreased 
metal-metal distance in this sample compared to that of the sample quenched at 10 ms (Figure 
4.15). First, the sample freeze quenched at 50 ms could be a mixture of EI (with a metal-metal 
distance of 3.82 Å) and of EP (with a metal-metal distance of 3.58 Å). However the average 
distance of 3.69 Å would mean that there is roughly 50% of each species in the sample. Our 
previous stopped-flow studies, albeit with a different substrate and under different conditions, do 
not support a 50:50 ratio of EI and EP at 50 ms.[19] In addition, inclusion of a Co-S interaction in 
the first shell fit model of Co K-edge EXAFS data along with the 4 N/O scatterers did not improve 
the fit residual of the sample quenched at 50 ms, which argues against a sample containing a 50:50 
ratio of EI and EP at 50 ms. A second possibility is that a water binds to the Zn2 site, resulting in 
the loss of one metal-substrate bond (possibly the bond between Zn2 and oxygen of the carboxylate 
at the 2 position in substrate/intermediate) in EI (Figure 4.15). This “pre-EP” complex would be 
expected to have a metal-metal distance shorter than a species with three substrate-metal bonds 
(EI) because of the “strain” imposed by the substrate/intermediate. However, this “pre-EP” 
complex would be expected to have a metal-metal distance longer than a species with a bridging 
hydroxide. The newly-bound water could be oriented by Asp120 to protonate intermediate, and 
this hypothesis was offered several years ago based on mutagenesis studies.[49] It is not clear from 
EXAFS data alone the exact structure of the species quenched at 50 ms.  
EXAFS results on the ZnCo-L1/chromacef sample freeze quenched at 100 ms (EP) showed 
a coordination number of 4 for Zn(II) and a coordination number of 5 for Co(II), which is identical 
to the values in the resting sample, sample quenched at 10 ms, and the sample quenched at 50 ms. 
The metal-metal distance in this sample was 3.59 Å. Interestingly, the best fit of the EXAFS data 
for this sample required the inclusion of a sulfur scatterer. The EXAFS spectrum of the ZnCo-
L1/product complex was identical to that of the sample quenched at 100 ms, suggesting that the 
reaction of ZnCo-L1 and chromacef was complete at 100 ms.[19] The only sulfur near the active 
site is the sulfur in substrate chromacef. Previously, RFQ-EXAFS data on ZnZn-L1 reacted with 
nitrocefin revealed the presence of a sulfur-Zn interaction in the spectrum of the enzyme-product 
129 
 
complex, and this result was explained by a rotation of the C6-C7 bond in product.[23, 29] In this 
previous study, the authors could not ascertain whether the rotation of the bond occurred in the 
active site or whether the product released from the active site, there was the rotation, and the 
rotated product re-bound to the active site. With the data presented herein, it is most likely that the 
rotation of the bond occurs in the active site and that this species is kinetically-competent. These 
data also demonstrate that that sulfur coordinates to the metal ion in the Zn2 site, indicating that 
substrate binds with the 6-membered dihydrothiazine ring over the Zn2 site. This result is not 
consistent with either reaction mechanism presented in Figures 4.13 and 4.14 nor is it consistent 
with any of the published structures of MBL bound to reaction products.[19, 47] This result 
suggests that the -lactam carbonyl is positioned over the Zn1 metal ion; however as discussed 
above, more studies are required to determine if the -lactam carbonyl binds to Zn1. 
 In summary, this study was designed to build on a previous RFQ-EXAFS study, in which 
several questions remained. The preparation of a ZnCo-heterometallic analog of L1 allowed for 
refinement of the reaction mechanism gleaned from this previous study (Figure 4.13 and Figure 
4.15). In this mechanism, the free enzyme has a 4-coordinate metal ion in the Zn1 site and a 5-
coordinate metal ion in the Zn2 site. Binding of substrate results in the loss of the terminally-bound 
water on the Zn2 site and the Zn2/bridging hydroxide bond, and these bonds are replaced by the 
oxygen of the carboxylate at position 2 and the nitrogen of the six-membered ring in substrate. The 
loss of the Zn2/bridging hydroxide bond results in a lengthening of the metal-metal distance during 
the very early stages of the reaction (before 10 ms). Zn1-bound hydroxide is oriented by Asp120 
and acts as a reactive nucleophile that attacks the activated -lactam carbonyl. The loss of -lactam 
bond results in the formation of ring-opened, nitrogen anionic intermediate (EI). The 
corresponding EI converts to a pre-EP complex, which favor the protonation of the anionic 
nitrogen. We propose a loss of the Zn2-oxygen (of the carboxylate of the 6-membered ring of the 
substrate) bond in the pre-EP complex, which is replaced by a terminally-bound water to the Zn2 
site. This loss of one metal ion-substrate/intermediate bond results in a decrease in the metal-metal 
distance of the pre-EP complex. A rotation of the substrate occurred in the sample quenched at 
100 ms and in the product complex, and it suggests substrate rearrangement occurred in the active 
site (Figure 4.15). However as discussed above, there is no direct evidence yet available for 
interaction between the Zn1 and β-lactam carbonyl during the reaction catalyzed by the MBLs. 
Given the lack of a conserved positively-charged amino acid in the vicinity of the -lactam 
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carbonyl, it would be surprising that the metal ion in the Zn1 site do not activate the -lactam 
carbonyl during catalysis. Future studies are planned to address this issue. This study suggests that 
the involvement of both (Zn1 and Zn2) sites in the β-lactam hydrolysis; therefore, both metal sites 
should be targeted for inhibitors in future design efforts.  
Figure 4.15. Revised proposed reaction mechanism of L1 for the hydrolysis of chromacef. 
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5.1. Abstract  
The metallo-β-lactamases (MβLs), which require one or two Zn(II) ions in their active sites 
for activity, hydrolyze the amide bond in β-lactam-containing antibiotics, and render the antibiotics 
inactive. All known MβLs contain a mobile element near their active sites, and these mobile 
elements have been implicated in the catalytic mechanisms of these enzymes. However little is 
known about the dynamics of these elements. In this study, we prepared a site-specific, double 
spin-labeled analog of homotetrameric MβL L1 with spin labels at position 163 and 286 analyzed 
the sample with DEER (double electron electron resonance) spectroscopy. Four unique distances 
were observed in the DEER distance distribution, and these distances were assigned to the desired 
intramolecular dipolar coupling (between spin labels at positions 163 and 286 in one subunit) and 
to intermolecular dipolar couplings. To rid the spin-labeled analog of L1 of the intermolecular 
couplings, spin-labeled L1 was “diluted” by unfolding/refolding the spin-labeled enzyme in the 
presence of excess wild-type L1. DEER spectra of the resulting, spin-diluted enzyme revealed a 
single distance corresponding to the desire intramolecular dipolar coupling. 
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5.2. Introduction 
The antibiotics most commonly prescribed to treat infections are β-lactam-containing 
compounds, which inhibit peptidoglycan cross-linking in bacterial cell walls.[1] Since their clinical 
debut, resistance to these antibiotics has become increasingly prevalent. The most common 
mechanism for β-lactam resistance is the production of β-lactamases, which hydrolyze the β-
lactam ring and render the drugs inactive.[2] A classification system has been developed that 
groups the 1,300 known β-lactamases into 4 classes: A, B, C, and D.[3-5] Class A, C, and D 
enzymes possess an active site serine that nucleophilically attacks the β-lactam carbonyl. Class B 
β-lactamases, which are known as metallo-β-lactamases (MβLs), are unique in that they require 
one or two Zn(II) ions in the active site for activity.[6, 7] MβLs are of increasing medical concern 
due to their potential for horizontal gene transfer on mobile plasmids and the lack of a clinical 
inhibitor against them.[8-12]  
Metal content and sequence homology data provide criteria for dividing the MβLs into the 
B1, B2, and B3 subclasses.[3, 4] B1 and B3 enzymes generally utilize two Zn(II) ions in their 
active sites and exhibit wide-spectrum β-lactamase activity. B2 enzymes carry only one active site 
Zn(II) and preferentially hydrolyze carbapenems. Despite structural and functional variance, 
certain characteristics are ubiquitous across the MβLs. Most notably is the αββα tertiary structure 
characteristic of the β-lactamase fold superfamily.[6, 7] Another important feature is a mobile motif 
near the active site of MβLs, which manifests itself as an unstructured loop in B1 and B3 enzymes 
and as an α-helix in B2 enzymes. Early crystallographic studies on B1 and B3 MβLs identified a 
position-conserved, highly-disordered loop near the active site of the enzymes; subsequent crystal 
structures of enzyme-inhibitor complexes have demonstrated migration of the loop towards the 
active site.[13-19] Dyson and coworkers conducted NMR studies and showed that Trp64 on the 
position-conserved loop of CcrA may play a role in inhibitor (and by analogy substrate) binding 
and further speculated that Trp64 and the loop play a role in promotion of catalysis.[20] Mutations 
and partial and complete deletions of the loop have resulted in marked changes in steady-state 
kinetics and formation of a reaction intermediate, as well as suggested a role for the loop in 
substrate binding.[19-22] Stopped-flow fluorescence experiments on L1 (a B3 enzyme) show a 
catalytically relevant rate of loop movement, further suggesting an important role for the loop in 
catalysis,[23] and EPR studies showed movement of the position-conserved -helix above the 
active site of ImiS, which belongs to the B2 class.[24] 
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We hypothesize that the mobile loop of L1 activates bound substrate for hydrolysis by 
“clamping down” and sterically-distorting the planar β-lactam ring and thereby raising the ground 
state energy of the substrate. One potential way to probe loop motion during catalysis is to use 
rapid-freeze quench double electron electron resonance (RFQ-DEER) spectroscopy. A necessary 
first step in the use of this technique is the generation of site-specifically, spin-labeled analogs of 
the enzyme. This work describes our efforts at spin-labeling a homotetrameric MβL in only one 
of the subunits. 
 
5.3. Methods 
Materials. Site-directed mutagenesis kits were purchased from Stratagene (Carlsbad, CA). 
E. coli strains DH5α and BL21(DE3) cells were purchased from Novagen (Madison, WI). 
Sequencing and mutagenesis primers were purchased from Integrated DNA Technologies. 
Isopropyl-β-D-galactoside (IPTG) was purchased from Anatrace (Muamee, OH). Q-Sepharose 
and Sephacryl S-200 chromatographic media were purchased from GE Healthcare. S-(2,2,5,5-
tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methylmethanesulfonothioate (MTSL) was purchased 
from Toronto Research Chemicals TRC (Canada). Substrate nitrocefin was purchased from Becton 
Dickinson. All buffer solutions and growth media were prepared by using Barnstead Nanopure 
water. The standard metallo--lactamase numbering scheme is used throughout this work.[25] 
Preparation and characterization of L1 mutants. To generate single and double mutants 
of L1, site-directed mutagenesis was carried out using a QuikChange mutagenesis kit (Stratagene) 
according to manufacturer’s instructions. The T163C and K286C L1 mutants were generated using 
the L1 over-expression plasmid, pET26bL1,[26] as the template and the following primers: T163C 
(5'-cggcgatggcatctgctacccgcctgcc-3'), T163C_antisense (5'-ggcaggcgggtagcagatgccatcgccg-3'), 
K286C (5'-gccagggccggtgcctgcgcactgacctgcaag-3'), and K286C_antisense (5'-
cttgcaggtcagtgcgcaggcaccggccctggc-3'). The T163C/K286C L1 double mutant was generated 
using pT163CL1 as the template and the K286C primers listed above. Mutated DNA was 
confirmed by DNA sequencing at CBFG facility Miami University, and plasmids containing the 
mutated DNA were transformed into E. coli BL21(DE3) cells. Wild-type L1 and the single mutants 
of L1 were over-expressed and purified as described previously[26] except that the induction 
temperature for the mutants was lowered from 37 °C to 28 °C. 
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The T163C/K286C mutant was found to over-express as an insoluble protein. After protein 
over-expression, E. coli cells were centrifuged at 8000 xg for 10 minutes. The supernatant was 
discarded, and the cell pellets were resuspended in 100 mL of 50 mM HEPES pH 7.0. Lysis was 
achieved by passage through a French press three times at 1000 psi. The resulting solution was 
centrifuged (25 minutes at 23,400 xg), and the supernatant was discarded. The pale white inclusion 
bodies were resuspended in 80 mL of 7 M guanidinium hydrochloride containing 100 µM Zn(II). 
The solution was subjected to vortexing for 5 minutes and then centrifuged (25 minutes at 23,400 
xg) to remove insoluble debris. The supernatant was dialyzed vs. 4 X 1 L 50 mM HEPES, pH 7.0, 
containing 100 mM NaCl. The resulting sample was then centrifuged (25 minutes at 23,400 xg) to 
remove insoluble species. The supernatant was concentrated to 4 mL using an Amicon apparatus 
equipped with a YM-10 membrane, and the concentrated protein was purified using a G-25 size 
exclusion column with 50 mM HEPES, pH 7.0, containing 100 mM NaCl as the chromatography 
buffer. Fractions containing the purified T163C/K286C mutant were identified by using SDS-
PAGE.  
Wild-type L1 and L1 mutants were characterized using metal analyses and steady state 
kinetic studies.[26] Metal content of L1 samples was determined with a Perkin-Elmer Optima 7300 
DV inductively coupled plasma spectrometer with atomic emission detection as described 
previously.[26] Steady-state kinetic studies were conducted at 25 °C with an Aligent 8453A UV-
Vis Diode Array spectrophotometer, with nitrocefin as the substrate and 50 mM cacodylate, pH 
7.0, containing 50 µM Zn(II) as the buffer. 
Preparation of spin-labeled L1 mutants. L1 mutants were dialyzed versus 1 L of 50 mM 
HEPES, pH 7.0, containing 100 mM NaCl. One equivalent of dithiothreitol (DTT) was added to 
the samples 30 minutes prior to addition of (1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl) 
methanethiosulfonate (MTSSL). A 15-molar excess of MTSSL was dissolved in 100 μL of neat 
dimethyl sulfoxide, and the entire solution of MTSSL was added into DTT-pretreated L1 samples. 
The spin-labeling reaction was carried out in the dark on a rocking platform overnight at 4 °C. 
Unbound MTSSL was removed by passing the sample through a G-25 (1.5 cm X 40 cm of bed 
volume 60 ml) chromatography column using 50 mM HEPES, pH 7.0, containing 100 mM NaCl 
as the buffer. The efficiency of the spin labeling was estimated by using cw-EPR at room 
temperature. Briefly, 35 mm quartz capillary tubes (1.1 mm inner diameter and 1.6 mm outer 
diameter) were filled with ca. 30 μL of 100 μM spin-labeled protein samples. Capillary tubes were 
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placed in 3 mm inner diameter quartz EPR tubes and inserted in the microwave cavity. CW EPR 
spectra were collected at X-band on a Bruker EMX CW-EPR spectrometer using an ER041xG 
microwave bridge and ER4119-HS cavity coupled with a BVT 3000 nitrogen gas temperature 
controller at the Ohio Advanced EPR Laboratory. CW EPR spectra were collected by using 
parameters previously published by Feldmann et al. [27] Spectra were collected by signal 
averaging 25 scans (consisting of 1024 points and 40 ms time constants). The instrument 
parameters were a center field of 3370 G and a sweep width of 100 G, microwave frequency of 
9.5 GHz, modulation frequency of 100 kHz, modulation amplitude of 1 G, and microwave power 
of 1 mW at 298 K. Spin label concentrations of protein samples were quantified as previously 
described.[27] 
Preparation of spin-diluted, spin-labeled L1 mutants. Wild-type metallo--lactamase L1 
was over-expressed and purified according to the procedure by Crowder et al.[26] Metal-free (apo) 
L1 samples, both wild-type and mutants, were generated as described by Hu and coworkers.[28] 
The metal-free, double mutant of L1 (1 mL, 200 µM) was mixed with 1 mL of 800 µM apo-wild-
type L1, and the mixture was unfolded in 18 mL of 7 M Gdn-HCl containing 100 μM Zn(II). After 
incubation on ice for 30 minutes, the mixture was dialyzed versus 4 X 1 L of 50 mM HEPES, pH 
7.0, containing 100 mM NaCl (six hours for each dialysis step). The refolded protein was 
centrifuged (23,400 xg for 25 minutes) to remove any insoluble species. The refolded double 
mutant of L1 was labeled with MTSSL using the procedure described. 
Double Electron Electron Resonance (DEER) studies.  Spin-labeled mutants of L1 were 
concentrated to 60-100 μM by using an Amicon ultrafiltration concentrator equipped with an YM-
10 membrane. The samples were analyzed by using either Q-band DEER spectroscopy at the Ohio 
Advanced EPR Laboratory or X-band DEER at the National Biomedical EPR Center, Medical 
College of Wisconsin. DEER was performed at 80 K using Bruker EleXsys E-580 Pulse EPR 
spectrometers equipped with nitrogen cooling and either a Bruker SuperQFTu bridge, 10 W AmpQ 
microwave amplifier and Q-band EN 5107D2 dielectric resonator (34.2 GHz), or a Bruker 
SuperXFT bridge, Applied Systems Engineering 2 kW traveling wave tube amplifier and X-band 
EN4118X-MD4 resonator (9.7 GHz). The MD4 resonator is designed for 3.8 mm O.D. tubes but 
was used here with 4 mm O.D. tubes (Wilmad 706-SQ-250M) that were cut to 7 cm length and 
loaded through the bottom of the resonator.[29]  A four-pulse /2O - 1 - O - E - P - (1 + 2 -E) 
- O DEER sequence was employed, where the superscripts "O" and "P" denote pulses at the 
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observe and pump frequencies, respectively, E is the time between the first inversion pulse and 
the pump pulse, and 2 is the dipolar evolution time. At X-band, /2O and O were 16 and 32 ns, 
respectively, with, 2 = 1200, and P = 32 ns; at Q-band, /2O and O were 20 and 40 ns, 
respectively, with, 2 = 2200, and P = 48 ns. Spectra were pumped at the ml = 0 center line and 
observed at the low-field ml = 1 line, with a  = 73 MHz at X-band and 61 MHz at Q-band. Shot 
repetition times of 1200 s (X-band), and 500 s (Q-band) were used. Distances were obtained 
using DEERAnalysis v.2009 and v.2011.[30] The use of two frequencies deserves comment. In 
principle, exactly the same information is available at both frequencies provided that the relaxation 
times allow for reasonable dipolar evolution times. In the present study, we were able to capture 
at least one full oscillation of the dominant DEER modulation at each frequency. Q-band DEER 
is a much more efficient technique in terms of time and material and is the preferred method. 
However, it is important to demonstrate that high quality interpretable data could be also obtained 
at X-band, as one of the goals of this work is to develop a magnetically-diluted labeled tetramer, 
free of inter-subunit dipolar interactions, which can be probed using rapid-freeze-quench (RFQ) 
to trap conformational intermediates in the catalytic cycle. RFQ sample preparation, and 
maintenance of samples at cryogenic temperatures during loading and transfer, is significantly 
simpler and more reliable with the larger and thermally-massive X-band samples, and X-band 
DEER is being used in ongoing RFQ-DEER studies.[31] In the present study, useful X-band 
DEER data were observed out to 1.1 s; data collected for longer times actually resulted in 
quantitatively poorer fits (higher uncertainty) that were qualitatively identical to the fits to 1.1 s 
data. With these data, we would expect to be able to confidently assign distances of up to about 
4.3 nm, with decreasing confidence in longer distances. 
Molecular Dynamics Simulations. The atomic coordinates for the L1 crystal structure 
(PDB ID: 1SML) from Fischerella were downloaded from the Protein Data Bank and used to 
generate the structures of various spin-labeled L1 mutants with the Nanoscale Molecular 
Dynamics (NAMD) program.[32] The T163C and K286C mutations were created using the 
molecular graphics software VMD.[33] The nitroxide spin-probe MTSL was attached using 
CHARMM force field topology files incorporated into NAMD. The modified protein assembly 
was solvated into a spherical water environment and further equilibrated and minimized by running 
NAMD simulations at room temperature using CHARMM force field parameters. The distance 
distribution between the T163C and K286C residues was predicted with rotamer library modeling 
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of MTSL conformations using Multiscale modeling of macromolecular systems (MMM version 
2010).[32] 
 
5.4. Results 
Preparation and characterization of L1 mutants. Our overall goal in this project was to 
prepare analogs of metallo--lactamase L1 that contained site-specific spin labels that could be 
used to probe motions of the protein during catalysis. One label was designed to be positioned on 
the catalytic loop that extends over the active site, and the other label was designed to be positioned 
on a more static part of the enzyme, such as on an -helix, 20-35 Å away from the loop. Using the 
crystal structure of L1 as a guide,[18] we initially identified Asp160 on the loop as the optimum 
position to introduce a cysteine residue for the site-specific spin label (Figure 5.1). The side chain 
of Asp160 is in the center of the flexible loop in L1 and appeared to protrude away from the active 
site, and we reasoned that this position might tolerate a mutation. The D160C mutant was over-
expressed and purified. While the D160C mutant bound 2 equivalents of Zn(II), steady-state 
kinetic studies with nitrocefin as the substrate demonstrated that the mutant exhibited a kcat of 5.5 
s-1 and a Km of 7 M, as compared to the kcat and Km values of 40 s-1 and 4 M, respectively, for 
wild-type L1 (Table 5.1). In an effort to identify a mutant with activity more similar to that of the 
wild-type enzyme, we prepared and characterized the S153C mutant. Given our results with the 
D160C mutant, we reasoned that the introduction of a mutation on a part of the loop that was not 
as flexible (closer to an -helix) would result in a mutant that exhibited steady-state kinetic 
behavior closer to that of the wild-type enzyme. We chose position 153 because there is a serine 
in this position in the wild-type enzyme, and a Ser to Cys mutation would not be a huge structural 
change.  Unfortunately, this mutant exhibited a low kcat value (Table 5.1). We chose a T163C 
mutant for similar reasons as we used for the S153C mutant. The T163C mutant was over-
expressed and purified, and the protocol described in Materials and Methods yielded 
approximately 30 mg of >95% pure, soluble T163C mutant per 4 liters of growth culture, compared 
with the 80 mg typically obtained from preparations of wild-type L1. The T163C mutant bound 
1.7 + 0.2 equivalents of Zn(II) and exhibited a kcat of 40 + 1 s
-1 and a Km of 11 + 2 M; these values 
are similar to those of wild-type L1 (Table 5.1). Since Ser153, Asp160, and Thr163 are found on 
the “mobile loop” in L1, it is clear that the mobile loop on L1 is very sensitive to point mutations. 
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Nonetheless, the T163C mutant exhibited sufficient catalytic properties to be used in the proposed 
double labeling studies.  
 We successfully generated the T163C/K286C double mutant. The spin label on Thr163 is 
estimated to be 25 Å away from the spin label on Lys286 (Figure 5.2), and this distance is amenable 
to interrogation by DEER spectroscopy. Lys286 is found on one of the 310 -helices in L1,[34] 
and we reasoned that the motion of residues on -helices would be less than those on unordered 
loops. In other words, any changes in distances between the introduced spin labels could be 
attributed to motions of the spin label on the loop (Thr163). The K286C mutant exhibited a kcat of 
 
Figure 5.1. Structure of L1 monomer with Ser153, Asp160, and Thr163 shown and hydrolyzed 
moxalactam in the active site (PDB ID: 2AIO).  
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13 + 1 s-1 and a Km of 0.5 + 0.1 M and bound 1.7 + 0.1 equivalents of Zn(II) (Table 1). The 
T163C/K286C double mutant was shown to bind 1.7 + 0.1 equivalents of Zn(II) and exhibit a kcat 
of 21 + 1 s-1 and a Km of 3.7 + 0.5 M.  
Spin-labeling of the L1 mutants. Wild-type L1 and the T163C, K286C, and T163C/K286C 
mutants of L1 were spin-labeled as described in the Methods section. Unbound spin label was 
removed by gel filtration. The efficiency of spin labeling was evaluated by using cw-EPR 
spectroscopy, as described previously,[27] and the spectra demonstrate that spin-labeled T163C, 
K286C, and T163C/K286C mutants were labeled with 95%, 91%, and 92% efficiency, 
respectively (Figure 5.3). Since wild-type L1 has two cysteines (Cys252 and Cys280) that form a 
disulfide bond, cw-EPR spectroscopy was used to show that wild-type L1 was not spin-labeled 
with MTSSL and that the T163C/K286C double mutant binds 2 MTSL groups (Figure 5.3). Spin-
 
Figure 5.2. L1 monomer labeled with MTSL at positions 163 and 286. The Zn(II) ions are 
purple. The figure was generated using molecular graphing software VMD and molecular 
dynamics simulation starting from the L1 monomer crystal structure (PDB ID: 1SML) as 
described in the Methods section.[33] 
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labeled T163C L1 bound 2.0 ± 0.2 eq of Zn(II) and exhibited a kcat of 51 + 4 s
-1 and a Km of 4 ± 1 
µM, which are values similar to those of wild-type L1 (Table 5.1). Spin-labeled K286C bound 1.8 
± 0.1 eq of Zn(II) and exhibited a kcat of 9 + 1 s
-1 and a Km of 0.9 ± 0.3 µM, which are values 
similar to those of wild-type L1 (Table 5.1). The spin-labeled T163C/K286C mutant bound 2.1 + 
0.1 eq. of Zn(II) and exhibited a kcat of 9.2 + 2.2 s
-1 and a Km of 1.4 + 0.1 M, which are values 
similar to those of wild-type L1 (Table 5.1). 
DEER studies on the spin-labeled T163C/K286C mutant of L1. The time- and distance 
domain Q-band DEER spectra of the spin-labeled T163C/K286C mutant of L1 are shown in Figure 
5.4.  The spin-labeled T163C/K286C L1 mutant yielded four distinct distances at 23, 31, 37, and 
48 Å (+ 10%). An examination of the crystal structure of tetrameric L1 shows one intramolecular 
dipolar coupling between a spin label at position 163 with a spin label at position 286 and a number 
of potential intermolecular dipolar couplings (Figure 5.4). Judging by distances alone, we can 
3300 3330 3360
Magnetic field [G]
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dB
   Spin-labeled
T163C/K286C L1
Spin-diluted spin-labeled
    T163C/K286C L1
WT-L1 reacted with spin label
 
Figure 5.3. CW-EPR spectra of the spin-labeled T163C/K286C mutant of L1, the spin-diluted 
T163C/K286C mutant of L1, and wild-type L1 after reacting with spin label as described in 
the Methods section. 
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tentatively assign the distance-domain DEER peaks at 31, 37, and 51 Å to Thr163 on subunit D 
coupled to Thr163 on subunit C, Thr163 on subunit A coupled to Thr163 on subunit C, and Lys286 
on subunit A coupled to Thr163 on subunit C, respectively (Figure 5.5). We were unable to detect 
any dipolar couplings between spin-labeled Thr163 on A and D (or B and C) subunits, most likely 
because the distances were < 10 Å.[30] While we were able to detect the desired intramolecular 
dipolar couplings between spin-labeled Thr163 and Lys286, the other undesired intermolecular 
dipolar couplings render this form of the labeled enzyme unsuitable for ongoing mechanistic 
DEER studies.  
Preparation and characterization of a “spin-diluted”, spin-labeled T163C/K286C 
mutant of L1.  To prepare a spin-diluted, spin-labeled analog, wild-type L1 and the T163C/K286C 
mutant were over-expressed and purified. The enzymes were made metal-free according to 
previously reported procedures.[28] The apo-enzymes were unfolded with Gdn-HCl, and the spin-
diluted sample was made by refolding 4 molar equivalents of unfolded wild-type L1 with 1 molar 
Table 5.1. Steady state kinetic constants and metal content of wild-type L1 and L1 mutants. 
 
Enzyme kcat (s-1) Km (M) Metal     
content (eq) 
Wild-type L1 40 + 1 4 + 1 1.9 + 0.2 
D160C 5.5 + 0.5 7 + 1 2.0 + 0.1 
S153C 13 + 1 2.3 + 0.2 2.0 + 0.1 
T163C 40 + 1 11 + 2 1.7 + 0.2 
Spin-labeled T163C 51 + 4 4 + 1 2.0 + 0.2 
K286C 13 + 1 0.5 + 0.1 1.7 + 0.1 
Spin-labeled K286C 9 + 1 0.9 + 0.3 1.8 + 0.1 
T163C/K286C 21 + 1 3.7 + 0.5 1.7 + 0.1 
Spin-labeled T163C/K286C 9.2 + 2.2 1.4 + 0.1 2.1 + 0.1 
Spin-diluted, unlabeled 
T163C/K286C 
20 + 1 2.5 + 0.5 1.7 + 0.1 
Spin-diluted, spin-labeled 
T163C/K286C 
23 + 1 2.1 + 0.7 1.8 + 0.1 
 
 
 
147 
 
equivalent of the unfolded T163C/K286C in the presence of Zn(II) (Figure 5.6). The spin-diluted, 
unlabeled T163C/K286C mutant bound 1.7 + 0.1 eq of Zn(II) and exhibited a kcat of 20 + 1 s
-1 and 
a Km of 2.5 + 0.5 M (Table 5.1). 
The spin-diluted T163C/K286C mutant was spin-labeled by reacting the double mutant 
with a 15-fold excess of MTSSL. Unbound spin label was removed by gel filtration 
chromatography. Cw-EPR spectroscopy showed that the spin-diluted, double mutant was spin-
labeled with 92% efficiency. The spin-labeled, spin-diluted T163C/K286C mutant bound 1.8 + 0.1 
eq of Zn(II) and exhibited a kcat of 23 + 1 s
-1 and a Km of 2.1 + 0.7 M.  
DEER studies on the “spin-diluted”, spin-labeled T163C/K286C mutant of L1.   In 
marked contrast to the fully spin-labeled homotetramer, X-band DEER of the spin-diluted, spin-
labeled T163C/K286C L1 mutant indicated only a single interspin distance at 26 + 3 Å (Figure 
5.7), which corresponds to the expected intramolecular dipolar coupling between a spin label at 
position 163 and a spin label at position 286. Other weak features in the distance domain trace 
were observed at 20, 43, 47 and 51 Å, though the significance of these is debatable due to the 
limited range of useful DEER data in the time domain, corresponding to uncertainty beyond 43 Å, 
and the calculated uncertainties in the magnitudes indicates dependence on the details of the data 
processing parameters. Low levels of intermolecular interactions at 31, 37, and 51 Å were 
expected. There is a shoulder on the 26 Å peak corresponding to 31 Å. Nothing, however, was 
observed at 37 Å, and although a peak at 51 Å was in fact detected, its significance is in doubt. A 
 
 
Figure 5.4. (a) Time-domain Q-band DEER spectrum of spin-labeled T163C/K286C mutant 
of homotetrameric L1.  (b) Distance domain DEER spectrum of the spin-labeled T163C/K286C 
mutant of homotetrameric L1. 
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small but apparently significant peak was observed at 43 Å and may correspond to the peak 
observed at 37 Å in the undiluted sample if the limits of the errors are considered.  
To study the loop dynamics in 
catalysis 10 ms catalytic intermediate of 
the spin diluted, spin labeled 
T163C/K286C L1 and nitrocefin were 
quenched using RFQ and collected the 
DEER spectrum on the 10 ms 
intermediate and thawed 10 ms 
intermediate (referred as thaw product). 
Distance domain DEER spectra of these 
two samples shown no change with the 
 
Figure 5.5. Structure of spin-labeled homotetrameric L1. Subunits are labeled with A, B, C, or 
D. Spin labels are at position 163 (in center of tetramer) and position 286 (on outer corners of 
tetramer) in all four subunits. Distances between spin labels are included: intramolecular 
distance of 25 Å is shown in subunit A (spin labels at positions 163 and 286) and intermolecular 
distances (see text for description). The figure was generated using by using molecular 
graphing software VMD and molecular dynamics simulations starting with the L1 tetramer 
crystal structure (PDB ID: 1SML) as described in the Methods section. 
 
 
Figure 5.6. Spin dilution procedure. Spin labeled 
protein in red, unlabeled protein in white.   
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resting enzyme. The predominant distance peak of these three samples were almost identical, 
however thaw product shown higher noise levels in the time domain data (Figure 5.8).                                        
 
Figure 5.7. (Left) Time-domain X-band DEER spectrum of spin-diluted, spin-labeled 
T163C/K286C mutant of homotetrameric L1. (Right) Distance domain DEER spectrum of 
spin-diluted, spin-labeled T163C/K286C mutant of homotetrameric L1. The vertical lines on 
the distance domain trace are the calculated uncertainties in the data due to the dependence on 
the data processing parameters. 
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Figure 5.8. (Left) Time-domain X-band DEER spectrum of spin-diluted, spin-labeled 
T163C/K286C mutant of homotetrameric L1 Resting (Top), 10 ms (Mid) and Thaw product 
(Bot). (Right) Distance domain DEER spectrum of spin-diluted, spin-labeled T163C/K286C 
mutant of homotetrameric L1 (Top), 10 ms (Mid) and Thaw product (Bot). The vertical lines 
on the distance domain trace are the calculated uncertainties in the data due to the dependence 
on the data processing parameters. 
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5.5. Discussion 
An understanding of enzyme dynamics is central to the characterization of protein function. 
Information about changes in enzyme structure during catalysis has been approached using several 
techniques, each with their advantages and shortcomings. One strategy is to determine the crystal 
structure of various enzyme-substrate complexes along the catalytic pathway, a technique which 
has been shown to provide a wealth of information about reaction mechanism.[35, 36] However, 
this strategy has had only limited application due the rarity of systems involving intermediate 
complexes sufficiently stable for the generation of crystals. A more common technique is 
fluorescence spectroscopy, which measures changes in fluorescence due to tryptophan 
residues.[37] While fluorescence spectroscopy provides information about the rate of a catalytic 
reaction, it fails to provide specific structural data. Fluorescence Resonance Energy Transfer 
(FRET) can be used to probe the interaction between site-specific donor and acceptor fluorophores 
in a molecule and give distance information ranging from 10 to 75 Å.[38, 39] When combined 
with stopped-flow fluorescence, FRET can be used to measure changes in inter- or intramolecular 
distances over time.  
We initially attempted to use stopped-flow FRET studies to probe loop motion in L1 during 
catalysis. However, our attempts to generate a doubly-labeled mutant were unsuccessful; we were 
unable to label any of the loop residues with the large fluorophores. As a result we turned to DEER 
spectroscopy, which utilizes relatively small spin-labels and provides distance distributions from 
approximately 20 to 80 Å.[30, 40] Results from CW EPR spectroscopic experiments demonstrated 
successful spin-labeling of L1 mutants. Steady-state kinetics and ICP-AES studies showed that 
spin-labeled L1 mutants exhibited similar steady state kinetic constant and metal content as wild-
type L1. In addition, gel filtration chromatography and CD spectroscopy were used to verify that 
the refolded enzyme was tetrameric (Figure 5.8). 
DEER of the spin-labeled T163C/K286C mutant revealed four distinct interspin distances 
at 23, 31, 37 and 48 Å) (Figure 5.4). Based on the crystal structure of L1, the expected 
intramolecular distance between spin labels at position 163 and 286 was 25 Å (Figure 5.2). The 
other observed distances were assigned to dipolar coupling between spin labels on different 
subunits of tetrameric L1. The use of the fully spin-labeled, tetrameric L1 in future spectrokinetic 
studies to probe conformational change during reaction would be significantly complicated by the 
presence of these additional DEER modulations due to inter-subunit dipolar couplings. Given the 
151 
 
position of the spin-labels on the loop in L1, it would also be impossible to probe for motion using 
dipolar couplings between Co(II) in a Co(II)-substituted L1 and a spin label on the loop, as we 
reported for ImiS.[41] The resulting broadening of the EPR signals of the spin labels would require 
that all four subunits were synchronized to obtain meaningful spectrokinetic information.  A 
monomeric form of L1 would circumvent these problems, and it is indeed possible to generate 
monomeric L1 by introducing an M175D substitution.[42] Unfortunately, the M175D variant 
exhibits markedly different kinetic behavior (e.g., Km = 900 M for nitrocefin) that raises the 
possibility of an altered catalytic mechanism. Previously, several groups have reported adding 
unlabeled protein to spin-labeled oligomeric proteins to remove intermolecular dipolar 
couplings.[43, 44] For example, Kim et al. added fully-folded, cysteine-free arrestin-1 to fully-
folded, spin-labeled arrestin-1 tetramers to remove the dipolar couplings of spin labels on adjacent 
subunits.[45] Xu et al. used a similar method to “dilute” BtuB.[46] We attempted a similar strategy 
with L1; however, we were unable with L1 to “dilute” the intermolecular dipolar couplings using 
this method.  
 
Figure 5.9. CD spectra of the refolded T163C/K286C mutant and wild-type L1. Experiments 
were conducted using 10 mM phosphate buffer, pH 7.6 at 25 °C. 
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Here, we have described a novel method of unfolding and monomerization of a spin-
labeled homomultimeric metalloprotein, followed by dilution with unlabeled protein, and 
reassembly of the spin-diluted multimer. The use of a metalloprotein complicated this approach. 
In our hands, we could not unfold Zn(II)-containing L1 with Gdn-HCl. Therefore, the metal-free 
analog of L1 was used in the unfolding step. This method has the potential advantage of being able 
to generate metal-substituted analogs of the spin-label, spin-diluted protein since metal ion is 
added back to the protein during the refolding step. This approach, therefore, could be used to 
prepare single spin-labeled proteins containing paramagnetic metal ions, and the resulting proteins 
could be interrogated with cw-EPR. 
Here, with a dilution of a labeled tetramer, we can predict the composition of the 
reassembled protein. Taking the symbols "X" and "O" to represent labeled (doubly) and unlabeled 
monomers, we expect 42% of the desired XOOO species, along with 32% of the unlabeled OOOO 
species, 21% of the XXOO species, 5% of XXXO and 0.4% of XXXX. The unlabeled OOOO 
species can be ignored, and the very small amounts of XXXO and XXXX may also be neglected. 
For purposes of magnetic resonance, we can consider our population as one of singly- and doubly-
labeled tetramers in a ratio of 2:1. For a generalized fully-labeled homotetramer with equivalent 
subunits A, B, C and D, one could expect up to six sets of intersubunit interactions, AB, BC, CD, 
AD, BD, and AC, compared to the four sets of intrasubunit interactions, giving a signal-to-
interference ratio (SIR) of 4:6, or 1:1.5. Applying our dilution method to this general population, 
we now have only one intrasubunit interaction in two-thirds of the population, and have two 
intrasubunit and one intersubunit interaction in one-third of the population. This technique yields 
an SIR of 4/3:
1/3, or 4:1, a six-fold improvement over the fully-labeled system. In the present case, 
the improvement is better yet, because the intersubunit interactions are specific for either AB (or 
AD), or else AC; that is to say that XXOO is not equivalent to XOXO. The expected relative 
intensities of the desired ~ 25 Å signal and the undesirable 31 Å signal are 6:1, and those for the 
25 Å signal versus the 37 and 51 Å signals are 12:1. Thus we have improved the SIRs by factors 
of 9 and 18 by the use of the dilution method for L1. In practice, our DEER data show that these 
improvements are sufficient to render the unwanted couplings, at 8 and 17% prevalence, 
undetectable among the much stronger ~ 25 Å modulations.  
Interestingly DEER spectrum of the 10 ms spin diluted, spin labeled T163C/K286C L1 has 
shown no change in the distance with the resting sample, this might be due to T163C was not 
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located on the hairpin loop. In process of finding the active mutant on the hairpin we had to go few 
residues away from the hairpin loop. To study the hairpin dynamics we will consider other MBLs, 
which can allow the mutation on the hairpin loop without altering its activity.  
In general, we anticipate that this method will have great utility in the design of 
specifically-labeled multimers where inter-subunit interactions contaminate spectroscopic data. 
This technique can be used with multimers that are tightly-associated, such as hemocyanin[47], 
xanthine oxidase[48], nitrogenase[49], and aspartate transcarbamoylase[50], and cannot be diluted 
with dialysis. Specific to L1, we anticipate that this method will provide much higher confidence 
in the interpretation of changes in the DEER spectra observed as a function of reaction time in 
ongoing RFQ spectrokinetic studies.  
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6.1. Abstract 
Previous crystallographic and mutagenesis studies have implicated the role of a position-
conserved hairpin loop in the metallo--lactamases in substrate binding and catalysis. In an effort 
to probe the motion of that loop during catalysis, rapid-freeze-quench double electron electron 
resonance (RFQ-DEER) spectroscopy was used to interrogate metallo--lactamase CcrA, which 
had a spin label at position 49 on the loop and spin labels (at positions 82, 126, or 233) 20-35 Å 
away from residue 49, during catalysis. At 10 milliseconds after mixing, the DEER spectra show 
distance increases of 7, 10, and 13 Å between the spin label at position 49 and the spin labels at 
positions 82, 126, and 233, respectively. In contrast to previous hypotheses, these data suggest that 
the loop moves nearly 10 Å away from the metal center during catalysis and that the loop does not 
clamp down on the substrate during catalysis. This study demonstrates that loop motion during 
catalysis can be interrogated on the millisecond time scale.   
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6.2. Introduction 
The -lactamase-fold superfamily of metalloenzymes binds 1 or 2 transition metal ions per 
protein and has an tertiary structure.[1] The prototypical members, the metallo--lactamases 
(MLs), hydrolyze amide bonds found in -lactam containing antibiotics. The Zn(II)-containing 
MLs constitute an ever-growing and troubling class of -lactamases that have been found in 
clinical isolates of Bacillus anthracis (anthrax), Pseudomonas aeruginosa, Klebsiella pneumoniae, 
and a host of other pathogenic organisms.[2-6] The MLs contain either 1 or 2 moles of Zn(II) per 
mole of enzyme, hydrolyze all known cephalosporins, carbapenems, and penicillins, and are not 
inhibited by clavulanic acid or any other clinically-useful inhibitor. Previous studies have shown 
that there is significant structural and mechanistic diversity among the MLs, leading to the 
grouping of the enzymes into three distinct 
subclasses: B1, B2, and B3.[2, 5, 7, 8] The B1 
enzymes have one Zn(II) site (the Zn1 site) 
consisting of His116, His118, and His196, a second 
Zn(II) site (the Zn2 site) consisting of Asp120, 
Cys221, and His263, and are typified by ML CcrA 
from Bacteroides fragilis.[9] The B2 enzymes are 
mono-zinc enzymes chiefly found only in species of 
Aeromonas,[10, 11] with the same Zn2 binding site 
as the B1 enzymes (His116 is replaced by a 
conserved asparagine, which abolishes metal binding at the Zn1 site), and include ML ImiS from 
Aeromonas sobria.[12] The B3 enzymes have the same metal binding sites as the B1 enzymes 
except that Cys221 is replaced with a conserved histidine, and include ML L1 from 
Stenotrophomonas maltophilia.[13] The B1 and B3 enzymes most often require two bound Zn(II) 
ions for full catalytic activity.[14-16] The diversity of the MLs is best exemplified by the 
enzymes’ vastly differing susceptibilities towards inhibitors,[4, 5, 7, 8, 17-23] metal binding 
properties (cooperative versus sequential),[15] and reaction mechanisms (i.e., whether a ring-
opened nitrogen anionic intermediate is formed when using nitrocefin or chromacef as substrate 
(Scheme 1)).[24] 
      
 
Scheme 6.1. Structures of chromacef 
(top), hydrolyzed chromacef (middle), 
and nitrocefin (bot) 
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Crystal structures of several B1 and B3 MLs identified a position-conserved loop that 
extends over the metal binding site, [13, 25-28] and similar loops have been observed in other 
enzymes belonging to the -lactamase fold superfamily, suggesting a common role for these 
loops.[29-31] Crystal structures of ML-inhibitor complexes showed decreased flexibility and 
reorientation of the loop towards the metal center.[5, 7, 8, 25-28, 32] NMR studies indicated that 
Trp49 on the loop in CcrA may play a role in inhibitor (and by analogy substrate) binding and 
suggested that Trp49 and the loop plays a role in promotion of catalysis.[33, 34] These results are 
supported by mutagenesis studies in which mutations of Trp to other amino acids resulted in over 
50-fold decreases in kcat/Km (depending on the identity of the residue that replaced Trp49).[34] 
Deletion of residues 47-49 induced a >100-fold decrease in kcat/Km, for CcrA [34] and deletion of 
the entire loop led to a reduction of kcat/Km by factors of up to 5,000.[35] It should be noted, 
however, that Trp49 is not conserved across the MLs.  
Studies of variants of IMP-1 and BcII containing deletions or substitutions in the loop 
region identified altered kinetic parameters and suggested that Trp64 plays a role in substrate 
binding by interacting with hydrophobic portions of the substrate,[34, 36] thus extending the 
mechanistic importance of the loop beyond CcrA.  It has been speculated, however, that enzyme 
molecules from which the loop was deleted may have altered folding, and caution should be 
exercised when interpreting the data in terms of structure-function relationship.[36] Vila has 
speculated that the differences in reaction mechanisms indicated for BcII relative to other B1 and 
B3 MLs may be due to a comparatively smaller loop over the BcII active site.[37]  
The B2 enzymes have an -helix in the same position as the loop in the B1 and B3 enzymes 
that appears to have the same function.[38, 39] The helix in the resting state of the B2 ML CphA 
has been structurally characterized by X-ray diffraction, but mechanistic data are lacking, whereas 
an earlier EPR spectrokinetic study of the related enzyme ImiS identified rotation of the helix 
about its axis during the catalytic cycle.[39] The available data suggest that the loop in B1 and B3 
MLs and the position-conserved α-helix in B2 MLs play a role in substrate binding and 
catalysis. In this study, further information was sought on the role of the hairpin loop in CcrA by 
the use of pulsed double electron-electron resonance (pELDOR or "DEER") spectroscopy of 
trapped catalytic intermediates of doubly spin-labeled CcrA containing one spin label on the 
putative mobile loop and another in one of three presumed immobile sites in -helices.    
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6.3. Methods 
Materials. Site-directed mutagenesis kits were purchased from Strategene (Carlsbad, CA). 
E. coli strains DH5α and BL21(DE3) cells were purchased from Novagen (Madison, WI). 
Sequencing and mutagenesis primers were purchased from Integrated DNA Technologies. 
Isopropyl-β-D-galactoside (IPTG) was purchased from Anatrace (Muamee, OH). Q-Sepharose 
and Sephacryl S-200 chromatographic media were purchased from GE Healthcare. S-(2,2,5,5-
tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methylmethanesulfonothioate (MTSL) was purchased 
from Toronto Research Chemicals (Toronto, Canada). The substrates nitrocefin and chromacef 
were purchased from Becton Dickinson and Sopharmia, respectively. All buffer solutions and 
growth media were prepared with Barnstead Nanopure water. 
Design and generation of site-directed variants of CcrA. The site-directed variants 
CcrA:C155S/W49C/N82C, CcrA:C155S/W49C/D126C, and CcrA:C155SW49C/E233C (referred 
to as CcrA*(49/82), CcrA*(49/126) and CcrA*(49/233), respectively, hereafter)  were generated 
using the primers in Table 6.1 and the Stratagene Site-Directed Mutagenesis kit, using previously 
reported procedures and manufacturer’s instructions.  Plasmids were sequenced at the Center for 
Bioinformatics and Functional Genomics (CBFG) facility at Miami University.[40] W49 is a 
residue on the mobile loop and N82, D126 and E233 are immobile residues that form the base of 
a pyramid in the resting state, with W49 at the apex. Any displacement of the spin label at the 49 
position during the reaction can therefore be calculated by triangulation of the W49 to N82, D126, 
and E233 distances measured by DEER, respectively (Figure 6.1). 
Table 6.1. Primers used for mutagenesis. 
CcrA Mutant Forward Primer Reverse Primer 
C155S 5'-acggcatgcctctccaaagttattatttaggaggc-3' 5'-gcctcctaaataataactttggagaggcatgccgt-3’ 
C155S/W49C 5'-gccgaaatcgaaggatgtggtatggtaccttccaa-3' 5'-ttggaaggtaccataccacatccttcgatttcggc-3' 
C155S/W49C/N82C 5'-acaaacggaaatgctggtctgctgggtgacagactctttg-3' 5'-caaagagtctgtcacccagcagaccagcatttccgtttgt-3' 
C155S/W49C/D126C 5'-catacgcgaaccagatgacgatatgcctcgccaagga-3' 5'-tccttggcgaggcatatcgtcatctggttcgcgtatg-3' 
C155S/W49C/E233C 5'-tatggcggaaccgaactgatatgccataccaagcagatcgtgaac-3' 5'-gttcacgatctgcttggtatggcatatcagttcggttccgccata-
3' 
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Over-expression and purification of CcrA. Recombinant CcrA was over-expressed and 
purified as previously reported.[41] The homogeneities of the preparations were estimated by 
visual inspection of SDS-PAGE, and protein was quantitated spectrophotometrically using an 
extinction coefficient (280nm) of 39,000 M-1cm-1 as previously reported.[41] The procedure yielded 
> 100 mg of > 95 % CcrA from each 4 L growth culture. 
Metal analyses. Metal content was estimated by inductively-coupled plasma optical 
emission spectrophotometry (Perkin-Elmer Optima 7300 DV), using reference calibration curves 
(R2 > 0.999) generated with standard solutions of Zn(II), Co(II), Cu(II), Fe, Mn(II), and Ni(II).[24] 
Steady-state kinetic studies. All steady state kinetic studies were conducted on an Agilent 
8453 diode array spectrophotometer at 25 oC. Michaelis constants (Km) and turnover numbers (kcat) 
were determined by monitoring product formation at 442 nm using chromacef as substrate in 50 
mM cacodylate, pH 7. Rate data were converted to concentration data using the extinction 
                          
Figure 6.1. Positions of site-directed spin labels in CcrA (PDB id: 2BMI) used in this study. 
Figure generated using previously described procedures.[42] Positions of the 49, 82, 126, and 
233 residues in the CcrA and estimated distances from the position 49 to the 82, 126, and 233 
are shown.  
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coefficient of hydrolyzed chromacef (442nm = 18,600 M-1cm-1). Concentrations versus time data 
were then fitted to the Michaelis-Menton equation, as previously reported.[24] 
Spin labeling of CcrA and quantification by CW-EPR spectroscopy.  Recombinant CcrA 
(100 μM in 10 mL volume) was incubated with 1 eq. DTT per mol CcrA for 30 mins in 50 mM 
Tris, pH 7, followed by 10 - 20 molar equivalents of MTSL in 50 - 100 μL  DMSO at 4 oC for  3 
to 4 days in the dark with stirring. Unbound spin label was subsequently removed by size exclusion 
chromatography on a Sephacryl S-200 column (1.5 cm X 40 cm of bed volume 60 ml). The 
efficiency of the spin labeling was estimated from the intensity of the cw-EPR signal at 25 C, as 
described elsewhere.[43]  
Samples for DEER spectroscopy.  Concentrations of 0.06 to 0.10 mM CcrA were 
employed in stable samples (i.e., the resting state, and the product complex that was prepared by 
incubating resting enzyme and substrate on the ice for 1 hour), which were concentrated by 
ultrafiltration prior to substrate addition and frozen in liquid nitrogen. All initial enzyme and 
substrate concentrations were 0.4 and 2 mM, respectively, and the samples were prepared in 50 
mM Tris, pH 7.0. A model 715 Update Instruments ram controller was used to drive a PMI-
Kollmorgen stepping motor (model 00D12F-02001-1) connected to a ram that in turn drove two 
Update Instrument syringes of the same inner diameter. The syringes, mixer, and tubing were all 
contained in a water bath that was maintained at 2 °C.[39, 44, 45] 10 ms intermediate samples 
were collected in isopentane at -100 C contained in a glass funnel attached to 4 mm O.D. EPR 
sample tube (Wilmad 706-SQ-250M, 7 cm length). The resulting concentration of CcrA in the 
frozen aqueous phase was 0.2 mM (the effective spin concentration was further diluted by a factor 
of about two due to the  50 % immiscible isopentane matrix). 
DEER spectroscopy.  DEER was performed at 80 K using Bruker EleXsys E-580 pulsed 
EPR spectrometers equipped with nitrogen cooling and either a Bruker SuperQFTu bridge, 10 W 
AmpQ microwave amplifier and Q-band EN5107D2 dielectric resonator (34.2 GHz) or a Bruker 
SuperXFT bridge, Applied Systems Engineering 2 kW traveling wave tube amplifier and X-band 
EN4118X-MD4 resonator (9.7 GHz). The MD4 resonator is designed for 3.8 mm O.D. tubes but 
was used here with 4 mm O.D. tubes (Wilmad 706-SQ-250M) that were cut to 7 cm length and 
loaded through the bottom of the resonator.[46] A four-pulse /2O - 1 - O - E - P - (1 + 2 -E) 
- O DEER sequence was employed, where the superscripts "O" and "P" denote pulses at the 
observe and pump frequencies, respectively, E is the time between the first inversion pulse and 
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the pump pulse, and 2 is the dipolar evolution time. At X-band, /2O and O were 16 and 32 ns, 
respectively, with, 2 = 1200 ns, and P = 32 ns; at Q-band, /2O and O were 24 and 48 ns, 
respectively, with, 2 = 1600 to 1800 ns, and P = 48 ns. Spectra were pumped at the ml = 0 center 
line and observed at the low-field ml = 1 line, with a  = 73 MHz at X-band and 61 MHz at Q-
band. Shot repetition times of 1200 s (X-band), and 500 s (Q-band) were used. The use of two 
frequencies deserves comment. As pointed out earlier,[43] the same information is available at 
both frequencies provided that the relaxation rates allow for reasonable dipolar evolution times. 
Q-band DEER is a much more efficient technique in terms of time and material,[47, 48] and was 
used whenever possible. However, the RFQ sample tubes were of too large a diameter for Bruker 
Q-band resonators and necessitated the use of X-band. Signal averaging was carried out for 8 to 
12 h. at Q-band data and 20 h. at X-band. Fits presented were obtained using DEERAnalysis 
v.2009 and v.2011,[49] and additional verification was carried out using LongDistance (Dr. 
Christian Altenbach, UCLA).[50] Auto-phasing was used for consistency, with the flatness of the 
highest-t 85 % of the imaginary data as the phasing criterion, though phasing resulted in very little 
change in the appearance of the data or the distance distributions. A homogeneous three-
dimensional model was used for background correction, where the background contribution 
reduces to a simple exponential, e-kt, and where k is the only fit parameter. Default suggestions 
were adopted for low-t data cut-off: data thus treated represent the time-domain traces presented 
herein. The distance distributions P(r) were obtained by Tikhonov regularization in the distance 
domain, incorporating the constraint P(r) > 0. The regularization parameter in the L curve was 
optimized by examining the fit of the time domain. The dipolar evolution times, t, were used to 
calculate limits for the distances, d, that provided (i) reliable distance distributions, that allow 
deconvolution of overlapping distances; (ii) reliable distribution widths, that describe the overall 
heterogeneity of distances around the mean; (iii) reliable mean distances, the most important limit 
for the present study; and (iv) reliable distance recognitions, that describe the maximum distance 
that can be observed but not necessarily accurately measured. Calculations were based on the 
relationship d  t1/3, and constants of proportionality for each of the four limits were calculated 
from Jeschke's empirical calibrations,  described in the user manual for DEERAnalysis 
(http://www.epr.ethz.ch/software/DeerAnalysis2013_manual.pdf) and based on fitting simulated 
data with known distances and distributions. 
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Molecular dynamics simulations. The atomic coordinates for the CcrA crystal structure 
(PDB id: 2BMI) from Bacteroides fragilis were downloaded from the Protein Data Bank and used 
to generate the structures of various spin-labeled CcrA mutants with the Nanoscale Molecular 
Dynamics (NAMD) program.[51] All mutated CcrA structures were created using the molecular 
graphics software VMD.[42] The nitroxide spin-probe MTSL was attached using CHARMM force 
field topology files incorporated into NAMD. The modified protein assembly was solvated into a 
spherical water environment and further equilibrated and minimized by running NAMD 
simulations at room temperature using CHARMM force field parameters.[52] The distance 
distribution from the W49C to N82C, D126C, or E233C residues were predicted with rotamer 
library modeling of MTSL conformations using Multiscale Modeling of Macromolecular systems 
(MMM version 2010).[51] 
 
6.4. Results 
Properties of spin-labeled recombinant CcrA.  Native CcrA has cysteine residues at 
positions 104, 181, and 155.[53] An examination of several crystal structures of CcrA suggested 
that Cys104 and 181 would likely not be accessible to the MTSL label, whereas Cys155 did appear 
to be solvent-accessible; therefore, Cys155 was substituted with serine (referred to as CcrA* 
hereafter). From examination of the CcrA structure with VMD,[42] three distinct doubly-labeled 
CcrA species were identified (Figure 6.1) as being likely to provide useful structure-function 
information on the loop: CcrA:C155S/W49C/N82C, CcrA:C155S/W49C/D126C, and 
CcrA:C155SW49C/E233C (referred to as CcrA*(49/82), CcrA*(49/126) and CcrA*(49/233), 
respectively, hereafter). The label at residue 49 provides the dynamic probe of the loop, while 
residues 82, 126, and 233 reside on more rigid -helices at 4.0, 3.6, and 2.3 nm (40, 36, and 23 Å) 
distances, respectively, from residue 49. Residues 82, 126, and 233 were chosen to “triangulate” 
the position of the residue 49 on the loop (Figure 6.1).  
 CcrA* was shown to bind 2.0 + 0.1 equivalents of Zn(II) and < 0.1 eq. MTSL. It exhibited 
a kcat value of 65 + 3 s
-1 and a Km value of 6 + 3 μM, when using chromacef as the substrate (Table 
5.2). CcrA*(49/82), CcrA*(49/126) and CcrA*(49/233) were shown to bind 1.7 + 0.1, 1.8 + 0.1 
and 2.0 + 0.1 equivalents of Zn(II), respectively (Table 6.2). Observed Km values were 2-3 fold 
higher than for wild-type CcrA, but similar to those for CcrA*(49) (Table 6.2). Observed kcat values 
for CcrA*(49/82), CcrA*(49/126) and CcrA*(49/233) were similar to those of wild-type CcrA and 
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CcrA*(49) (Table 1). CcrA*(49/82), CcrA*(49/126) and CcrA*(49/233) were found to bind 1.6, 
1.7, and 2.0 eq. of MTSL, respectively, under the conditions employed; poorer labeling efficiency 
was observed with shorter incubation times. Spin-labeling did not significantly affect the metal 
content or kinetic parameters for the CcrA species (Table 6.2). Ambient-temperature EPR (Figure 
6.2) indicated that the spin labels on residues 126 and 233 experienced somewhat, though not 
severely, restricted local motion whereas the local motion of the label on residue 82 was barely 
restricted at all. Molecular modeling of the possible rotamers of the spin labels suggested likely 
interspin distances of 3.0, 2.6 and 2.5 nm (30, 26, and 25 Å) for CcrA*(49/82), CcrA*(49/126), 
and CcrA*(49/233), respectively (Figure 6.1). 
DEER Spectroscopy.  Time-domain DEER data of resting CcrA*(49/82) and 
CcrA*(49/82) after completed reaction with chromacef were collected to 1.7 s, which allowed 
reliable measurement of a mean distance of up to 4.73 nm and a distribution overall width for 
distances up to 3.79 nm, but no further information could be reliably obtained from the distribution 
shape for distances beyond 2.84 nm.[49] The distance-domain DEER spectrum of resting 
CcrA*(49/82) indicates a broad interspin distance distribution centered at 3.1 nm (31 Å; Figure 
6.3); this distance is consistent with the modeling studies that were used to identify the sites at 
which spin labels were introduced. The width of this peak [(r)  1.1 nm] indicates significant 
Table 6.2. Metal content and steady state kinetic constants of CcrA mutants. 
 
Enzyme(Abbreviation) 
 
Metal 
content 
(eq) 
 
Km 
(M) 
 
kcat (s-1) 
Metal 
content 
after 
spin-
labeling 
Km (M) 
after 
spin-
labeling 
kcat (s-1) 
after 
spin 
labeling 
Wild-type(CcrA) 1.9 + 0.1 7 + 1 65 + 3 1.8 + 0.1 8 + 3 57 + 2 
C155S(CcrA*) 2.0 + 0.1 8 + 1 62 + 2 2.0 + 0.1 6 + 1 65 + 1 
C155S/W49C(CcrA*49) 2.1 + 0.1 15 + 3 31 + 3 2.0 + 0.1 17 + 2 25 + 1 
C155S/W49C/N82C(CcrA*49/82) 1.7 + 0.1 17 + 5 41 + 5 1.8 + 0.1 22 + 6 48 + 1 
C155S/W49C/D126C(CcrA*49/126) 1.8 + 0.1 18 + 4 63 + 1 1.8 + 0.1 17 + 4 74 + 4 
C155S/W49C/E233C(CcrA*49/233) 2.0 + 0.1 15 + 4 42 + 2 2.1 + 0.1 16 + 4 34 + 2 
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heterogeneity of the inter-spin distance. This is hardly surprising given that the X-ray diffraction 
indicated that one of the labeled residues, Trp49, did not occupy a defined volume of space within 
the resolution of the diffraction; residues 48 and 49 comprised the only disordered region of the 
structure.[9] Indeed, the hypothesis that this region represents a dynamic element in catalysis, and 
hence the reason for labeling this residue, may be considered to presuppose flexibility in solution 
and, therefore, heterogeneity in the frozen state.[27] The ambient temperature continuous-wave 
EPR signal of CcrA*(49/82) confirmed a high degree of mobility of at least one of the labels 
(Figure 6.2). 
Time-domain DEER data of resting CcrA*(49/82) reacted with chromacef for 10 ms were 
collected to 1.2 s, which allowed reliable measurement of a mean distance of up to 4.22 nm and 
a distribution overall width for distances up to 3.37 nm, but no further information could be reliably 
obtained from the 
distribution shape for 
distances beyond 2.53 nm. 
Upon reaction of 
CcrA*(49/82) with 
chromacef for 10 ms, a 
clear change in the time-
domain DEER spectrum 
was observed and yielded 
two interspin distance 
distributions. The shorter 
mean distance accounted 
for about two-thirds of the 
sample and was 2.6 nm 
(26 Å), with a distribution 
(r)  0.8 nm.  In addition to the 2.6 nm interspin distance, a longer distance of 3.8 nm (38 Å) was 
also observed that accounts for about one-third of the sample. After the reaction with chromacef 
was allowed to run to completion, the DEER spectrum indicated a reliable single mean interspin 
distance of 3.1 nm (31 Å), as in the resting enzyme, though with a narrower distribution, (r)  
0.9 nm.   
3280 3300 3320 3340
Field (G)
A
B
C
D
E
Figure 6.2. Room temperature CW-EPR spectra of doubly spin-
labeled A) CcrA*(49/82), B) CcrA*(49/126), C) CcrA*(49/233), 
D) CcrA, and E) CcrA*, after reacting with spin label as described 
in Experimental Procedures. 
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 The DEER data for CcrA*(49/126) qualitatively reinforced the data from CcrA*(49/82) in 
that the resting species exhibited a broad interspin distance distribution centered around the 
predicted value [r = 2.5 nm (25 Å); (r)  1.2 nm], the catalytic intermediate exhibited two 
distances, and the product complex exhibited the same mean interspin distance as the resting 
enzyme but with a significantly smaller distribution (Figure 6.4). The spectra of the CcrA*(49/126) 
catalytic intermediate and product complex did differ quantitatively, however, from those of their 
CcrA*(49/82) analogues. For the CcrA*(49/126) catalytic intermediate, data were collected to 1.0 
s, implying a maximum reliable mean distance measurement of 3.97 nm, and a reliable 
 
Figure 6.3. DEER spectra of resting, 10 ms intermediate, and product analogs of doubly spin-
labeled CcrA*(49/82) using a chromacef as a substrate. (Top) CcrA*(49/82) vs chromacef 
resting and product time domain spectra overlay (left) and corresponding distance domain 
DEER spectra overlay (right) (Q-Band). (Bot) CcrA*(49/82) vs chromacef 10 ms intermediate 
time domain spectrum (left) and corresponding distance domain (right) DEER spectrum (X-
Band). 
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distribution width measurement of 3.16 nm. The shorter of the distances corresponded to the 
resting state mean interspin distance of 2.5 nm (25 Å), though with a much narrower distribution, 
(r)  0.6 nm, that is comparable to the corresponding CcrA*(49/82) data. Interestingly, the 
difference between the higher mean interspin distance of 3.7 nm (37 Å; within the reliable mean 
distance limit) in the CcrA*(49/126) catalytic intermediate and the resting distance is 3.7 - 2.5 = 
1.2 nm (12 Å), significantly larger than the corresponding difference for CcrA*(49/82) (3.8 - 3.1 
= 0.7 nm).  The time domain DEER spectrum of the CcrA*(49/126) product complex shows 
resolved DEER modulations that reflect the narrow distribution, (r)  0.5 nm, of the dominant 
2.5 nm peak in the distance domain spectrum. Additionally resolved features appeared at about 
 
Figure 6.4. DEER spectra of resting, 10 ms intermediate, and product analogs of doubly spin-
labeled CcrA*(49/126) using a chromacef as a substrate. (Top) CcrA*(49/126) vs chromacef 
resting and product time domain spectra overlay (left) and corresponding distance domain 
DEER spectra overlay (right) (Q-Band). (Bot) CcrA*(49/126) vs chromacef 10 ms 
intermediate time domain spectrum (left) and corresponding distance domain (right) DEER 
spectrum (X-Band). 
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2.2, 2.9, and 3.3 nm appear to account for about one-third of the sample, although the latter two 
are close to the reliable distribution limit of 2.95 nm (for a 1.9 s dipolar evolution time), and the 
phenomenon should be treated with caution. 
The DEER data for CcrA*(49/233) parallel those for CcrA*(49/126) very closely (Figure 
6.5). The mean values of the interspin distance distributions are indistinguishable, although the 
widths of the dominant distributions for the resting and product-bound states are very narrow [(r) 
 0.3 nm]. Uniquely among the spin-labeled CcrA variants, the distance distribution for the resting 
state is as narrow as for the product complex. The observed distribution widths for the catalytic 
Figure 6.5. DEER spectra of resting, 10 ms intermediate, and product analogs of doubly spin-
labeled CcrA*(49/233) using a chromacef as a substrate. (Top) CcrA*(49/233) vs chromacef 
product and resting time domain spectra overlay (left) and corresponding distance domain 
DEER spectra overlay (right) (Q-Band). (Bot) CcrA*(49/233) vs chromacef 10 ms 
intermediate time domain spectrum (left) and corresponding distance domain (right) DEER 
spectrum (X-band). 
 
171 
 
intermediate distances are much larger than for the other species, though the width of the longer 
distance cannot be taken as reliable [(r)  1.0 nm for r = 2.5 nm; (r)  0.6 nm for r = 3.7 nm]. 
There is some resolution of the 2.5 nm peak in the distance domain spectrum of the CcrA*(49/233) 
catalytic intermediate, suggesting distinct distances at 1.9, 2.5, and 2.9 nm; the resolution of the 
1.9 and 2.5 nm distances is within the resolution limit whereas the resolution of the 2.5 and 2.9 nm 
distances is not. Minor populations with distances at 2.1 and 2.9 nm also appear in the spectra of 
the other CcrA*(49/233) species and are well within the resolution reliability limits of these 
spectra. 
 
6.5. Discussion 
 Molecular modeling suggested that the interspin distances in the resting-state spin-labeled 
recombinant CcrA variants CcrA*(49/82), CcrA*(49/126), and CcrA*(49/233) are 3.0, 2.6, and 
Figure 6.6. Proposed model with results of this study (Top). (PDB id: 2BMI) (Left) DEER 
distances from the spin label at position 49 to the spin labels at positions 82, 126 and 233 spin 
labels in resting CcrA (Center) DEER distances from the spin label at position 49 to the spin 
labels at positions 82, 126 and 233 in the CcrA + chromacef samples quenched at 10 ms. 
(Right) DEER distances from the spin label at position 49 to the spin labels at positions 82, 
126, and 233 in the CcrA-chromacef product complexes. Distances between the spin labels are 
shown with dotted lines, and proposed loop movement in the 10 ms intermediate shown with 
the dotted line with arrow. (Bot) Surface structure of CcrA (PDB id: 2BMI). Metal center 
shown in the red color and hairpin loop shown in the blue color. Figure generated using 
VMD[42] software package in built surface representation option. 
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2.5 nm, respectively. The corresponding dominant distances obtained experimentally by DEER 
spectroscopy were 3.1, 2.5, and 2.5 nm, i.e., within 0.1 nm (1 Å) of those predicted. The distance 
distribution in resting CcrA*(49/82) was broad, consistent with the flexibility of the label at residue 
82 that was identified by EPR (Figure 6.2). The dominant distance distribution in resting 
CcrA*(49/233) was narrow but subpopulations with distinct distances were also observed. These 
data are consistent with the EPR spectrum of CcrA*(49/233) showing partially restricted motion 
and, interestingly, suggest that the label at residue 49 on the loop is not the main determinant of 
distance distribution width and must, therefore, be under motional constraint. The distance 
distribution in CcrA*(49/126) is far greater than in CcrA*(49/233). One possible explanation that 
reconciles these observations is that rotation of the label on residue 49 translates the spin density 
along the 49-126 connecting vector but perpendicular to the 29-233 connecting vector; this seems 
entirely reasonable in the light of the modeled structure (Figure 6.6) and the fact that the two 
interspin vectors are essentially orthogonal. 
 Incubation of CcrA with substrate that allows the reaction to run to completion may be 
expected to generate a product complex under the conditions employed, where the concentration 
of chromacef was about 100  Km. While we have not measured the KD for binding of hydrolyzed 
chromacef to CcrA, the KD for hydrolyzed nitrocefin binding to ML L1 is >300 M.[54] 
Simulations of stopped-flow kinetic progress curves suggest weak binding of hydrolyzed 
nitrocefin or chromacef to all MLs.[24, 54-56] Consistent with weak product binding, there was 
little evidence from DEER for product complex formation with either CcrA*(49/82) or 
CcrA*(49/233) other than the exhibition of narrower distance distributions in the product species. 
With CcrA*(49/126), the narrowing effect was more dramatic. Rotation of the spin label at residue 
49 is expected to have a small effect on the 49-82 and 49-233 distances whereas it will result in a 
large translation of the spin density along the 49-126 connecting vector. It is likely, therefore, that 
product interacts with the spin label on residue 49 to restrict rotation of the nitroxide, while the 
position of residue 49 corresponds to that in the resting enzyme. The larger width of the distance 
distribution in the product complex of CcrA*(49/82) can be tentatively assigned to motion of the 
label at residue 82.     
 Of greatest interest are the data from the RFQ-trapped catalytic intermediates. Perhaps the 
simplest to interpret are the data from CcrA*(49/126), where the distance domain spectrum is 
entirely consistent with a dominant (65%) contribution from a species with an interspin distance 
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of  3.7 nm and a smaller contribution exhibiting a distance that is consistent with the resting 
enzyme and/or the fully reacted enzyme. CcrA*(49/233) behaves in an analogous manner to 
CcrA*(49/126).  Previous stopped-flow kinetic studies with CcrA (and other MLs) showed that 
no detectable product is formed at 10 ms,[16, 24, 54, 55, 57-59] and it is, therefore, tempting to 
assign the shorter of the two distances in CcrA*(49/126) and (49/233) to unreacted enzyme, though 
it is entirely possible that a second intermediate is present, albeit one in which the distances 
between residues 49, and 126 and 233, respectively, remain unchanged. Such an intermediate may 
correspond to substrate forming an initial complex prior to loop movement and binding at the 
active site. With 
CcrA*(49/82), a 
population with r = 3.8 
nm is observed, which 
corresponds to the loop-
opened intermediate. 
An additional 
population is observed 
with r = 2.6 nm, which 
represents a change in 
the distance between residues 49 and 82 but does not correspond to loop opening. The origin of 
this shorter distance is unclear but may be tentatively assigned to an additional pre-Michaelis 
intermediate that is associated with allosteric substrate recognition prior to loop opening and 
formation of the Michaelis complex at the active site, with concomitant movement of either or 
both the loop and the residue 82-bearing helix. Further studies with additional CcrA variants 
CcrA*(82/233) and CcrA*(82/126) are needed to identify any movement of residue 82, and 
additional work is necessary to confirm (or refute) and characterize the putative allosteric substrate 
recognition site. Control experiments have been carried out with the related L1 enzyme from S. 
maltophilia to determine the influence of the method of sample generation by RFQ on the DEER 
signal, using spin labeled variants in which distance changes would not be expected due to the 
reaction (Figure 6.7). The data indeed indicated the expected distances; although, the data quality 
were poorer with RFQ samples due to dilution of the spin-containing frozen aqueous suspension 
in the immiscible isopentane matrix.[60] 
 
Figure 6.7. DEER spectra of doubly-spin labeled, spin-diluted 
T163C/K286C L1. Resting enzyme (Top), 10 ms RFQ intermediate 
(Middle) and thawed product (Bottom). 
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6.7. Conclusion 
 One can consider the labeled residues 82, 233, and 126 in CcrA as forming the base of a 
(distorted) tetrahedron with reside 49 at the apex and the metal center at the centroid (see Figure 
6.1). The DEER data clearly identify a catalytically-competent species, which is formed upon 
incubation with substrate for a time that is short compared to the turnover time, in which the 
distances between residue 49 and residues 82, 126, and 233 have increased by 0.7, 1.0, and 1.3 
nm, respectively (Figure 6.6). Since previous NMR studies identified the loop, which contains 
residue 49, as being very flexible,[33, 34] the increases in distances are most likely due to 
movements of the loop, and residue 49, away from the other residues. This corresponds to a 
movement of the spin label on residue 49, at the extremity of the hairpin loop, of 0.94 nm (9.4 Å) 
away from the plane described by residues 82, 216, and 233, and a further translation of 0.21 nm 
(2.1 Å) roughly along the direction from residue 233 towards residue 82. Thus the residue 49 
moves a net 0.92 nm (9.2 Å) away from the metal center during the catalytic reaction. It is 
important to note that we cannot unambiguously rule out contributions from movements of 
domains relative to each other to explain the distance increases. The additional distances observed 
in DEER are due to a small amount of the product-bound species in the variant with the highest 
kcat, CcrA*(49/126), and are consistent with either or both unreacted enzyme and product complex 
in CcrA*(49/82) and CcrA*(49/233). 
 Examination of the surface plot of CcrA (Figure 6.6) illustrates how well the mechanistic 
model provided by DEER complements the three-dimensional structure information. In the resting 
state, the active site is effectively guarded by the hairpin loop. This may be to prevent promiscuous 
reaction of metal-bound nucleophile with non-substrate molecules that could otherwise diffuse 
into the active site. Substrate recognition appears to somehow trigger the DEER-observed retreat 
of the hairpin loop from the active site, allowing substrate access. Following reaction, the loop is 
reinstated, even in the product-bound complex. 
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7.1. Abstract  
In an effort to examine the role of a hairpin loop in metallo--lactamase NDM-1 during 
catalysis, rapid freeze quench double electron electron resonance (RFQ-DEER) spectroscopy was 
used. A doubly-labeled mutant of NDM-1, which had one MTSL label on the invariant loop at 
position 69 and another label at position 235, was prepared and characterized. The reaction of the 
doubly spin label mutant with chromacef was freeze quenched at 500 s and 10 ms, and DEER 
spectra showed that the average distance between labels decreased by 4 Å in the 500 s quenched 
sample and by 2 Å in the 10 ms quenched sample, as compared to the distance in the unreacted 
enzyme, although the peaks corresponding to distance distributions were very broad. DEER 
spectra with the doubly spin labeled enzyme with two inhibitors showed that the distance between 
the loop residue at position 69 and the spin label at position 235 does not change upon inhibitor 
binding. This study suggests that the hairpin loop in NDM-1 moves over the metal ion during the 
catalysis and then moves back to its original position after hydrolysis, which is consistent with a 
previous hypothesis based on NMR solution studies on a related metallo--lactamase. This study 
demonstrates that this loop motion occurs in the millisecond time domain. 
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7.2. Introduction  
A recent study conducted by the British government concluded that the failure to fight 
antibiotic resistance would lead to 10 million deaths annually and would cost up to $100 trillion  
globally by the year 2050.[1] According to a 2013 CDC report, bacterial resistance to antibiotics 
is a major global threat, and in 2013 alone, more than 2 million people in the United States were 
infected with antibiotic-resistant infections, resulting in over 23,000 deaths.[2] By far, the largest 
class of antibiotics contains -lactam containing compounds, such as penicillins, cephalosporins, 
and carbapenems. The most common resistance pathway is bacterial production of -lactamases, 
which hydrolyze and inactivate most -lactam containing antibiotics. In the early 1990s extended-
spectrum β-lactamases (ESBLs) were isolated from certain Enterobacteriaceae strains, and most 
of clinical strains responded to carbapenems. However within a decade, carbapenemase-producing 
Enterobacteriaceae and Klebsiella pneumonia strains appeared throughout the world.[3, 4] Over 
the last 20 years, bacterial strains, which produce metallo--lactamases (MBLs), appeared, and 
these strains exhibit mortality rates as high as 67% and high morbidity rates.[5-7] Of the >50 MBLs 
that have been isolated, IMiPenemase (IMP), Verona Integron Metallo--lactamase (VIM), and 
New Delhi Metallo--lactamase (NDM) appear to be most clinically important due to rapid 
dissemination of the genes to many organisms, to the high relative mortality rates caused by 
bacteria that harbor the genes for these enzymes, and to the rapid proliferation of variants of these 
enzymes.[8, 9] To date no clinical inhibitors are available to combat the MBLs, and MBL-
producing bacteria have been declared to be a serious medical threat by the Centers for Disease 
Control and Prevention. To date there are a total of 16 variants of NDM (NDM-1 – NDM-16), 
which have been isolated from clinics throughout the world.[10]  
 Most of the MBLs contain a hairpin loop directly above the invariant zinc binding site(s), 
and this loop has been implicated in catalysis.[11] Deletion of entire hairpin loop or mutations on 
the loop resulted in significantly lower activities of MBLs CcrA and IMP-1.[12-14] Previous 
studies also suggested that this loop is dynamic during catalysis;[12, 13] however, it is not clear 
how the loop moves during catalysis. In our recent studies on CcrA, the loop appears to move 
about 10 Å away from the metal center, presumably to accommodate substrate binding in the active 
site.[15] Given the importance of the loop in catalysis,[15] we speculated that the loop might be 
targeted for the generation of an inhibitor. However before the loop is targeted, a better 
understanding of the role of the loop is necessary.  
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7.3. Methods  
Materials. Site-directed mutagenesis kits were purchased from Stratagene (Carlsbad, CA). 
E. coli strains DH5α and BL21(DE3) cells were purchased from Novagen (Madison, WI). 
Sequencing and mutagenesis primers were purchased from Integrated DNA Technologies. 
Isopropyl-β-D-galactoside (IPTG) was purchased from Anatrace (Muamee, OH). Q-Sepharose 
and Sephacryl S-200 chromatographic media were purchased from GE Healthcare. S-(2,2,5,5-
tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methylmethanesulfonothioate (MTSL) was purchased 
from Toronto Research 
Chemicals (Toronto, 
Canada). The substrate 
chromacef was a gift from 
Sopharmia, Inc. Captopril 
was purchased from Fisher 
Scientific, and inhibitor G11 
was provided by Professor 
Walt Fast from the 
University of Texas at Austin. All buffer solutions and growth media were prepared with Barnstead 
Nanopure water. 
Protein purification, characterization, and spin labeling. Protein over-expression and 
purification were performed using previously-described procedures.[16] Steady-state kinetic 
studies, metal analyses, site directed mutagenesis and spin labeling, and spin efficiency were 
conducted as previously described.[8, 11, 16, 17]  
Molecular dynamics. Molecular dynamics were conducted as previously described.[11] 
DEER spectroscopy. Four-pulse DEER experiments were performed at 80 K using Bruker 
ELEXSYS E580 pulsed EPR spectrometer equipped with SuperQ-FT pulse Q-band system with a 
10 W amplifier and EN5107D2 resonator (34.2 GHz). All DEER samples were prepared at a spin 
concentration of 80-100 M containing 20% glycerol as a cryoprotectant agent.  A four pulse  
[(π/2)ν1 − τ1 − (π)ν1 − t − (π)ν2 − (τ1 + τ2 − t) − (π)ν1 − τ2 − echo] DEER sequence was employed at 
Q-band with a probe pulse width of 10/20 ns, pump pulse width of 24 ns, 80 MHz of frequency 
difference between probe and pump pulse, short repetition time determined by spin-lattice 
Scheme 7.1. Primers used in this study. 
G69C Forward: 5'-atctcgacatgccgtgtttcggggcagtc-3' 
G69C Reverse: 5'-gactgccccgaaacacggcatgtcgagat-3' 
A235C Forward: 5'-ccgcgtcagcgcgctgctttggtgcggcgtt-3' 
A235C Reverse: 5'-aacgccgcaccaaagcagcgcgctgacgcgg-3' 
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relaxation rate (T1), 100 echoes/point, and 2-step phase cycling at 80 K collected out to 2.3 to 2.7 
S for 8 to 12 hours data acquisition time.[18]  
Fits presented were obtained using DEERAnalysis v.2013.[19] The distance 
distributions P(r) were obtained by Tikhonov regularization in the distance domain, incorporating 
the constraint P(r) > 0. A homogeneous three-dimensional model was used for background 
correction. The regularization parameter in the L curve was optimized by examining the fit of the 
time domain. Uncertainties in distances were determined by observing the shift in the peak maxima 
upon fitting the data with different background subtraction processes and fittings at different L-
curve inflection points.[20] 
7.4. Results 
 To probe the motion of the hairpin loop in NDM-1 during catalysis, RFQ-DEER 
spectroscopy was used. In order to use DEER spectroscopy to evaluate intramolecular distances 
in a single enzyme, 
a site-specifically 
labeled enzyme 
must be generated 
with two spin 
labels roughly 25-
45 Å apart. By 
using a crystal 
structure of NDM-
1,[21] we identified 
Gly69 on the 
hairpin loop and 
Ala235 on a remote 
α-helix as optimal 
sites for MTSL 
labeling (Figure 
7.1).  Molecular 
dynamics calculations[22] showed that the MTSL labels in these positions were 38 Å apart.  
 
Figure 7.1. NDM-1 crystal structure with the positions Gly69 and 
Ala235, (PDB id: 3ZR9 was used). Previously-described procedures 
were used to generate this figure.[11] 
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The G69C and G69C/A235C mutants (hereafter referred to as NDM-1* and NDM-1**, 
respectively) were over-expressed and purified using previously described procedures.[16, 17] 
Steady-state kinetic constants, kcat and Km, and metal content of NDM-1* and NDM-1** were 
found comparable with those of wild-type NDM-1 (Table 7.1). NDM-1* and NDM-1** were 
labeled with MTSL as previously described,[11] and the resulting double spin labeled mutants 
exhibited metal content and steady-state kinetic constants almost identical with those of the 
unlabeled enzymes (Table 7.1). The spin labeling efficiencies of NDM-1* and NDM-1** were 
96% and 94%, respectively, as determined by using cw-EPR spectroscopy.[11]  
The Q-band DEER spectrum for the resting, doubly spin-labeled NDM-1** is shown in 
Figure 7.2. The distance domain spectrum showed a broad peak centered at 38 + 2 Å, and this 
distance nicely matches the calculated distance as determined by Molecular Dynamics 
calculations. Doubly spin-labeled NDM-1** (160 M) was mixed with 160 M chromacef, and 
the reaction was freeze quenched in a liquid nitrogen bath at 500 s and 10 ms using a home-built 
RFQ system.[23] The distance domain, Q-band DEER spectrum of the NDM-1**/chromacef 
sample quenched at 500 s showed a broad peak centered at 34 + 2 Å, while the sample quenched 
at 10 ms exhibited a peak centered at 36 + 2 Å. For comparison’s sake, an enzyme product complex 
was prepared by incubating doubly spin labeled 160 M NDM-1** and 160 M chromacef on ice 
for one hour. The distance domain, Q-band DEER spectrum of this sample showed a broad peak 
centered at 39 + 2 Å. These data suggest that the hairpin loop in NDM-1 moves over the metal 
binding site during catalysis, thereby closing the active site. This movement supports previous 
hypotheses that the hairpin loop, particularly in CcrA, closes down on the substrate and potentially 
activates the substrate for nucleophilic attack.[15] As the reaction intermediate is produced at 10 
Table 7.1. Metal content and steady state kinetic constants of NDM-1 mutants. 
 
Enzyme 
(Abbreviation) 
Metal 
content (eq) 
 
Km (M) 
 
kcat (s-1) 
Metal content 
after spin-
labeling 
Km (M) 
after spin-
labeling 
kcat (s-1) 
after spin 
labeling 
Wild-type (NDM-
1) 
1.9 + 0.1 5.1 + 0.9 4.2 + 1 1.8 + 0.1 5.0 + 0.5 4.0 
G69C (NDM-1*) 1.9 + 0.1 5.3 + 0.5 4.0 + 0.5 1.9 + 0.1 4.8 + 0.5 4.1 
G69C/A235C 
(NDM-1**) 
2.0 + 0.1 4.9 + 0.8 3.9 + 0.6 1.9 + 0.1 5.1 + 0.3 3.7 
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ms, the loop starts to move back to its original position, possibly to allow product to leave the 
active site.  
To evaluate whether 
loop dynamics are also 
important for inhibitor 
binding, doubly spin 
labeled NDM-1** was 
incubated with captopril 
and G11 (structures shown 
in Scheme 7.2), which are 
competitive inhibitors of 
NDM-1. Interestingly, 
distance domain, Q-band 
DEER spectra of both 
enzyme-inhibitor 
complexes revealed peaks 
centered at 39 + 2 Å (Figure 
7.3), which almost matches 
the peak of the resting 
enzyme. These data suggest that the loop movements observed with the RFQ samples are 
associated with catalysis rather than binding.  
One concern in all of the data with MTSL-labeled NDM-1** was the broadness of the 
resulting distance domain peaks. In an effort to obtain sharper distance domain peaks,[24] Br-
MTSL was used to label NDM-1** in the place of MTSL. While the MTSL and Br-MTSL labeled 
enzymes yielded distance domain spectra with identical distances (38 + 1 Å), the Br-MTSL labeled 
sample yielded a DEER spectrum that had a much larger amplitude of the dip and possibly 
improved modulation (Figure 7.4). However, this sample also showed a small peak at 18 Å and a 
shoulder at 45 Å, both of which may be fitting artifacts. Importantly, the distance domain peak for 
the Br-MTSL sample was narrower by about 30% (peak width at one-half height). This result 
demonstrates that Br-MTSL may be a better spin label for future RFQ-DEER studies on NDM-1; 
however, we will need to more fully characterize the Br-MTSL labeled samples with steady-state 
Scheme 7.2. Substrate, inhibitors and spin labels used in this 
study. 
  
A) Chromacef 
                         
B) Captopril                             C) G11 
                                
D) MTSL                                                    E) Br-MTSL 
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kinetic studies and metal analyses. We will also need to better understand the extra peaks in the 
distance domain spectra. 
 
7.5. Discussion 
Recently, we reported RFQ-DEER studies on MBL CcrA, and our data showed that the 
hairpin loop in CcrA moves 10 Å away from the metal site during catalysis when the 10 ms sample 
 
Figure 7.2. Q-band DEER spectra of double MTSL-labeled NDM-1** samples. Time domain 
spectra of the resting enzyme, enzyme product complex, and RFQ samples quenched at 500 
M and 10 ms (left). Distance domain spectra of the resting NDM-1** (black), 500 s freeze 
quenched sample (blue), 10 ms freeze quenched sample (green), and enzyme-product (red) 
(right).  
 
 
Figure 7.3. Q-band DEER spectra of double MTSL-labeled NDM-1** samples. Time domain 
spectra of the resting enzyme, enzyme captopril and enzyme G11 complexes (left). Distance 
domain spectra of the resting NDM-1** (black), complex with captopril (blue), and complex 
with G11 (green), (right). 
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was characterized.[15] This result did not support previous hypotheses on CcrA that suggested that 
the hairpin loop “clamps” down on substrate during catalysis.[15] We interpreted our DEER 
results to suggest that the loop in CcrA needed to “move out of the way” so that catalysis could 
occur. The studies described herein on NDM-1 suggest that the loop does in fact “clamp down” 
on the substrate during catalysis (Figure 7.11), suggesting that the loop may play different roles in 
the different MBLs. We will need to repeat the studies on CcrA and use samples that are quenched 
at earlier times during catalysis to ensure that the loop in CcrA does not clamp down at a faster 
rate than it does in NDM-1; the relative steady-state kcat’s are 5 times faster for CcrA than for 
NDM-1.[15] Previous studies suggested that the hairpin loop in NDM-1 appears to be more 
flexible than the loops in other MBLs and that the increased flexibility may explain the extended 
spectrum of activity of NDM-1, including for carbapenems.[25] Studies to quench the reaction at 
shorter times and efforts to make to improve the error on reported distance are on-going. 
 One concern of our DEER data, and most DEER data in the literature, is poor data (signal 
depths and lack or small modulations of signals in the time domain data)[18, 26-31]. These poor 
data often result in very broad distance domain peaks. There does not appear to be a very good 
understanding of what sample properties improve these data, and in many cases, multiple samples 
with spin labels in different positions are prepared until good data (large signal depths, resolved 
modulations, and narrow distance domain peaks) are achieved.[18, 20, 32] There are some reports 
that higher energy power sources and the use of spin labels with restrictive motion can result in 
 
Figure 7.4. Time domain DEER spectra and best fit of the NDM-1** labelled with MTSL (top) 
and labelled with Br-MTSL (bot) (left); Distance domain DEER spectra overlay of the NDM-
1** labelled with MTSL (black), labelled with Br-MTSL (red) (right). 
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narrower distance domain spectra.[24, 33-36] There also does not appear to be standardized 
approaches to fitting the data,[26, 29, 37-39] and data fitting can significantly affect the resulting 
distance domain spectra (see Figures 7.5 – 7.10). We certainly face these issues in the data 
presented above.  
 In the preparation of our spin-labeled sample, we chose a mutant with an appropriate 
distance between the spin labels. This mutant was shown to bind the same amount of Zn(II) and 
exhibit steady-state kinetic constants as the wild-type, recombinant enzyme. This mutant also 
could be spin-labeled with high efficiency. The time domain DEER spectrum of this sample had a 
signal depth of 4% and very little signal modulation between 0.5 and 2.0 s (Figure 7.2). The 
resulting distance domain spectrum, using an L-curve inflection point of 10,000, was broad, with 
an average distance of 38 Å. The error in the distance was 7 Å, when using a statistical formula 
(Tikhonov regularization) and was 5 Å when using the peak width at ½ maximum. Both methods 
to determine error are used in the literature[15, 40]; however, most studies have not reported the 
error using these methods when it appeared larger than expected.[18, 20, 29, 37-39] When we first 
started this study, we really did not know how far, if at all, the loop would move so we could not 
possibly know if the broadness of the distance domain peak for NDM-1** would be sufficient to 
probe loop motion.  For the data presented in this chapter, the average distances are statistically-
equivalent, regardless of which method is used to determine error. However, there are clear 
differences in the data. 
To improve the data, additional studies are necessary. Alternative double mutants need to 
be prepared in an effort to find mutants that yield deeper signal depths and improved modulation 
resolution.[18] It is not clear why some samples yield small depths and unresolved modulation 
while others yield better spectra; however, it is likely due to the orientation of the respective spin 
labels (there is distance and angle dependence in the hyperfine coupling strengths)[41]. This 
approach is straightforward for some systems;[15] however, our system requires that we recover 
double mutants with appropriate metal content and catalytic activities. In our DEER study on MBL 
L1, we tried 9 different double mutants before we found one that exhibited the correct biochemical 
properties.[11] The application of DEER for probing intramolecular hyperfine couplings during 
catalysis will always have this issue. The use of higher power pulses may be a way to improve 
signal depth (and resolution of signal modulations).[33] Dr. Lorigan has recently been awarded a 
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supplemental grant to upgrade our current pulsed EPR spectrometer in order that these higher 
powers are possible.  
 
Figure 7.5. Overlay of the time domain DEER fits of NDM-1** resting (Top) at different L-
curve inflection points and overlay of the respective distance spectra (Bot). 
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Figure 7.6. Overlay of the time domain DEER fits of NDM-1** 500 s (Top) at different L-
curve inflection points and overlay of the respective distance spectra (Bot). 
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Figure 7.7. Overlay of the time domain DEER fits of NDM-1** 10 ms (Top) at different L-
curve inflection points and overlay of the respective distance spectra (Bot). 
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Figure 7.8. Overlay of the time domain DEER fits of NDM-1** product (Top) at different 
L-curve inflection points and overlay of the respective distance spectra (Bot). 
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Figure 7.9. Overlay of the time domain DEER fits of NDM-1** and captopril complex 
(Top) at different L-curve inflection points and overlay of the respective distance spectra 
(Bot). 
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Figure 7.10. Overlay of the time domain DEER fits of NDM-1** and G11 complex (Top) at 
different L-curve inflection points and overlay of the respective distance spectra (Bot). 
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One contributing factor in the broad distance domain peaks is poor signal to noise, 
particularly in the RFQ data. While our data are better than most already published in the literature 
[26, 31, 42], we will need to optimize the concentration of samples after mixing. Surprisingly, we 
have found that mixing of enzyme and substrate does not dilute the sample by 50%, and we believe 
that the different viscosities of the samples result in RFQ samples that have lower than expected 
concentrations. 
Another major 
contributor to broad 
distance domain peaks is 
the motion of the spin-
labels. DEER spectra 
allow for the 
measurement of average 
distances, with a large 
distribution of spin 
label/spin label 
distances. The MTSL 
spin label has a number 
of different 
rotamers,[43] which 
adds to the distribution 
of DEER-determined 
distances[44]. The use of spin labels with restricted mobilities will reduce the number of possible 
rotamers and will result in narrower distance domain peaks.[24] In fact, our data with Br-MTSL 
showed improvement of the width at ½ height of the distance domain peak. TOAC (2,2,6,6-
tetramethyl-N-oxyl-4-amino-4-carboxylic acid) in unnatural amino acid, which can be used as a 
spin label, and the use of TOAC has been shown to improve DEER signals.[45-47] The use of 
TOAC will require the use of auxotrophic cell lines to over-express NDM-1. While we will be 
able to improve distance uncertainties with these restricted mobility spin labels, we do 
acknowledge that the distance domain DEER peaks of NDM-1 will always be relatively broad 
because it is impossible to have all of the enzyme molecules at the exact same time point in the 
 
Figure 7.11. Proposed model based on our results. Previously 
described procedures were used to generate the figure.[11] 
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reaction coordinate. We are designing and testing a new RFQ system that will allow for us to freeze 
quench samples faster than 500 s, which may allow for us to have more of the enzyme in a loop-
closed conformation. If loop movements are less than 5 Å, it may be impossible to use DEER to 
probe these intramolecular couplings.  
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8.1. Antibiotic resistance - current status 
 Antibiotic resistance has become a major challenge in the treatment of bacterial infections. 
A recent study conducted by the United Kingdom government speculated that antibiotics 
resistance will directly lead to world health care cost up to $100 trillion by the year 2050 and result 
in 10 million deaths per year. According to the 2013 CDC Antibiotic Resistance Threat Report, 
more than two million people in the United States were infected with an antibiotic-resistant 
bacterial infections, and more than 23,000 of these patients died.[1] To counter antibiotic 
resistance in the clinic, two main efforts have been adopted. The first effort involves the search for 
new antibiotics and bacterial agents. Recently, new antibiotics like daptomycin, bedaquiline, and 
cefraroline were discovered. However, corresponding antibiotic- resistant bacteria appeared before 
these antibiotics were introduced into the clinic. The second main effort to combat antibiotic 
resistance in the clinic involves the production of inhibitors that target the bacterial 
enzymes/proteins that render bacteria resistant to antibiotics. By far, the most prevalent inhibitors 
are β-lactamase inhibitors, which can be given in combination with existing -lactam containing 
antibiotics to combat bacteria that produce -lactamases. Examples of -lactamase inhibitor/-
lactam antibiotic combinations include Augmentin (amoxicillin + clavulanic acid), Timentin 
(ticarcillin + clavulanic acid), Unasyn (ampicillin + sulbactam), Zosyn (piperacillin + tazobactam), 
and Avycaz (ceftazidime + avibactam).[2] However, to date, no clinical inhibitors are available to 
target the metallo-β-lactamases. Understanding the catalytic mechanism of these enzymes will be 
a useful guide for the inhibitor development process. 
 
8.2. Contributions of this dissertation 
This dissertation describes efforts to understand the structure and function of several MBLs 
using kinetic, crystallographic, and spectroscopic techniques. In this dissertation, two major issues 
were addressed: (1) the role of the metal ions in catalysis and (2) the role of the invariant hairpin 
loop that extends over the active sites in the B1 and B3 MBLs.  
The IMiPenamase (IMP), Verona integrin-encoded (VIM), and New Delhi metallo--
lactamase (NDM) enzymes are the most clinically-significant MBLs because they (and their 
derivatives) appear in bacterial strains that exhibit high mortality rates.[3] IMP-1 and NDM-1 have 
been extensively studied biochemically, crystallographically, and spectroscopically.[4-7] In 
contrast, while there were 9 crystal structures of VIM variants available before the work described 
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in this dissertation, including two of VIM-2 at 1.9 and 2.2 Å resolution,[8, 9] there were no detailed 
kinetic/mechanistic or spectroscopic studies reported on any variant of VIM. To address this 
deficit, chapter 2 describes our efforts to characterize VIM-2. We solved the highest resolution 
crystal structure (1.55 Å) of VIM-2 and prepared a catalytically-active Co(II)-substituted analog 
of VIM-2. Spectroscopic studies demonstrated that the metal ions (Zn(II)/Co(II)) bind to the VIM-
2 in a positive-cooperative manner, which prevents the preparation of heterobimetallic analogs of 
VIM-2 using common metallation strategies.[10] However, role of Zn1 and Zn2 sites of VIM-2 in 
the substrate binding still remain unanswered. One could address this deficit by investigating the 
heterobimetallic forms of 
VIM-2 (Figure 8.1) by using 
RFQ-EXAFS and RFQ-EPR. 
Our efforts to prepare the 
heterobimetallic form VIM-2 
have failed, because VIM-2 
showed cooperative binding. 
However, it could be possible by mutating the second coordination sphere residues of VIM-2 as 
NDM-1 (which showed the sequential metal binding and allowed to prepare the heterobimetallic 
forms). 
Chapter 3 described the use of X-ray Absorption Spectroscopy (XAS) to address questions 
about three different MBLs. Firstly, EXAFS spectroscopy was used to characterize the metal 
binding site in NDM-1, and our data clearly show that NDM-1 is a typical B1 MBL. Our data also 
addressed a long-standing conflict on NDM-1 concerning the metal-metal distance in this enzyme. 
The data serve as the baseline information on NDM-1, and we are currently planning to use 
EXAFS to probe the binding of potential new inhibitors to the enzyme. Secondly, XAS was used 
to determine the fidelity of heterobimetallic forms of NDM-1 (ZnCo, CoCo, and CoCd-analogs). 
These data were part of a larger study published by the group on NDM-1.[11] These 
heterobimetallic analogs now allow for us to utilize rapid-freeze quench EPR and EXAFS studies 
to probe the reaction mechanism of NDM-1. With a new rapid freeze quench system that is being 
tested in the lab and will allow for quench times of 100-200 microseconds, we will be able to probe 
the reaction mechanism (specifically the chemistry at the metal centers) at a detail that has never 
been possible before. Thirdly in this chapter, we reported RFQ-EXAFS results on one 
     
Figure 8.1. Heterobimetallic forms of VIM-2 (Zn(II) at the 
Zn1 site and Co(II) at the Zn2 site (Left), Co(II) at the Zn1 site 
and Cd or Zn at the Zn2 site (Right) of VIM-2). 
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representative MBL from each of the distinct B1, B2, and B3 classes (BcII, SfhI, and GOB18) to 
understand the similarities/differences among these subclasses. In contrast to previous 
predictions[12] our EXAFS results suggest that the metal centers do not behave the same way for 
all three enzymes during catalysis. This information is problematic because it suggests that a single 
compound, which was designed based on the mechanism, may not inhibit all MBLs. This 
conclusion also indicates that careful characterization of several MBLs is needed for the discovery 
of clinical inhibitors. 
In Chapter 4 we examined the role of the metal ions in the Zn1 and Zn2 sites of L1 in 
substrate binding by using RFQ-EXAFS spectroscopy. This work was meant to build on previous 
work in the lab.[7] Our data showed that Zn(II) binds at the Zn1 site and Co(II) binds at the Zn2 
site in the ZnCo analog of L1. The metal-metal distance of Zn-Co in this analog is 3.49 Å in the 
resting enzyme, and this distance increases by 0.3 Å in the sample of ZnCo-L1 with chromacef 
that was quenched at 10 ms. The metal ions move back together as the reaction proceeds, reaching 
a distance of 3.58 Å in the L1-product complex. Results from EXAFS data demonstrate that a Co-
S interaction is present in the 100 ms quenched sample and in the L1-product complex, which 
suggests a significant rearrangement of product in the active site during catalysis. This result 
suggests that the -lactam carbonyl is positioned over the metal ion in the Zn1 site, and we favor a 
reaction mechanism in which the metal ion in the Zn1 site directly binds to the -lactam carbonyl 
and activates it for a nucleophilic attack. In contrast to recent hypotheses[12], these results suggest 
an involvement of both metal ions (Zn1 and Zn2 sites) during β-lactam hydrolysis. This result 
suggests that both metal ions should be targeted for inhibitors in future design efforts. These results 
strongly encourage the use of the new RFQ system that is being developed in the lab. EXAFS on 
samples quenched at 100-200 microseconds could give a glimpse into the structure of the ES 
complex in this enzyme. 
The second main theme of this this dissertation was examining the role of the hairpin loop, 
which is found in most MBLs, during substrate binding and catalysis. Early crystallographic 
studies on B1 and B3 MBLs identified a position-conserved, highly-disordered loop near the active 
site of the enzymes, and subsequent crystal structures of enzyme-inhibitor complexes 
demonstrated migration of the loop towards the active site in the enzyme-inhibitor complexes.[13-
19] Dyson and coworkers conducted NMR studies and showed that Trp64 on this position-
conserved loop in CcrA may play a role in inhibitor (and by analogy substrate) binding and further 
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speculated that Trp64 and the loop play a role in “promotion of catalysis.”[20] Mutations and 
partial and complete deletions of the loop resulted in marked changes in steady-state kinetic 
behavior and formation of the reaction intermediate, as well as suggested a role for the loop in 
substrate binding.[19-22] Stopped-flow fluorescence experiments on L1 showed a catalytically-
relevant rate of loop movement, further suggesting an important role for the loop in catalysis.[23] 
EPR studies showed movement of the position-conserved -helix above the active site of ImiS, 
which belongs to the B2 class.[24]  
In Chapter 5, we initially proposed to examine the role of the hairpin loop in L1 during 
substrate binding and catalysis.[25] Double electron-electron resonance (pELDOR or "DEER") 
spectroscopy was used to probe the distance between two spin labels (one on the hairpin loop and 
second one on the α-helix roughly 25 Å away). We obtained distance domain spectra that had 
peaks corresponding to the desired intramolecular spin interaction and additional peaks 
corresponding to intermolecular spin interactions between the subunits in tetrameric L1. In this 
chapter we offered a “spin-dilution” solution to the “tetrameric problem.” The spin-dilution 
technique involved an unfolding/refolding process that is easy to perform and could be applied to 
many multimeric proteins. Importantly, the “spin-diluted” enzyme retained 100% activity and had 
only one subunit spin-labeled. Before this tetrameric problem was addressed, CcrA (which exists 
as a monomer in solution) had been chosen to study the role of the hairpin loop during catalysis. 
In Chapter 6 we probe the movement of the hairpin loop in CcrA during catalysis.[26] RFQ-DEER 
spectra were collected on three resting, doubly-spin labeled enzymes, three spin-labeled enzyme-
product complexes, and three samples freeze quenched at 10 ms (CcrA + substrate). DEER results 
showed that the hairpin loop of CcrA moves 10 Å away from active site in the sample of enzyme 
and substrate freeze quenched at 10 ms. Future studies will involve performing RFQ-DEER on 
samples quenched earlier in the reaction. In addition, the upgrade of our current pulsed EPR will 
allow for better signal to noise (particularly the height of the dip and hopefully more resolved 
modulations of the echo) and narrower distance distributions. In Chapter 7 we extended the use of 
RFQ-DEER spectroscopy to NDM-1, which is one of the most clinically-relevant MBLs. This 
study was our first effort to use a RFQ system that could quench samples under 10 ms. DEER 
spectra of NDM-1 freeze quenched at 500 s and 10 ms were obtained and analyzed. Our results 
showed that the average distance between the site-specifically introduced spin labels in NDM-1 
decreased by 4 Å in the 500 s quenched sample and by 2 Å in the 10 ms quenched sample, as 
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compared to the distance in the unreacted enzyme. Unlike in studies with CcrA, this study suggests 
that the hairpin loop in NDM-1 moves over the metal ions during catalysis and then moves back 
to its original position after hydrolysis, which is consistent with a previous hypothesis based on 
NMR solution studies on a related metallo--lactamase.REF However, the results on CcrA and 
NDM-1 suggest that the loop may not play an identical role in all MBLs. We do acknowledge that 
the work on NDM-1 is preliminary and that future studies are needed to improve the signal to noise 
and corresponding distance distributions. The new upgrade of our pulsed EPR spectrometer may 
lead to some improvement. We will also need to test other positions on the hairpin loop of NDM-
1 for the spin label to be introduced. We may also need to use different spin labels (other than 
MTSL), which are more motionally-restrained. Nonetheless, the work in Chapters 6 and 7 offer 
the first ever application of the rapid-freeze quench approach to DEER, and this work demonstrates 
that loop motions can be monitored on the micro- to millisecond time scale.  
 An interesting way to further probe loop dynamics would be to couple the RFQ-EPR 
approaches that we describe in Chapters 5, 6, and 7 with the heterobimetallic analogs that we 
described in Chapters 3 and 4. For 
example, the ZnCo-analog of 
NDM-1 has a paramagnetic metal 
ion in the Zn2 site, and we could 
monitor the dipolar coupling of 
the unpaired electrons on the 
metal ion with the unpaired 
electron on a site-specifically 
introduced spin label on the 
hairpin loop. CW-EPR 
(continuous wave-EPR) 
spectroscopy could be used to 
probe the distance between Co(II) 
in the active site and the spin label 
on the hairpin loop (with 
distances predicted to be 8-20 Å. 
RFQ-Electron Spin Echo Envelope Modulation (ESEEM) spectroscopy could be used to probe the 
 
Figure 8.2. Demonstration of the three possible 
spectroscopic techniques can be applied on ZnCo-NDM-1 
to investigate the active site or hairpin loop. 
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distance between Co(II) in the active site and positions on a deuterated substrate (with separations 
predicted between 4-8 Å). The development of these two approaches will allow for us to have a 
number of possible “rulers” to probe substrate binding/catalysis in these enzymes: (1) ESEEM 
spectroscopy to measure distances of 4-8 A, (2) CW-EPR spectroscopy to measure distances of 8-
20 Å, and (3) DEER spectroscopy to measure distances of 20-60 Å (Figure 8.2). 
 The work presented in this dissertation significantly strengthens our understanding of 
metallo-β-lactamases in general and of VIM-2, BcII, GOB18, SfhI, L1, CcrA, and NDM-1 
specifically. Since the long-standing goal of the project is the development of clinical inhibitors, 
this work positions the group to “take the next step”. The samples that were characterized with 
spectroscopic methods are now available for the characterization of enzyme-inhibitor complexes. 
Indeed, these efforts have already begun with the group examining a series of novel metal binding 
group inhibitors, which were identified from library screenings. The group is also examining a 
group of cephalosporin-based inhibitors/slow substrates, and spectroscopic characterization of 
these enzyme-inhibitor complexes is essential for future inhibitor re-design efforts.  
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